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Medroxyprogesterone acetate (MPA) and norethisterone (NET) and its derivatives (norethisterone 
enanthate (NET-EN); norethisterone acetate (NET-A)), designed to mimic the actions of the 
endogenous hormone progesterone (Prog), are extensively used by women as contraceptives and in 
hormone replacement therapy (HRT). A number of reports have indicated that these synthetic 
progestins affect immune function in the female genital tract thereby increasing the risk of acquiring 
sexual transmitted infections. Despite these findings, very little is known about their mechanism of 
action at the cellular level, in particular their steroid receptor-mediated effects on cytokine gene 
expression. In the first part of this thesis, the effect of Prog, MPA and NET-A on the expression of 
the endogenous pro-inflammatory cytokine gene, interleukin (IL)-12p40, and anti-inflammatory 
cytokine gene, IL-10, was investigated in a human ectocervical epithelial cell line, Ect1/E6E7. 
Quantitative realtime PCR (qPCR) showed that all three ligands significantly upregulated the tumor 
necrosis factor alpha (TNFα)-induced IL-12p40 gene expression, while IL-10 gene expression was 
downregulated. Moreover, by reducing the glucocorticoid receptor (GR) levels with siRNA, these 
effects were shown to be mediated by the GR. A more detailed investigation into the molecular 
mechanism of the progestogen-induced upregulation of IL-12p40 gene expression, using chromatin 
immunoprecipitation (ChIP), siRNA, co-immunoprecipitation and re-ChIP analyses, showed that 
the progestogen-bound GR is recruited to the CCAAT enhancer binding protein (C/EBP)-β 
regulatory element of the IL-12p40 promoter, most likely via an interaction with the transcription 
factor C/EBPβ. Similar experiments for the progestogen-induced downregulation of IL-10 gene 
expression showed that the progestogen-bound GR is recruited to the signal transducer and activator 
of transcription (STAT)-3 regulatory element of the IL-10 promoter, most likely via an interaction 
with the transcription factor STAT-3. The second part of this study elucidated the influence of the 
HIV-1 accessory viral protein R (Vpr) on progestogen-induced regulation of IL-12p40, IL-12p35 
and IL-10 in the Ect1/E6E7 cell line. Results showed that in these cells, the overexpression of Vpr 
significantly modulated the effects of Prog, MPA and NET-A on the mRNA expression of IL-
12p40 and IL-10, while only the NET-A effect was modulated on IL-12p35. Moreover, reducing 
the GR protein levels by siRNA suggested that the GR is required by Vpr to mediate its effects. 
Taken together, these results show that Prog, MPA and NET-A promote the pro-inflammatory 
milieu in the ectocervical environment, and that during HIV-1 infections, this milieu is modulated. 
Furthermore, the results suggest that the use of MPA or NET in vivo may cause chronic 
inflammation of the ectocervical environment, which may have important implications for 








Medroksieprogesteroon asetaat (MPA), noretisteroon (NET) en derivate daarvan noretisteroon 
enantaat (NET-EN); noretisteroon asetaat (NET-A), ontwerp om die funksies van die natuurlike 
hormone progesteroon (Prog) na te boots, word wêreldwyd deur vroue as voorbehoedmiddels sowel 
as vir hormoon vervangingsterapie (HVT) gebruik. Daar is verskeie aanduidings dat hierdie 
sintetiese progestiene die immuunfunksie in die vroulike geslagskanaal kan beïnvloed en ook die 
moontlike vatbaarheid van seksueel oordraagbare infeksies kan verhoog. Ten spyte hiervan, is baie 
min bekend oor hulle meganisme van werking op ‘n molekulêre vlak, veral in die besonder hul 
effek op sitokinien geenuitdrukking. Die effek van Prog, MPA en NET-A op die geenuitdrukking 
van ’n endogene pro-inflammatoriese sitokinien, interleukin (IL)-12, en ’n anti-inflammatoriese 
sitokinien, IL-10, asook die onderliggend meganisme van werking, in ’n menslike ektoservikale 
sellyn, Ect1/E6E7, is in die eerste deel van hierdie studie ondersoek. Kwantitatiewe “realtime” 
polimerisasie ketting reaksie (PKR) het getoon dat al drie die ligande die tumor nekrosis faktor alfa 
(TNF-α)-geïnduseerde IL-12p40 geenuitdrukking opreguleer en IL-10 geenuitdrukking onderdruk. 
Verder is gevind dat induksie van IL-12p40 en inhibisie van IL-10 deur Prog, MPA en NET-A deur 
die glukokortikoïed reseptor (GR) gedryf word, aangesien volledige opheffing van die effekte op 
hierdie sitokinien gene waargeneem is wanneer die GR proteïen vlakke deur middel van kort 
inmengende ribonukleïensuur (siRNS) verminder is. 'n Meer beskrywende ondersoek in die 
molekulêre meganisme is uitgevoer deur gebruik te maak van chromatien immunopresipitasie 
(ChIP), siRNS, mede-immunopresipitasie en her-ChIP analises. Hierdie resultate het voorgestel dat 
die progestogeen (Prog en die sintetiese progestiene)-gebonde GR tot die CCAAT verbeterende 
bindings protein (C/EBP)-β regulatoriese element van die IL-12p40 promotor betrek word en dat 
die transkripsie faktor C/EBPβ benodig word om transkripsie van die IL-12p40 geen te aktiveer. 
Met betrekking tot IL-10, het die resultate voorgestel dat die progestogeen-gebonde GR tot die sein 
transduksie en aktiveerder van transkripsie (STAT)-3 regulatoriese element van die IL-10 promotor 
betrek word en dat die transkripsie faktor STAT-3 benodig word om transkripsie van die IL-10 geen 
te onderdruk. Die tweede deel van die studie het die invloed van die MIV-1 aksesorale virale 
proteïen R (Vpr) op sitokinien geenuitdrukking, spesifiek die progestogeen-geïnduseerde regulering 
van IL-12p40, IL-10 en IL-12p35, in die Ect1/E6E7 sellyn ondersoek. Resultate het getoon dat 
ooruitdrukking van Vpr in hierdie sellyn die effekte van Prog, MPA en NET-A op die mRNS 
uitdrukking van IL-12p40 en IL-10, en slegs die NET-A effek op IL-12p35, aansienlik moduleer. 
Vermindering van die GR proteïen vlakke deur middel van siRNS het getoon dat Vpr die GR 
benodig om hierdie veranderinge mee te bring. In samevatting, die resultate van hierdie proefskrif 
stel voor dat Prog, MPA en NET-A die pro-inflammatoriese milieu in die ektoservikale omgewing 
bevorder, en dat hierdie milieu gedurende MIV-1 infeksies verander. Verder, die resultate van 
hierdie studie impliseer dat die gebruik van MPA en NET in vivo nadelige lokale 
immuunonderdrukkende effekte mag hê wat kan lei tot kroniese inflammasie van die ektoservikale 
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 THESIS OUTLINE 
____________________________________________________________________ 
This thesis consists of five chapters. Chapters 3 and 4 include a brief introduction of the particular 
study, and report and discuss the results obtained. The references for all the chapters are included in 
one section following Chapter 5.  
 
1. Chapter 1: Literature review. This chapter provides an overview of the relevant knowledge 
currently available in the literature, with a particular focus on the molecular mechanisms of 
action of medroxyprogesterone acetate (MPA) and norethisterone enanthate (NET-
EN)/norethisterone acetate (NET-A) and mucosal immunity in the lower female genital 
tract.  
2. Chapter 2: Materials and Methods. This chapter provides a detailed description of the 
experimental protocols and materials used to obtain the results presented in Chapters 3 and 
4. 
3. Chapter 3: The molecular mechanism of progestin-induced regulation of interleukin 
(IL)-12p40 and IL-10 in a human ectocervical epithelial cell line. This chapter contains 
the results of a study investigating the regulation of the endogenous cytokine genes, IL-
12p40 and IL-10, by progesterone (Prog), MPA and NET-A, and underlying mechanism, in 
an Ect1/E6E7 (human ectocervical) cell line.  
4. Chapter 4: Modulation of cytokine gene expression in a human ectocervical epithelial 
cell line by the HIV-1 accessory viral protein R (Vpr). This chapter reports on the 
findings of a study investigating whether HIV-1 Vpr can modulate the effects of Prog, MPA 






5. Chapter 5: Concluding discussion. The results of the overall study are discussed and 
conclusions drawn in this final chapter.  
 
Addendums A and B at the back of the thesis include data not shown, but referred to in Chapters 2-
4, additional results not included in the chapters, as well as experimental optimisations. Addendum 
C includes the publication to which the candidate contributed. 
Although the collective terms “we” and “our” are sometimes used in the thesis, all the experimental 
work was performed by the candidate, except for the maintenance of the Ect1/E6E7 cell line, which 
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Synthetic progestins are used clinically in a wide variety of applications, such as contraception, 
hormone replacement therapy (HRT) and certain gynaecological disorders. These progestins were 
designed to mimic the actions of the endogenous hormone progesterone (Prog) and to elicit their 
biological effects via the progesterone receptor (PR). However, the clinical use of some synthetic 
progestins has been reported to cause undesirable side-effects, most likely due to binding to other 
members of the steroid receptor family such as the androgen- (AR), mineralocorticoid- (MR) and 
glucocorticoid receptor (GR) (reviewed in (Africander et al., 2011b). Medroxyprogesterone acetate 
(MPA) and norethisterone/norethindrone enanthate (NET-EN) are examples of synthetic progestins 
used as progestin-only injectable contraception. Side-effects associated with the use of MPA and 
oral contraceptive pills include an increased risk of genital tract infections due to the regulation of a 
variety of components of the immune system (reviewed in (Kaushic, 2009, Gravitt and Ghanem, 
2010, Kaushic et al., 2010))(Brabin, 2002, Morrison et al., 2004). Hormonal contraceptives have 
been shown to affect mucosal immunity in the female genital tract, which may increase 
susceptibility to genital tract infections like human papilloma virus (HPV), herpes simplex virus 
(HSV), human immunodeficiency virus (HIV) and Chlamydia trichomatis and Candida albicans 
(UNAIDS, 2007, Ochiel et al., 2008, Gravitt and Ghanem, 2010). It is thus important to understand 
the role of factors such as hormonal contraceptives that may affect local immune responses in the 
female genital tract, as this my shed light on the molecular events occurring during infections. The 
epithelial cells lining the ectocervix play a protective role when the female genital tract is exposed 
to pathogens (Wira et al., 2005a, Gravitt and Ghanem, 2010, Wira et al., 2010, Wira et al., 2011). In 
addition to providing a physical barrier against sexually transmitted infections these epithelial cells 
are capable of eliciting both innate and acquired local immune responses at the mucosal surface 






2008, Dubicke et al., 2010). This chapter provides a brief overview of some of the therapeutic 
applications and diverse biological activities of MPA, also known as Depo-Provera®, and NET-EN, 
also known as Nuristerate®, extensively used as injectable contraceptives in South Africa (Smit et 
al., 2001, Medical Research Council, 2003, Kleinschmidt et al., 2007, Morrison et al., 2012). 
Furthermore, the effect of MPA and/or norethisterone/norethindrone (NET) on genital tract 
immunity and the association between the use of these contraceptives and risk of susceptibility to 
genital tract infections, specifically HIV, will be reviewed.  
 
1.2. The progestogens: Natural Prog and the synthetic progestins, MPA and 
NET 
The term progestogens refer to compounds that exhibit progestational activity, and include both the 
endogenous Prog and the synthetic progestins designed to mimic its actions. The endogenous 
ovarian hormone, Prog, is the first biologically active compound synthesised from cholesterol (Hu 
et al., 2010) and serves as the precursor for the synthesis of androgens, estrogens, glucocorticoids 
and mineralocorticoids (Gellersen et al., 2009, Skouby and Jespersen, 2009, Hu et al., 2010). Prog 
plays an important, yet diverse, role in the regulation of female reproduction (Ottesen and Pedersen, 
1996, Graham and Clarke, 1997, Schindler et al., 2003, Sitruk-Ware, 2004a, Sasha et al., 2008, 
Gellersen et al., 2009). For example, in the uterus and ovaries of mammalians Prog is responsible 
for the release of mature oocytes, facilitates implantation of the fertilised ovum, prevents 
contraction of the myometrium, maintains pregnancy via its anti-estrogenic activity, and inhibits 
further ovulation through its anti-gonadotropic activity (Graham and Clarke, 1997, Sitruk-Ware, 
2004a). During pregnancy, Prog stimulates the growth and development of the mammary gland for 
milk production, storage and secretion (Graham and Clarke, 1997). There is also evidence that Prog 






the γ-aminobutyric acid (GABA) signalling pathways in specific areas of the brain, thereby playing 
a role in neuroprotection (Graham and Clarke, 1997). Interestingly, changes in the concentration of 
Prog due to reproductive processes such as pregnancy and menstruation can affect the local immune 
system (Bouman et al., 2005, Wira et al., 2005a, Gravitt and Ghanem, 2010). For example, high 
Prog concentrations during the luteal phase of the human menstrual cycle and pregnancy, the 
maternal immune system changes from a pro-inflammatory to an anti-inflammatory state thereby 
decreasing inflammation. As inflammation contributes to preterm birth (Romero et al., 1994), this 
decrease in the inflammatory response provides protection for the developing fetus (Fleischman and 
Fessler, 2010). 
Low Prog production in females has been associated with miscarriages, preterm labor, infertility, 
endometriosis, abnormal menstrual bleeding, breast and endometrial cancer, depression and anxiety 
(Gellersen et al., 2009). As a result, synthetic progestins were designed to mimic the actions of 
Prog, and have been used in a number of therapeutic or clinical applications (Speroff, 1996, Howell 
et al., 1998, Kimmick and Muss, 1998, Li et al., 2000, Schweppe, 2001, Stahlberg et al., 2004). 
These synthetic progestins can be used either on their own or in combination with estrogen (Solter, 
1999, Greydanus et al., 2001, Truitt et al., 2003, Mansour, 2005, Archer et al., 2011). Combined 
oral contraceptives are available in different forms such as pills, transdermal patches or vaginal 
rings, whereas the progestin-only contraceptives can be taken in the form of pills (orally), 
intramuscular injections, implants or intrauterine devices (Greydanus et al., 2001, Mansour, 2005, 
Simon, 2007).  
MPA is a 17α-hydroxyprogesterone derivative, while NET is a 19-nortestosterone derivative 
(Schindler et al., 2003, Stanczyk, 2003, Sitruk-Ware, 2004b). The chemical structures of Prog, 






   
 
Figure 1.1. The chemical structures of (A) Prog, (B) MPA and (C) NET (R = OH), NET-A (R = 
OCOCH3) and norethisterone enanthate (NET-EN) [R = OCO(CH2)5CH3] (Taken from Africander et 
al., 2011b). 
 
1.3. Therapeutic applications 
1.3.1. Contraception 
For injectable contraceptive use in women, MPA and NET-EN are administered by intramuscular 
injections (Westhoff, 2003, Sitruk-Ware, 2004b, Bakry et al., 2008). MPA is administered as an 
aqueous suspension at a dose of 150 mg every three months (Mishell, 1996, Kaunitz, 1998, Bakry 
et al., 2008), while NET-EN is administered as an oily suspension at a dose of 200 mg every two 
months (Howard et al., 1975, Fotherby et al., 1978, Goebelsmann et al., 1979). MPA and NET-EN 
are known to be long-acting progestins as they are slowly released from the muscle (Mishell, 1996). 
Both MPA (Schindler et al., 2003, Bakry et al., 2008) and NET-EN (Stanczyk and Roy, 1990, 
Schindler et al., 2003) are metabolised in the liver. However, MPA itself is known to be the major 
progestogenic compound, while NET-EN and NET-A are hydrolysed to NET, which together with 
its metabolites form the active contraceptive agents (Stanczyk and Roy, 1990). NET-A is used in 
oral contraception and HRT.  
It has been reported that women using the intramuscular injection of 150 mg MPA have serum 
concentrations ranging between 2.6 and 3.9 nM (Mathrubutham and Fotherby, 1981, Mishell, 
1996), while women receiving the intramuscular administration of 200 mg NET-EN have serum 






concentrations ranging between 1.5 and 59 nM (Fotherby et al., 1983). However, serum 
concentrations of these parenterally administered progestins vary depending on the time after 
administration (Stanczyk, 2003). For example, the intramuscular injection of 150 mg MPA has been 
reported to reach peak plasma concentrations of 1.75 - 9 ng/ml (4.5 - 23.3 nM), 1 - 7 ng/ml (2.6 – 
18.1 nM) and  0.68 – 2.6 ng/ml (1.8 – 6.7 nM) one, three and eleven weeks, respectively, after 
administration, followed by a gradual decrease to undetectable levels (<100 pg/ml or 0.26 nM) after 
17 to 29 weeks (Depo-Provera contraceptive injection, 2006, New York, Pharmacia and Upjohn 
Company, Pfizer Inc.)(Shrimanker et al., 1978). In contrast, NET has been shown to reach a peak 
plasma concentration of 50 nM one week after intramuscular administration of 200 mg NET-EN, 
and then gradually decreases to ~ 13 nM, which is maintained for one to four months (Howard et 
al., 1975, Fotherby et al., 1978, Goebelsmann et al., 1979).  
 
The primary mode of action by which MPA and NET exert their contraceptive action is by 
inhibiting ovulation. This is achieved by the release of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) from the pituitary being suppressed, or by decreasing the pulsatile 
secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus (Mishell, 1996, 
Greydanus et al., 2001, Mansour, 2005, Bakry et al., 2008, Beijerink et al., 2008). In addition, MPA 
and NET limit sperm penetration by thickening the cervical mucus (Greydanus et al., 2001, Bakry 
et al., 2008), as well as causing atrophy of the endometrium, thus preventing the implantation of 
fertilised ova (Bakry et al., 2008). Moreover, MPA and NET-EN are under investigation as male 
contraceptives, since MPA or NET-EN combined with testosterone, suppress spermatogenesis, by 
synergistically suppressing the secretion of gonadotropic hormones (Kamischke et al., 2000a, 







1.3.2. Hormone replacement therapy (HRT) 
HRT is commonly prescribed to postmenopausal women to alleviate symptoms such as hot flushes, 
vaginal atrophy and dryness, as well as bone loss. These symptoms are as a consequence of 
decreased estrogen levels. Estrogen combined with progestins such as MPA or NET is administered 
to menopausal women with an intact uterus, so as to prevent estrogen-induced endometrial cancer, 
while women without a uterus are administered estrogen alone (Whitehead et al., 1979, Gambrell et 
al., 1980, Taitel and Kafrissen, 1995, Greendale et al., 1999, Sitruk-ware, 2006). The combined 
HRT is administered either continuously (daily) or sequentially (part of a month) (Kuhl, 2005). The 
typical daily dosages of the progestins used in HRT range between 2.5 and 10 mg for MPA and 0.5 
– 1 mg for NET-A (Kuhl, 2005, Kuhl, 2011). 
 
The serum levels of MPA have been reported to range between 0.01 – 0.1 ng/ml (0.02 and 0.2 nM) 
(Ghatge et al., 2005). In addition, it has been shown that postmenopausal women using 2.5 mg/day 
and 5 mg/day MPA have serum concentrations ranging between 0.3 – 0.45 ng/ml (0.776 – 1.16 nM) 
and 0.6 – 0.9 ng/ml (1.55 – 2.33 nM), respectively (Jarvinen et al., 2004). For the 10 mg MPA/day, 
peak serum levels ranged between 3 -5 ng/ml (8 - 13 nM) (Hiroi et al., 1975). The reported serum 
levels of NET seem to be higher than those of MPA. When administered 0.5 mg NET-A in 
combination with 1 mg estradiol, NET serum levels range between 5 - 7 ng/ml (14.7 and 20.6 nM) 
(Stadberg et al., 1999, Zdravkovic et al., 2001) and 1.2 - 6.0 ng/ml (3.64 – 17.7 nM) (Activelle 
package insert reg. no. 33/21.8.2/0532, Novo Nordisk Inc.) Similarly, peak serum levels of 5 – 10 









1.3.3. Other applications 
MPA and NET/NET-A/NET-EN are also used for other therapeutic applications. Both MPA 
(Kaunitz, 1998, Harrison and Barry-Kinsella, 2000, Irahara et al., 2001) and NET (Muneyyirci-
Delale and Karacan, 1998, Vercellini et al., 2003, Williams and Creighton, 2012) are used for the 
treatment of ovulatory pain, endometriosis and menstrual disorders such as dysmenorrhea and 
menorrhagia, while MPA can also be used in cancer therapy (Etienne et al., 1992, Yamashita et al., 
1996). Depending on the treatment the administered dosage varies. For example, both MPA and 
NET are used for the treatment of endometriosis at a dosage of 50 – 100 mg/day (Harrison and 
Barry-Kinsella, 2000; Telimaa et al., 1989), while for cancer therapy the dosages range between 
500 and 1500 mg/day for approximately 12 weeks (Blossey et al., 2006, a revised edition of 
Blossey et al., 1984; (Kim et al., 2012). 
  
1.4. Molecular mechanism of action via steroid receptors 
Following the administration of MPA and NET, these steroids enter the bloodstream where they 
interact with several serum-binding proteins (reviewed in Africander et al., 2011b). MPA binds to 
plasma proteins such as albumin (± 90%), but does not bind to sex-hormone-binding globulin 
(SHBG) or corticosteroid-binding globulin (CBG) (Schindler et al., 2003, Bakry et al., 2008). Thus 
< 10% of MPA is free in the blood. In contrast, 36% of NET binds to SHBG, while 61% is bound to 
albumin and 3% is free (unbound) (Hammond et al., 1982, Schindler et al., 2003). The free steroid 
is biologically active and can readily diffuse from the blood into the cells of target tissues, while the 
bound steroids are unavailable to tissues. Once the free MPA and NET enters the cell, they will 
elicit their effects on target genes by binding to intracellular steroid receptors, such as the PR, AR, 






below, the general mechanism of action of the above-mentioned steroid receptors, as well as known 
effects of MPA and NET via these receptors, are briefly described. 
 
1.4.1. General mechanism of action of steroid receptors 
The PR, AR, MR, ER and GR are ligand activated transcription factors which belong to the nuclear 
hormone receptor family (Evans, 1988, Mangelsdorf et al., 1995, Griekspoor et al., 2007, Huang et 
al., 2010, Sladek, 2010, Aagaard et al., 2011, Ahmad and Kumar, 2011, Bagamasbad and Denver, 
2011). In general, these receptors all contain three functional domains: a variable N-terminal 
transactivation domain, a central highly conserved DNA-binding domain (DBD), a hinge region and 
a moderately conserved ligand-binding domain (LBD) found at the C-terminal (figure 1.2) 
(Mangelsdorf et al., 1995, Griekspoor et al., 2007, McEwan, 2009, Aagaard et al., 2011); reviewed 
in (Africander et al., 2011b). The N-terminal transactivation domain contains an activation function 
(AF)-1 domain, which has been reported to be responsible for protein-protein interactions between 
general transcription factors and is required for optimal transcriptional activity (reviewed in 
(Aagaard et al., 2011, Africander et al., 2011b). The DBD, known to be highly homologous 
between steroid receptors, plays an important role in DNA-binding specificity, receptor 
dimerization and interaction with co-factors (Griekspoor et al., 2007); reviewed in Aagaard et al., 
2011 and Africander et al., 2001b), while the LBD is involved in protein-protein interactions with 
chaperone proteins (McEwan et al., 1997, Moras and Gronemeyer, 1998, Beato and Klug, 2000). 
Furthermore, the signal for nuclear localisation is embedded in the DBD and LBD (Tang et al., 
1998, Griekspoor et al., 2007). A second activation function domain (AF-2), found within the LBD, 
is present and is important for the induction of transcriptional activity of the receptor. This AF-2 
domain also contains a LXXLL motif to which co-factors bind (Weatherman et al., 1999); reviewed 







Figure 1.2. A schematic illustration of the general structure and organisation of the functional 
domains of steroid receptors. In general, steroid receptors consist of various functional domains: region 
A/B denotes the variable N-terminal domain containing the AF-1 transactivation domain, region C denotes 
the highly conserved DBD, region D denotes the hinge region between the DBD and LBD, and region E 
refers to the moderately conserved LBD, which contains the second transactivation domain AF-2. The ER-α 
is unique in that it also contains an additional carboxy-terminal F domain. The numbers represent the length 
of the steroid receptors in amino acids. Figure redrawn from Africander et al., 2011b. 
 
The lipohilic nature of steroid hormones enables them to readily diffuse across the cell membrane 
into the target cell (Hammes and Levin, 2007, Sladek, 2010). Once inside the target cell, the 
hormone binds to the intracellular steroid receptor at its LBD. In the absence of ligand, the AR, 
MR, GR and PR-B isoform are found mainly in the cytoplasm, whereas the PR-A isoform and ER 
are found predominantly in the nucleus (Lim et al., 1999, Griekspoor et al., 2007). The unliganded 
receptor is bound to chaperone proteins such as heat shock protein 90 (hsp 90), hsp 70, hsp 56 and 
hsp 26, immunophilin p59 and phosphoprotein p23 (Pratt and Toft, 1997, Griekspoor et al., 2007). 
Upon ligand binding, the receptor undergoes a conformational change, allowing it to dissociate 






nucleus (Zhou and Cidlowski, 2005, Griekspoor et al., 2007). The ligand bound receptor then binds 
to specific regulatory elements within the promoter region of target genes, to either activate 
(transactivation) or repress (transrepression) transcription of target genes (reviewed in (Huang et al., 
2010, Africander et al., 2011b).  
 
1.4.1.1. Transactivation 
Ligand-activated steroid receptors bind as a dimer to palindromic DNA sequences known as steroid 
responsive elements (SREs) (Webster and Cidlowski, 1999) in the promoter area of target genes 
(figure 1.3). Dimerisation of the GR has also been suggested to occur via the cooperative 
association of two GR monomers to half-GRE sites (Dahlman-Wright et al., 1990, Holmstrom et 
al., 2008). The consensus palindromic SREs consist of two hexanucleotide sequences separated by 
any three nucleotides, and in humans has the sequence GGTACAnnnTGTTCT (Newton, 2000); 
reviewed in (McEwan, 2009). Due to the highly conserved DBD of steroid receptors (reviewed in 
(Beato, 1989, Africander et al., 2011b), most receptors bind to the same SRE. For example, the PR 
binds to the progesterone response element (PRE), which can also serve as a response element for 
the AR, MR and GR, and is then called the androgen response element (ARE), mineralocorticoid 
response element (MRE) and glucocorticoid response element (GRE), respectively. The ER differs 
from the other steroid receptors in that it binds specifically to estrogen response elements (EREs), 
which consist of the DNA sequence GGTCAnnnTGACC (Klinge, 2001). Following DNA binding, 
multi-protein complexes including chromatin-remodelling proteins, co-activators and components 
of the basal transcription machinery are recruited to the promoter of target genes (Beato and Klug, 
2000, Lu et al., 2006, Griekspoor et al., 2007, Africander et al., 2011b). The recruitment of co-






acetylation, which results in the opening of the chromatin and recruitment of the basal transcription 
machinery (figure 1.4A), to positively regulate transcription (reviewed in (Griekspoor et al., 2007). 
 
1.4.1.2. Transrepression 
Inhibition of transcription or transrepression can occur when steroid receptors bind as a monomer to 
negative-SREs (nSREs), or more frequently to another transcription factor such as nuclear factor 
kappa-B (NFĸB), activator protein (AP)-1 and CCAAT enhancer binding protein (C/EBP) (figure 
3) (Cato and Wade, 1996, Almawi and Melemedjian, 2002, Zhou and Cidlowski, 2005, Gross and 
Cidlowski, 2008, De Bosscher and Haegeman, 2009). The latter mechanism of protein-protein 
interaction is known as tethering (Newton, 2000, De Bosscher and Haegeman, 2009), and is best-
studied and characterised for the GR through its interaction with AP-1 or NFĸB (Cato and Wade, 
1996, Almawi and Melemedjian, 2002, De Bosscher et al., 2003, Kassel and Herrlich, 2007). 
Although much less is known about the mechanism of transrepression via other members of the 
steroid receptor family such as the PR, AR, MR and ER, there is evidence that these receptors 
interact with NFκB to repress the expression of genes (Kalkhoven et al., 1996, Palvimo et al., 1996, 
De Bosscher et al., 2003, Kobayashi et al., 2010). In contrast to transactivation, co-repressors are 
recruited to the promoter of target genes to negatively regulate transcription (Heinlein and Chang, 
2002). The recruitment of co-repressors results in histone deacetylation, thereby producing compact 







Figure 1.3. General molecular mechanism of action of steroid receptors. A lipohilic steroid hormone 
such as MPA diffuses across the cell membrane and binds to an intracellular steroid receptor (depicted as 
SR). The ligand-activated steroid receptor binds either as a dimer to SREs in the promoter of a target gene to 
positively regulate transcription (transactivation) or as a monomer to other DNA bound transcription factors 
(NFĸB or AP-1) to negatively regulate transcription (transrepression).   
  
In addition, it has been established that tethering of the steroid receptors to other DNA-bound 
transcription factors can also enhance target gene expression. For example, glucocorticoids have 
been shown to positively regulate transcription of the MAPK-phosphatase gene in human epithelial 
lung carcinoma cells via a tethering mechanism between the glucocorticoid-bound GR and the 
transcription factor C/EBPβ (Johansson-Haque et al., 2008). The PR has also been shown to tether 
to the transcription factors Sp1 and C/EBPβ to increase target gene transcription (Faivre et al., 






whether the ligand bound to the steroid receptor is an agonist or antagonist (reviewed in (Africander 
et al., 2011b)). In general, an agonist-bound steroid receptor induces a conformational change that 
facilitates the binding of a co-activator to increase transcription, whereas an antagonist-bound 
receptor recruits a co-repressor to decrease transcription (figure 1.4) (McKenna et al., 1999, Nettles 




Figure 1.4. A general model showing the role of co-regulators in the transcriptional regulation of 
target genes by steroid receptors. (A) Binding of co-activators e.g. steroid receptor (SRC-1) and 
p300/CREB-binding protein (CBP) to steroid receptors stimulates histone acetylation. The latter causes 
remodelling of the chromatin structure, i.e. opening of the chromatin to make it more accessible for the basal 
transcription machinery, thereby increasing transcription. (B) Binding of co-repressors, e.g. nuclear receptor 
co-repressor (NCoR) to steroid receptors stimulates histone deacetylation. As a result the chromatin is more 
condensed and less accessible to proteins of the basal transcriptional machinery, which leads to a decrease in 
transcription. Abbreviations: A: N-terminal activation domain of steroid receptor; D: DBD and L: LBD of 
















1.4.2. Biological activities via the PR, AR, MR, ER and GR 
1.4.2.1. PR 
MPA and NET-A, like other synthetic progestins, were designed to mimic the biological actions of 
the endogenous PR ligand Prog by binding to the PR. Human PR is expressed in the female genital 
tract, mammary gland, pancreas, brain and the pituitary gland (reviewed in Africander et al., 
2011b). Two PR-isoforms exist, PR-A and PR-B, which are transcribed from two promoters of a 
single gene (Kastner et al., 1990). PR-B is known to be transcriptionally more active that PR-A and 
differs from PR-A in that it contains an additional 164 amino acids at the N-terminal domain 
encoding for an activation function (AF)-3 domain (Kastner et al., 1990, Edwards et al., 1995, 
Keightley, 1998, Leonhardt and Edwards, 2002, Lange, 2008). The differences in the transcriptional 
activity of PR-A and PR-B has been reported to be cell- and promoter-specific (Lim et al., 1999). 
Interestingly, the human PR-A has been shown to act as a strong repressor of human PR-B, as well 
as the AR, ER, MR and GR (Vegeto et al., 1993, McDonnell and Goldman, 1994, McDonnell et al., 
1994). Although the PR-isoforms are normally expressed at similar levels in female reproductive 
tissues, there is evidence that the ratio of PR-A and PR-B can vary extensively during the menstrual 
cycle, due to changing hormonal levels, as well as in breast, endometrial, cervical and ovarian 
cancers (Graham et al., 1996, Conneely et al., 2002, Mote et al., 2002, Richer et al., 2002, Scarpin 
et al., 2009). In addition to the differential expression of the PR-isoforms, these isoforms also have 
differential physiological functions in various tissues. For example, the biological effects of Prog 
are predominantly mediated by PR-A in the ovaries and uterus, while in the mammary gland it is 
primarily mediated via PR-B (Buser et al., 2007). Thus, it is possible that MPA and NET-A also 
exhibit differential biological activities, as well as different relative binding affinities (RBAs) via 






recent study using recombinant in vitro binding showed that NET-A has a ~ two-fold higher RBA 
for human PR-B than PR-A (Attardi et al., 2010).  
 
Numerous studies have shown that the synthetic progestins MPA and NET bind to the rat, rabbit 
and human PR, and that both these progestins have higher RBAs for the PR than Prog (Table 1), 
and are full PR agonists (reviewed in Africander et al., 2011b). Furthermore, MPA and NET-A 
have been shown to regulate the expression of several genes in the PR-positive T47D breast cancer 
cell line. In human endometrial stromal cells, a role for the PR in the MPA-induced inhibition of the 
chemokine Regulated-upon-Activation, Normal T Cell Expressed and Secreted (RANTES) 
transcriptional activity have been found (Zhao et al., 2002). In addition, the gene expression of two 
vascular inflammation markers, intracellular molecule (ICAM)-1 and vascular cell adhesion 
molecule (VCAM)-1, are upregulated by MPA and NET-A in part via the PR (Tatsumi et al., 2002).  
 
1.4.2.2. AR 
The AR is expressed in various tissues, such as the mammary gland, vagina, prostate, testes, 
muscle, skin and bone marrow (Lu et al., 2006). In addition to playing an important role in male 
reproduction, the AR also has a role in the development of the ovaries and the breast in females. 
Both MPA and NET-A have been shown to bind to endogenous AR in human breast cancer cell 
lines, as well as to the human AR overexpressed in the COS-1 (monkey kidney fibroblast) cell line 
(Table 1) (Bergink et al., 1983, Bentel et al., 1999, Kemppainen et al., 1999a, Deckers et al., 2000, 
Schoonen et al., 2000, Africander, 2010). In the latter model, high RBAs were reported for Prog (Ki 
= 36.6 nM), MPA (Ki = 19.4 nM) and NET-A (Ki = 21.9 nM) compared to the natural androgen 
dihydrotestosterone (DHT) (Ki = 29.4 nM ) (Africander, 2010), indicating that these progestogens 






AR, others have reported that Prog acts as an AR antagonist (reviewed in Africander et al., 2011b; 
(Fuhrmann et al., 1996, Bentel et al., 1999, Sasagawa et al., 2008, Africander, 2010), while both 
MPA and NET-A are reported to be AR agonists (Africander, 2010). In addition, using NFĸB and 
AP-1 promoter-reporter constructs, both MPA and NET-A, but not Prog, have been shown to act as 
agonists for transrepression via the AR (Africander, 2010). Thus, these progestins may exert 
inhibitory effects of inflammatory response genes via the AR. MPA has been shown to regulate the 
mRNA expression of a number of genes in human breast cell lines via the AR (Ghatge et al., 2005, 
Moore et al., 2012). In addition, a recent study in the human ectocervical epithelial cell line, 
Ect1/E6E7, showed a role for the AR in mediating the MPA induced downregulation of the pro-
inflammatory cytokine RANTES. Using the cervical epithelial cell line, Hela, NET has also been 
shown to have AR-mediated transcriptional activation (Garcia-Becerra et al., 2004). 
 
1.4.2.3. MR 
 The MR is expressed in epithelial tissues such as the kidney and colon, and nonepithelial cells such 
as the central nervous system, the heart and adipocytes (Krozowski and Funder, 1983, de Kloet et 
al., 2000, Funder, 2004). Both MPA and NET-A have been shown to bind to overexpressed MR in 
the COS-1 cell line with similar weak affinity to each other, but with much lower affinity than that 
of Prog (Table 1) (Africander, 2010). When comparing the RBAs of MPA and NET-A as 
percentages relative to aldosterone (Ald) (100%), the values obtained by the latter study for MPA 
(0.08%; Ki = 197 nM) and NET-A (0.07%; Ki = 229 nM) (Africander, 2010), are 40-fold lower 
than the previously reported values of 3.1% and 2.7%, respectively (Philibert et al., 1999, Winneker 
et al., 2003). Furthermore, Prog exhibits weak partial agonist and potent antagonist activity for the 
MR (Wambach and Higgins, 1978, Quinkler et al., 2002, Sasagawa et al., 2008, Africander, 2010), 






2008, Africander, 2010). Using a rat cardiomyocyte cell line transiently transfected with the human 
MR, 1 µM NET-A, but not 1 µM MPA, displayed similar antagonistic activity to 1 µM Prog on the 
endogenous MRE-containing genes, orosomucoid-1 (Orm-1) and plasminogen activator inhibitor-1 
(PAI-1). The anti-mineralocorticoid activity of NET-A may exert beneficial effects on blood 
pressure and have cardiovascular protective benefits. Moreover, unlike MPA, Prog and NET-A are 
agonists for transrepression via the MR (Africander, 2010). Although the concentration of MPA and 
NET-A used in this study is beyond the physiologically relevant concentrations, there is a 
possibility that in vivo, lower concentrations of NET-A may have the same effects. 
 
1.4.2.4. ER 
The ER has diverse physiological roles and is expressed in the female reproductive system 
(mammary glands, uterus, vagina and ovaries), male reproductive system (testis, epididymis and 
prostate), as well as the brain, lung and heart (Osborne et al., 2000, Mertens et al., 2001); reviewed 
in Africander et al., 2011b). For example, the ER plays a role in sexual development, reproduction 
and cardiovascular disease (Grese and Dodge, 1998, Fan et al., 2010). Two ER-isoforms, ERα (66 
kDa) and ERβ (56 kDa), have been identified which are transcribed from two different genes and 
differ mainly in the AF-1 domain located in the A/B N-terminal domain (Griekspoor et al., 2007, 
Bai and Gust, 2009). ERα also differs from ERβ, and other steroid receptors, in that it contains an 
additional F-domain at the C-terminal (Kong et al., 2003). Several studies have shown that unlike 
the endogenous ER ligand, estradiol, MPA and NET do not bind to the ER (Teulings et al., 1980, 
Bergink et al., 1983, Schoonen et al., 2000, Lemus et al., 2009), while a single study showed that 
both MPA and NET bind to the ER (Di Carlo et al., 1983). However, whether it is MPA or NET 
themselves, or in fact their metabolites that bind to the ER is not clear. Indeed it has been shown 






It has been shown that NET and its A-ring reduced metabolites display weak agonist activity via the 
ER (Oropeza et al., Markiewicz and Gurpide, 1994, Schoonen et al., 2000, Schindler et al., 2003), 
while other studies have reported no estrogenic activity for MPA or NET via the ER (Markiewicz 
and Gurpide, 1994, Schindler et al., 2003). Whether these effects are via ERα or ERβ is unknown. 
Interestingly, Sasagawa and co-workers showed that NET displayed more agonist activity towards 
ERα than ERβ (Sasagawa et al., 2008). Furthermore, a 5α-reduced metabolite of NET (3β, 5α-NET) 
showed ERα selective activity at low concentrations, while ERβ agonistic activity was observed at 
high concentrations (Larrea et al., 1987). Some of the observerd effects of progestogens on gene 
expression may occur due to indirect genomic effects via the PR or another steroid receptor. For 
example, progestogens elicit indirect estrogenic activity via the PR. Binding of the progestogens to 
the PR then causes upregulation of 17β-hydroxysteroid dehydrogenase (HSD) type 2 gene 
expression, which inactivates estradiol by converting it to estrone (Kuhl, 2005). Progestogens can 
also exert indirect anti-estrogenic effects in the endometrium by binding to the PR, which then 
suppresses gene expression of the ER (Kuhl, 2005).  
 
1.4.2.5. GR 
The GR has diverse roles and although ubiquitously expressed, its levels are regulated in a tissue- 
and cell-specific manner (Lu et al., 2006). Thus, the levels of GR expressed vary substantially 
between tissues. For example, the GR has been shown to be expressed at a concentration of 4.1 
ƒmol GR per mg protein in peripheral blood mononuclear cells (PBMCs) (Chriguer et al., 2005) 
and 893 ƒmol GR per mg protein in the skin (Guo et al., 1996). Furthermore, in certain disease 
states such as cancers, the concentration of the GR changes within the same tissue type of an 
individual. For example, the levels of the GR has been reported to increase by 5-fold in healthy vs 






al., 1981) and 2-fold in healthy vs cancerous lung tissue biopsies (30.3 – 84.9 ƒmol GR per mg 
protein vs 56.5 – 87.8 ƒmol GR per mg protein) (Beattie et al., 1985).  Moreover, expression of the 
GR was significantly higher in the tumour tissue within the skin of AIDS patients with Kaposi’s 
sarcoma compared with the noncancerous skin of the same patients (4663 vs 2777 ƒmol/mg protein) 
(Guo et al., 1996). GR expression levels (density) can affect the response of a ligand. Zhao and co-
workers have previously shown that, depending on the GR density MPA displays full agonist, 
partial agonist/antagonist or antagonist activity for transrepression (Zhao et al., 2003). 
 
Numerous studies have indicated that MPA binds the GR with a high RBA (Table 1) (reviewed in 
Africander et al., 2001b). One study in human mononuclear cells showed that MPA has a higher 
RBA for the GR than the natural glucocorticoid cortisol (42% vs 25%, respectively, relative to 
100% binding of the synthetic glucocorticoid dexamethasone (Dex)) (Kontula et al., 1983). In 
contrast, MPA has been shown to have a similar RBA to that of Dex via the GR in the human lung 
carcinoma cell line (A549), COS-1 cell line and rats (Winneker and Parsons, 1981, Koubovec et al., 
2005, Ronacher et al., 2009). In contrast, Prog and NET have been shown to bind with very low 
affinity to the human GR (Koubovec et al., 2005, Ronacher et al., 2009) (Table 1).  
 
The evidence in the literature suggests that Prog and MPA act as GR agonists for transactivation 
and transrepression, while NET-A acts as a weak GR antagonist for transactivation and very weak 
partial GR agonist for transrepression (Koubovec et al., 2005, Ronacher et al., 2009, Africander, 
2010, Courtin et al., 2011). Interestingly, Bamberger and co-workers have previously indicated that 
MPA exerts dissociative glucocorticoid-like properties in normal human lymphocytes (Bamberger 
et al., 1999), as MPA significantly repressed interleukin (IL)-2 promoter-reporter activity, while 






MPA dose-dependently suppressed the protein levels of IL-6 and IL-2 in normal human 
lymphocytes, most probably via the GR (Bamberger et al., 1999). These effects of MPA were 
assumed to be mediated via the GR, as this cell line does not express the PR or AR. Consistent with 
the transrepression abilities observed by Bamberger et al., other studies have also shown that MPA 
elicits anti-inflammatory activity via the GR (Bamberger et al., 1999, Kurebayashi et al., 2003, 
Koubovec et al., 2004, Koubovec et al., 2005). However, in contrast to Bamberger et al., most of 
these studies observed significant transactivation of a GRE promoter by MPA. Kurebayashi and co-
workers show that MPA, in a dose dependent manner, decreases the secretion and mRNA 
expression of the pro-inflammatory cytokine IL-6 in the human thyroid cancer cell line (KTC-2) via 
the GR (Kurebayashi et al., 2003). Furthermore, a role for the GR in mediating the MPA induced 
repression of the IL-6 protein and IL-6 and IL-8 promoter reporter activity at the level of 
transcription was demonstrated in the murine fibrosarcoma L929sA cell line (Koubovec et al., 
2004). In contrast, MPA and other GR ligands such as Dex and cortisol have been reported to also 
elicit pro-inflammatory responses (Visser et al., 1998, Enomoto et al., 2007, Verhoog, 2010, 
Lannan et al., 2012). For example, the GR endogenously expressed in human endocervical 
epithelial cell line (End1/E6E7) was shown to be involved in the upregulation of IL-6 mRNA 
expression by Prog, MPA and NET-A (Verhoog, 2010). Interestingly, NET has previously been 
shown to display no GR transactivational activity (Schoonen et al., 2000, Koubovec et al., 2005). 
 
Taken together, MPA, unlike NET-A and Prog has high affinity for the GR, and displays greater 
GR agonist activity for transactivation and transrepression that NET-A and Prog. Moreover, these 
ligands can exert both anti- and pro-inflammatory activity via the GR. In addition, the fact that GR 
levels determine whether MPA acts as a GR agonist or antagonist, may have implications for the 






designed to have similar biological activities via the PR, these collective studies described in 
section 1.4.2.2-1.4.2.5 indicate that these progestins also exert off-target biological effects via the 
AR, MR, GR and possibly the ER. It is thought that these off-target effects of MPA and NET 
contribute to the undesirable side-effects associated with their clinical use. To summarise, the 







Table 1. Relative binding affinities (RBAs) and biological activities of natural Prog and the synthetic progestins, MPA and NET/NET-A, via steroid 
receptors 
Progestogen 
PR AR GR MR ER 



























































































- 0.07b - 0   
aIn vitro human steroid receptor (Philibert et al., 1999, Krattenmacher, 2000, Attardi et al., 2010).   
b hAR (Kemppainen et al., 1999b, Africander, 2010), hGR  (Koubovec et al., 2005) or hMR (Fuhrmann et al., 1995, Africander, 2010) expressed in  the COS-1 cell line. 
c The A549 cell line expressing endogenous GR (Koubovec et al., 2005).  
d Values compiled by cross comparisons from several studies that used different methods and were taken from (Kuhl, 2005). Most of the data are from animal tissues or cell lines 
expressing several receptors.    
e Rabbit uterine cytosol (Zhang et al., 2000, Shields-Botella et al., 2003). 
f Different rat tissues (Phillips et al., 1990, Pollow et al., 1992, Zhang et al., 2000, Shields-Botella et al., 2003) 
g Dog liver cytosol (Selman et al., 1996). 
h T47D or MCF-7 cells lines  (Bergink et al., 1983, Deckers et al., 2000, Zhang et al., 2000, Shields-Botella et al., 2003). 
i Human uterine tissue (Pollow et al., 1992, Stanczyk, 2003). 
-, (+), +, ++ and ± denotes the different levels of activity: -, not effective; (+), weakly effective; +, effective; ++, strongly effective; ±, literature inconsistent. (Taken from Africander 






1.5. Side-effects associated with the therapeutic usage of MPA and NET  
A number of undesirable side-effects, some more severe than others, have been associated with the 
clinical use of MPA and NET. Examples of these side-effects include amenorrhea, irregular 
bleeding, weight gain, headaches, nausea, acne, fatigue, depression, insomnia, abdominal pain or 
discomfort, breast tenderness, hot flushes, reduced libido, vaginal itchiness as wells as decreased 
bone mineral density (Darney, 1995, Kaunitz, 2000, Li et al., 2000, Greydanus et al., 2001, Haider 
and Darney, 2007, Ojule et al., 2010, Williams and Creighton, 2012). Furthermore, clinical 
evidence from the Women’s Health Initiative (WHI) study indicated that MPA significantly 
increased the risk of invasive breast cancer, coronary heart diseases, strokes and venous 
thromboembolism (Rossouw et al., 2002, Anderson et al., 2004, Warren, 2004) in post-menopausal 
women using MPA and conjugated equine estrogens (CEE) in HRT, while the Million Women 
Study indicated that both MPA and NET increased the risk of breast cancer in long-term HRT users 
(Beral et al., 2003).  
 
There is clinical evidence in the literature to suggest that the use of MPA as a contraceptive increase 
the risk of acquiring genital tract infections such as HSV-2 (Mostad et al., 1997, Mostad et al., 
2000), Chlamydia (Morrison et al., 2004), Gonorrhoea (Morrison et al., 2004) and HIV-1 (Hel et 
al., 2010, Morrison et al., 2010, Heffron et al., 2012, Morrison et al., 2012). In addition, mice 
treated with contraceptive doses of MPA showed a 100-fold increased susceptibility to genital 
HSV-2 infection compared to untreated mice (Kaushic et al., 2003). Similarly, it has been shown 
that MPA increased susceptibility to vaginal simian-HIV (SHIV) in rhesus macaques. In the latter 
study, the increase in susceptibility was ascribed to an immune- rather than transmission-based 
mechanism (Trunova et al., 2006). Contraceptive doses of MPA have also been shown to modulate 






number of intraepithelial immune cells (Ildgruben et al., 2003). Surprisingly little research has 
investigated the effects of MPA and NET-A on immune function at the cellular level. A recent 
study using human ectocervical and vaginal epithelial cell lines as in vitro models for mucosal 
immunity, showed that Prog, MPA and NET-A differentially regulate the tumor necrosis factor 
(TNF)-α induced gene expression of IL-6, IL-8 and RANTES in a ligand-, promoter- and cell-
specific manner (Africander et al., 2011a). MPA has also been reported to decrease the 
lipopolysaccharide (LPS)-induced mRNA expression of cytokines/chemokines in the cervix of mice 
and include interferon (IFN)-γ, TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13 and IL-15 
(Elovitz and Gonzalez, 2008). Considering the above information, it is clear that more research is 
needed on the effects of MPA and NET-A on target genes involved in immune function, 
particularly in cells relevant to viral infections. 
 
In the next section, the evidence in the literature for an association between hormonal contraceptive 
use and HIV-1 pathogenesis will further be discussed. 
 
1.6. Hormonal contraception and HIV-1 
Numerous epidemiological studies have assessed the link between the use contraception and 
susceptibility to HIV-1, the disease progression to AIDS, as well as HIV viral shedding. However, 
whether hormonal contraception is indeed a risk factor for HIV-1 acquisition remains controversial. 
Re-analysis of published data (Morrison et al., 2007) by Morrison and co-workers showed that the 
use of DMPA, but not combined oral contraceptives containing estrogen and the progestin 
levonorgestrel, is associated with an increase in HIV acquisition (Morrison et al., 2010). Similarly, 
another study showed evidence for a modest increase in HIV acquisition risk among young DMPA 






injectable contraceptive use in seven African nations including South Africa, and of which DMPA 
was the most commonly used method, significantly increased the risk of HIV-1 acquisition in 
uninfected women (Heffron et al., 2012). In contrast, some studies report no association between 
use of DMPA or combined oral contraceptives and HIV-1 acquisition (Kleinschmidt et al., 2007, 
Myer et al., 2007). Limited data currently available for NET-EN, shows no association between 
contraceptive use of NET-EN and the risk of acquiring HIV infection (Kleinschmidt et al., 2007, 
Myer et al., 2007, Morrison et al., 2012). 
 
Whether hormonal contraception is been linked to HIV-1 disease progression to AIDS (Beaten et 
al., 2007, Hel et al., 2010), is also controversial. While some studies suggest that women infected 
with HIV-1 and using DMPA or oral contraceptives have higher viral loads, and more rapid loss of 
CD4+ T cells, compared to women not using any contraception, other studies show no relationship 
between hormonal contraception and HIV-1 disease progression (Cejtin et al., 2003, Richardson et 
al., 2007). There is also evidence in the literature that MPA and other hormonal contraceptives, 
increase cervicovaginal shedding of HIV-1 DNA (a marker of HIV-1 infected cells), in HIV-
infected women (Clemetson et al., 1993, Mostad et al., 1997, Wang, 2004, Stringer and Antonsen, 
2008, Hel et al., 2010). Furthermore, a recent study showed an increased risk of HIV-1 transmission 
from HIV-1 infected women using MPA to uninfected men (Heffron et al., 2012). The authors 
suggested that the increased levels of HIV-1 RNA, detected in the endocervical secretions of these 
women, could explain the increased risk of HIV-1 transmission. 
 
Nonetheless, the majority of studies seem to suggest that there is indeed an association between the 
use of MPA and increased susceptibility to HIV-1 infection. However, the exact mechanism 






that it may be due to the fact that sex steroid hormones affect the thickness and permeability of the 
vaginal mucosal epithelium in women as well as female macaques (Hel et al., 2010). For example, 
high estrogen and low Prog levels induce thickening of the vaginal stratified squamous epithelium 
(figure 1.5A), whereas high Prog and low estrogen levels are associated with thinning of the vaginal 
epithelium and vaginal atrophy (figure 1.5B). The latter can result in an increase in the 
susceptibility of the lower female genital tract to various sexual transmitted infections. As MPA and 
NET-EN are thought to act similar to Prog, it has been suggested that they should also cause 
thinning of the vaginal epithelium (Blish and Baeten, 2011). However, no studies have addressed 
this for NET-EN, while the effect of MPA on vaginal wall thickness appears to be controversial. 
Some studies have shown a vaginal thinning (Mauck et al., 1999), others have shown an increase in 
vaginal thickness (Ildgruben et al., 2003), while others show no effect (Cejtin et al., 2003, 
Richardson et al., 2007, Morrison et al., 2009) on vaginal epithelium thickness. There is evidence in 
the literature to suggest that genital tract inflammation may be a potential mechanism whereby 
hormonal contraceptives increase HIV-1 susceptibility (reviewed in (Stringer and Antonsen, 2008, 
Blish and Beaten, 2011, Roberts et al., 2012a). An increase in the cervical production of the pro-
inflammatory cytokines TNF-α, IL-1, IL-6 and IL-8 has been associated with increased levels of 
HIV-1 shedding in the female genital tract (Gumbi et al., 2008), suggesting that upregulation of pro-
inflammatory cytokines in the genital tract, and hence an increase in inflammation, may promote 
HIV-1 replication and shedding. Whether or not MPA and NET cause increase inflammation, and 
whether an increase in pro-inflammatory cytokines/chemokines increases HIV-1 infectivity, 










Figure 1.5. Prog affects the thickness and permeability of the vaginal mucosal epithelium. (A) At low 
Prog concentrations, a thick vaginal epithelium is shown. (B) Prog triggers thinning of the vaginal 
epithelium, and thereby increase susceptibility to infections such as HIV-1, candida and Chlamydia. Adapted 
from Hel et al., 2010. 
 
1.7. Mucosal immunity in the female genital tract 
The epithelial cells lining the lower female genital tract, as part of the mucosal immune system, are 
the first line of defence against invading pathogens (Wira et al., 2005a, Wira et al., 2010). These 
cells provide a physical barrier against sexual transmitted infections to protect women without 

















tract is made-up of three anatomical sites: the endocervix, ectocervix and vagina. The endocervix is 
lined with simple columnar epithelial cells, while the ectocervix and the vagina consist of multiple 
layers of stratified squamous epithelial cells (figure 1.6) (Fichorova et al., 1997, Fichorova and 
Anderson, 1999, Quayle, 2002, Wira et al., 2005a, Wira et al., 2005b). 
 
The majority of women infected with HIV-1 acquire the virus via the female genital tract, which is 
the primary route for heterosexual transmission of HIV-1 (Cummins and Dezzutti, 2000, Pope and 
Haase, 2003, Hladik and Hope, 2009, Kaushic et al., 2010). The ectocervix and vagina, as part of 
the lower female genital tract, is a non-sterile environment and the first portal of entry for pathogens 
(Fichorova and Anderson, 1999, Quayle, 2002, Wira et al., 2005a, Wira et al., 2005b, Ochiel et al., 
2008). In response to invading pathogens, the epithelial cells of the lower female genital tract are 
capable of evoking a local immune response via the production of cytokines and chemokines which 
activate and recruit immune cells such as macrophages, natural killer (NK) cells, neutrophils, B-
cells and T-cells (Fichorova and Anderson, 1999, Wira et al., 2005b, Wira et al., 2010, Hickey et 
al., 2011). These cells are also capable of secreting antimicrobial peptides, for example human α- 
and β-defensins, to provide protection against invading microbes and assist in innate immunity 
(Wira et al., 2010, Wira et al., 2011). Moreoever, these epithelial cells have been shown to express a 
variety of toll-like receptors (TLRs) (Fichorova et al., 2002, Wira et al., 2005b, Kaushic et al., 
2010) that recognize a wide range of microbial ligands and release intracellular signals which lead 
to the production of cytokines and chemokines (Fichorova et al., 2002, Zarember and Godowski, 
2002, Kaushic et al., 2010). 
 
A number of factors have been shown to influence the immune response in the female genital tract. 






function and distribution of various immune cells, such as T cells, B cells, natural killer (NK) cells, 
monocytes and macrophages (Ansar Ahmed and Talal, 1990, Bouman et al., 2005, Gomez et al., 
2009), antigen presentation, the production of antimicrobial peptides such as human beta defensins 
(HBD), as well as the production of cytokines and chemokines (Wira et al., 2005a, Fahey et al., 
2006, Ochiel et al., 2008, Gravitt and Ghanem, 2010, Wira et al., 2010, Wira et al., 2011). Other 
factors, such as the use of antibiotics, corticosteroids, oral contraceptives and HRT have been 
shown to increase the susceptibility of women to fungal vaginal infections (Spinillo et al., 1995, 
Geiger and Foxman, 1996, Magliani et al., 2002). 
 
Figure 1.6. An illustration of the human lower female genital tract. The cervix is divided into two parts, 
the endocervix and the ectocervix, which is separated by a mucus plug. The endocervix forms a sterile canal 
into the upper genital tract, whereas the ectocervix together with the vagina are non-sterile environments and 
the portal of entry for pathogens. The type of epithelial cells in each anatomical site is highlighted. (Taken 
from Hladik and McElrath, 2008). 
 
1.7.1. Cytokine and chemokine milieu in the lower female genital tract  
A number of studies have reported that cytokines and chemokines are constitutively secreted by 
primary epithelial cells of the female genital tract (Shrier et al., 2003, Ochiel et al., 2008, Dubicke 
Endocervix: 












et al., 2010). These include IL-1, IL-2, IL-6, IL-8, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), TNF-α and macrophage 
inflammatory protein (MIP)-1β. Pro-inflammatory cytokines and chemokines such as IL-6, IL-8, 
IL-12 and RANTES, which stimulate and recruit immune cells to the site of infection, are pivotal 
for the propagation and progression of inflammation (Altman et al., 1999, Dinarello, 2000, 
Fernandez and Lolis, 2002, Kayisli et al., 2002, Melchjorsen et al., 2003, Fahey et al., 2005, Wira et 
al., 2005b, Ochiel et al., 2008). Conversely, to control the course of the inflammatory process, anti-
inflammatory cytokines such as IL-10 are released (Opal and DePalo, 2000). In this way 
homeostasis is maintained to avoid the onset of unfavourable chronic inflammation (Pascual and 
Glass, 2006). 
 
The cytokine milieu in the vaginal and ectocervical mucosa is a vital determinant of inflammation 
and most likely susceptibility to infections such as HIV-1 (Gravitt and Ghanem, 2010, Kaushic et 
al., 2010). As pro- and anti-inflammatory cytokines are suggested to play opposing roles in the 
pathogenesis, transmission, susceptibility and resistance of HIV-1 (Fichorova, 2004), it is proposed 
that maintenance of a balance between pro- and anti-inflammatory mediators in the female genital 
tract is important. Acute inflammation in the female genital tract is considered a beneficial process 
to provide protection against intracellular pathogens (Hasko and Szabo, 1999, Barousse et al., 2007, 
Hamza et al., 2010), while chronic inflammation due to enhanced pro-inflammatory cytokine 
production by the epithelial cells of the female genital tract, and the consequent increase in the 
recruitment of HIV-1 target cells (e.g. CD4+ T cells and macrophages) into the site of infection, has 
been suggested to increase HIV-1 susceptibility (Bebell et al., 2008, Gumbi et al., 2008, 
Nkwanyana et al., 2009, Kaushic et al., 2010, Nazli et al., 2010, Mian and Ashkor, 2011, Roberts et 






known to be key role players during various types of infections, including HIV-1, and regulate the 
balance between pro- and anti-inflammatory immune responses (Trinchieri and Scott, 1995b, 
Trinchieri and Gerosa, 1996, Trinchieri, 1998, Schottelius et al., 1999, Leifeld et al., 2002, Pestka et 
al., 2004, Nemeth et al., 2005, Couper et al., 2008).  
 
1.7.1.1. IL-12 
IL-12 is produced during the early events of the immune response in response to pathogens, mainly 
by immune cells such as monocytes, macrophages, neutrophils and dendritic cells (Trinchieri and 
Scott, 1995b, Becker et al., 2001, Trinchieri, 2003, Watford et al., 2003, Del Vecchio et al., 2007). 
However, IL-12 can also be produced by non-immune cells such as epithelial and endothelial cells, 
infected-keratinocytes and osteoblasts (Aragane et al., 1994, Bost et al., 1999). Secretion of IL-12 
induces the activation of NK and cytotoxic T cells, which subsequently induce the production of 
interferon (IFN)-γ and other pro-inflammatory cytokines, stimulate proliferation of the activated 
NK and T cells, as well as enhancing the cytotoxic functions of the activated NK and T cells (figure 
7) (Kobayashi et al., 1989, D'Andrea et al., 1992, Brunda, 1994, Trinchieri, 2003). In addition to its 
pro-inflammatory function, IL-12 also acts as an immunoregulator (Trinchieri and Scott, 1995b, 
Trinchieri and Gerosa, 1996, Trinchieri, 1998).  
 
IL-12 is a 70 kDa heterodimeric glycoprotein consisting of two disulfide-linked subunits, a heavy 
chain of 40 kDa (IL-12p40) and a light chain of 35 kDa (IL-12p35) (Kobayashi et al., 1989, Stern et 
al., 1990, Aragane et al., 1994, Trinchieri and Scott, 1995b, Chizzonite et al., 1998, Trinchieri, 
2003, Byrnes et al., 2008), which are encoded by two separate genes, located on different 
chromosomes (Sieburth et al., 1992). Co-expression of the covalently linked IL-12p40 and IL-






et al., 1989, Hasko and Szabo, 1999). The IL-12p40 gene is regulated at the level of transcription, 
whereas the IL-12p35 gene is regulated at both the level of transcription and translation (Watford et 
al., 2003).  
 
 
Figure 1.7. Schematic representation of cis-regulatory elements found in the promoters of human (A) 
IL-12p40, (B) IL-12p35 and (C) IL-10.  
 
Human IL-12p40 gene expression can be regulated via several inducible transcription factors 
binding to specific regulatory elements within the IL-12p40 promoter. These regulatory elements 
are situated in close proximity to each other (figure 1.7A), and include a C/EBPβ binding site, a 
NFĸB half-site, an AP-1 binding site and specific protein (Sp)-1 sites (Jones and Tjian, 1985, 












2001, Cao et al., 2002, Chambers et al., 2004, Ma et al., 2004). In contrast to the human IL-12p40 
promoter, not much is known about the human IL-12p35 promoter. Transcriptional regulation of the 
human IL-12p35 gene is poorly characterized and appears to be quite complex (Hayes et al., 1998, 
Goriely et al., 2003). It is speculated that the proximal promoter of the human IL-12p35 gene 
contains IFN responsive elements, several GREs as well as elements for NFĸB, AP-1, Sp1 and 
C/EBP (figure 1.7B) (Kollet et al., 2001, Mirani et al., 2002).  
Despite its protective role, overproduction of IL-12 causes damage to normal tissues (Trinchieri, 
1997, Suzuki et al., 2002). To suppress the prolonged or excessive release of IL-12, anti-
inflammatory cytokines such as IL-10, IL-4, IL-13, transforming growth factor (TGF)-β, IFN-α, 
IFN-β and prostaglandin E2 (PGE2) are produced (D'Andrea et al., 1993, Kubin et al., 1994b, 




IL-10, originally known as cytokine synthesis inhibiting factor (CSIF) (Fiorentino et al., 1989), is 
produced by several immune cells such as CD4+ and CD8+ T cells, B cells, NK cells, dendritic 
cells, lymphocytes, monocytes and macrophages, as well as keratinocytes and epithelial cells 
(Fiorentino et al., 1989, Ma et al., 2001, Moore et al., 2001, Asadullah et al., 2003, Mocellin et al., 
2003). IL-10 functions as a key immunoregulator during infections due to its potent anti-
inflammatory and immunosuppressive activities (Schottelius et al., 1999, Pestka et al., 2004, 
Nemeth et al., 2005, Couper et al., 2008). It exerts its anti-inflammatory effects by inhibiting the 
activity of Th cells, NK cells and macrophages (Moore et al., 2001, Couper et al., 2008), thereby 






IFN-γ, as well as chemokines, such as RANTES and IL-8. In addition, IL-10 promotes the release 
of other anti-inflammatory cytokines (Selzman et al., 1998). 
 
Human IL-10 is a homodimeric protein (de Waal Malefyt et al., 1992, Moore et al., 1993, Pretolani, 
1999, Asadullah et al., 2003), which is regulated at the level of transcription by the binding of 
various inducible transcription factors to regulatory elements within IL-10 promoter (Kube et al., 
1995, Benkhart et al., 2000, Mosser and Zhang, 2008, Szalmas et al., 2008). These regulatory 
elements include (figure 1.7C), Sp1 binding sites, two putative signal transducer and activator of 
transcription (STAT) binding sites (STAT-1 and STAT-3), a C/EBPβ site, two AP-1 binding sites 
and GREs (Kube et al., 1995, Ma et al., 2001, Ziegler-Heitbrock et al., 2003, Kremer et al., 2007, 
Mosser and Zhang, 2008, Unterberger et al., 2008).  
 
1.7.2. HIV-1 entry through the female genital tract epithelium 
For HIV-1 to be successfully transmitted during heterosexual intercourse, the virus in the semen has 
to cross the mucosal barrier of the genital tract in order to infect HIV-1 target cells such as CD4+ T 
cells, macrophages and/or dendritic cells (reviewed in Hladik and McElrath, 2010; (Bobardt et al., 
2007, Kaushic et al., 2010). Evidence in the literature indicate that HIV-1 can bind and infect the 
stratified squamous epithelial cells of the ectocervix, and subsequently release the virus to infect 
susceptible leukocytes and CD4+ T cells in the mucosal stoma (Howell et al., 1997, Cummins and 
Dezzutti, 2000, Maher et al., 2005, Bobardt et al., 2007, Hladik and McElrath, 2008, Gali et al., 
2010, Haase, 2010). It has been suggested that local genital tract infection, due to HIV-1 infection 
of the cervicovaginal epithelium, can lead to the systemic spread of the virus (figure 1.8) (reviewed 






However, there has been no conclusive evidence of HIV-1 infection of the genital epithelium in 
vivo (reviewed in Shacklett, 2009 and Haase, 2010). 
 
Figure 1.8. Mucosal transmission of HIV-1 via the female genital tract can lead to the systemic CD4+ T 
cell depletion. Local genital tract infection of HIV-1 has been shown to cause systemic HIV-1 infection. 
Figure adapted from Haase, 2010.  
 
There are several lines of evidence to suggest that the HIV virus could exploit the host GR for 
successful pathogenesis and modulation of the host immune function. For example, AIDS patients 
have decreased innate and T-helper cell-directed immunity and muscle wasting (Kino et al., 2003), 
which could be explained by glucocorticoid-induced suppression of cytokines regulating the innate 






AIDS is the decrease in the expression of the pro-inflammatory cytokine gene IL-12 in peripheral 
blood mononuclear cells (PBMCs) (Chehimi and Trinchieri, 1994, Ma and Montaner, 2000, Byrnes 
et al., 2008). In contrast, IL-10 levels have been reported to increase during HIV-1 infection 
(Trinchieri and Scott, 1995a, Li and Lau, 2007). Elevated IL-10 protein levels in the female genital 
tract have been proposed to enhance HIV-1 acquisition (Cohen et al., 1999). On the other hand, it 
has been suggested that an increase in the production of IL-10 may reduce susceptibility to HIV-1 
infection and protect against disease progression (Naicker et al., 2009). A decrease in the IL-12/IL-
10 ratio in the epithelial cells of the vagina and cervix could lead to the inability to mount a Th1 
immune response, thereby weakening the defense mechanisms of the host against infections (Kelly 
et al., 1997, Stringer and Antonsen, 2008).  
 
The HIV-1 accessory viral protein R (Vpr) has been shown to affect the transcription of IL-12p35, 
but not IL-12p40 or IL-10 in human PBMCs (Mirani et al., 2002). Vpr, a small 14 kDa protein 
consisting of 96 amino acids, is one of fifteen viral proteins encoded by the HIV-1 retrovirus RNA 
genome (reviewed in Li et al., 2005; (Emerman, 1996b, Le Rouzic and Benichou, 2005, Morellet et 
al., 2009, Romani and Engelbrecht, 2009) and has been recognised as a vital pathogenic 
determinant of HIV-1 (Andersen and Planelles, 2005). Deletion of the Vpr gene has been found to 
yield HIV-1 strains that are not capable of maintaining successful infection in monocytes, thereby 
dramatically reducing the virulence of HIV-1 (Hattori et al., 1990, Westervelt et al., 1992, Levy et 
al., 1995). Consistent with this, inhibition of Vpr expression produces HIV-1 strains that decrease 
HIV-1 replication in monocytes (Balotta et al., 1993).  
 
Exogenous Vpr can invade various cells such as monocytes, macrophages, dendritic cells, resting 






Andersen and Planelles, 2005, Li et al., 2010). This protein has the ability to penetrate cell 
membranes and could potentially also exert its effects on epithelial cells (Hapgood and 
Tomasicchio, 2010). In addition to being found inside virions in cells, Vpr has also been detected in 
the nucleus of infected cells (Andersen and Planelles, 2005), as well as in blood plasma and 
cerebrospinal fluid of infected individuals (Paxton et al., 1993, Mirani et al., 2002, Le Rouzic and 
Benichou, 2005, Li et al., 2005). This protein has been shown to have a wide range of effects on the 
host (reviewed in Romani and Engelbrecht, 2009; (Ayyavoo et al., 1997, Le Rouzic and Benichou, 
2005, Li et al., 2005, Varin et al., 2005, Romani and Engelbrecht, 2009, Li et al., 2010). For 
example, it enhances viral replication and affects transcriptional regulation of several viral 
promoters, including the HIV-1 LTR promoter, and/or target genes of the host. In addition, Vpr 
facilitates nuclear translocation of viral DNA as a component of the HIV-1 pre-integration complex, 
induces host cell arrest in the G2/M phase of the cell cycle, induces apoptosis of infected cells, as 
well as decreases the antigen-mediated CD4+ and CD8+ response thereby promoting replication of 
the HIV-1 virus within the host (Kino et al., 1999, Sherman et al., 2000, Ayyavoo et al., 2002, Kino 
et al., 2002, Mirani et al., 2002, Le Rouzic and Benichou, 2005).  
 
Several studies using in vitro cell culture models have described an interaction between Vpr and the 
human GR (Refaeli et al., 1995, Kino et al., 1999, Muthumani et al., 2006); reviewed in Hapgood 
and Tomasicchio, 2010). As both Vpr and the host GR have been reported to affect viral replication, 
as well as transcriptional regulation of host genes (Kino et al., 1999, Sherman et al., 2000, Mirani et 
al., 2002, Muthumani et al., 2004), it has been suggested that the host GR is used by HIV-1 Vpr to 
achieve successful pathogenesis (reviewed in Hapgood and Tomasicchio, 2010).  
Kino and co-workers have shown that Vpr acts as a co-activator for the GR in the presence of the 






associates with the co-factors p300/CBP and SRC-1, as well as the transcription factors TFIIB, 
TFIID and TFIIH to increase the transcriptional activity of the GR (Kino et al., 1999, Kino et al., 
2002). In addition, Muthumani and co-workers showed that a GR-Vpr complex is required for Vpr-
mediated transcriptional suppression of NFĸB (Muthumani et al., 2006). A role for the GR was 
suggested in mediating some of the effects of Vpr (Schafer et al., 2006), as the GR antagonist 
mifepristone (RU486) blocked the Vpr-repressed cytokine production and T-cell proliferation. 
 
1.8. Conclusion 
The synthetic progestins MPA, NET-EN and NET-A are used by millions of women in 
contraception, HRT and other therapeutic applications. Although a number of side-effects are 
associated with the clinical use of these progestins, not much is known about their mechanism of 
action at the cellular level, particularly with respect to their effects on infections such as HIV. The 
importance of investigating these mechanisms is highlighted by the clinical evidence showing that 
the contraceptive use of MPA increases susceptibility to genital tract infections such as HSV-2 and 
HIV-1 (Clemetson et al., 1993, Mostad et al., 1997, Mostad et al., 2000, Kaushic et al., 2003, 
Wang, 2004, Morrison et al., 2010, Heffron et al., 2012). Epithelial cells of the female genital tract 
may serve as the first targets for the initial infection by sexually transmitted HIV-1 (Howell et al., 
1997, Cummins and Dezzutti, 2000, Maher et al., 2005, Bobardt et al., 2007, Hladik and McElrath, 
2008). Understanding the effects of MPA and NET on local immune function in this environment is 
likely to play a critical role in understanding the effects of MPA and/or NET on sexually 
transmitted infections. However, surprisingly little research has been done to investigate the effects 
of MPA and NET-A on immune function in the female genital tract. Our recent study using human 
ectocervical and vaginal epithelial cell lines as in vitro models for mucosal immunity, showed that 






RANTES in a ligand-, promoter- and cell-specific manner (Africander et al., 2011a). Clearly more 
research is needed to investigate the relative effects of MPA and NET-A on immune mediators in 
the female genital tract, in particular target genes involved in the inflammatory process. This may 
shed light on the molecular events occurring during infections and may assist with the design of 
new progestins with fewer side-effects. 
 
1.9. Hypothesis and Aims of study  
Little is known about the molecular mechanism of the synthetic progestins MPA and NET-A in the 
lower female genital tract, specifically their role on local ectocervical epithelial immune function 
and risk of susceptibility to infections. However, previous studies have indicated differential 
regulation of pro-inflammatory genes by MPA and NET-A. To this end, the primary hypothesis of 
this thesis was that these progestogens would differentially regulate the cytokine gene expression of 
IL-12 and IL-10 in the cervical mucosa as part of the lower female genital tract. Furthermore, it was 
hypothesised that the HIV-1 accessory Vpr would modulate the effects of MPA and/or NET-A on 
IL-12 and IL-10 gene expression in the female genital tract.  
Using an immortalised human ectocervical epithelial (Ect1/E6E7) cell line from the ectocervix, 
shown to constitutively express a wide variety of pro- and anti-inflammatory mediators which are 
upregulated in response to TNF-α (Fichorova and Anderson, 1999, Steele and Fidel, 2002), as an in 
vitro model system for mucosal immunity, the aims of this project were three-fold:  
 
Firstly, the regulation of the TNFα-induced pro-inflammatory cytokines IL-12p40 and IL-12p35, as 
well as the anti-inflammatory cytokine, IL-10, in response to the endogenous hormone Prog, and 
the synthetic progestins, MPA and NET-A, was investigated. Considering that the GR is known to 






a role for the GR in mediating the effects of these ligands by re-evaluating the regulation of IL-
12p40 and IL-10 gene expression when the endogenous GR protein levels were reduced. 
 
Secondly, the mechanism by which the GR mediates the effects of Prog, MPA and NET-A on IL-
12p40 and IL-10 gene expression was further examined by investigating which cis-regulatory 
elements within these promoters are required for the responses, as well as the transcription factor(s) 
involved.  
 
Thirdly, the possible modulation of the progestogen-induced regulation of IL-12p40, IL-12p35 and 
IL-10 gene expression by HIV-1 accessory protein Vpr was investigated. Furthermore, a putative 
role of the GR was investigated as it has previously been suggested that the host GR can be 
































2.1. Cell culture 
The human ectocervical epithelial cell line (Ect1/E6E7) immortalised with the E6 and E7 genes of 
the human papilloma virus 16 (HPV-16) was purchased from American Type Culture Collection 
(ATCC, USA). This cell line was maintained in keratinocyte serum-free medium (KSFM) 
(GibcoBRL, Paisley, UK or Sigma-Aldrich, South Africa) supplemented with 50 µg/ml bovine 
pituitary extract (BPE) (GibcoBRL, Paisley, UK or Sigma-Aldrich, South Africa), 0.1 ng/ml human 
epidermal growth factor (EGF) (GibcoBRL, Paisley, UK or Sigma-Aldrich, South Africa), CaCl2 to 
a final concentration of 0.4 mM, 100 IU/ml penicillin and 100 µg/ml streptomycin (penicillin-
streptomycin) (Gibco-BRL Life Technologies, United Kingdom). These cells were maintained at 
37°C in 75 cm2 culture flasks (Greiner Bio-One International, Austria), at 90% humidity and 5% 
CO2. These cells were passaged when a confluency of ~60 % was reached, and detached from the 
flask surface by the addition of trypsin (Highveld Biologicals, South Africa) for 10 minutes. The 
proteolytic activity was inhibited by adding 5 ml neutralisation medium (Dulbecco’s Modified 
Eagle’s Medium (DMEM)/F-12 nutrient mixture (Ham) (1:1) (Gibco-BRL Life Technologies, 
United Kingdom), 10% (v/v) fetal calf serum (FCS) (Sigma-Aldrich, South Africa) and 1% 
penicillin-streptomycin. Thereafter the cells were pelleted by centrifugation at 1 000 rpm for 5 
minutes. The pellet was subsequently resuspended in supplemented KSFM (see above) and 
maintained in 75 cm2 culture flasks as described above. Ect1/E6E7 cells were regularly tested for 
Mycoplasma infection by means of Hoechst staining (Freshney RI, 1987) and only Mycoplasma-
negative cells were used in experiments. A representative photograph of mycoplasma-negative 






2.2. Test compounds 
Prog (4-pregnene-3, 20-dione), MPA (6α-methyl-17α-hydroxy-progesterone acetate), NET-A (17α-
ethynyl-19-nortesterone 17β-acetate), Dex (11β, 16α-9-fluoro-11, 17, 21-trihydroxy-16-
methylpregna-1, 4-diene-3, 20-dione), cortisol (11β, 17α, 21-trihydroxy-4-pregnene-3, 20-dione), 
dihydrotestosterone (DHT; 5α-androstan-17β-ol-3-one), and β-estradiol (E2; 17β-estra-1, 3, 5 (10)-
triene-3, 17-diol) were purchased from Sigma-Aldrich, South Africa. NET-A, the acetate, was used 
as it is soluble in water compared to the insoluble ester, NET-EN. In vivo, both NET-A and NET-
EN are hydrolysed to NET and its metabolites (Stanczyk and Roy, 1990). Mibolerone (Mib; 17β-
hydroxy-7α, 17α-dimethylestr-4-en-3-one) was purchased from PerkinElmer Life and Analytical 
Science, South Africa. Stock solutions of all the test compounds were prepared in 100% ethanol and 
stored in light-protective screw cap glass vials at -20°C. These compounds were added to serum-
free culturing medium to obtain a final ethanol concentration of 0.1%. The cells were incubated 
with 0.1% ethanol to serve as control. [3H]-Dex (82.8 Ci/mmol) and [3H]-E2 (110 Ci/mmol) were 
purchased from AEC-Amersham (South Africa). Tumor necrosis factor-alpha (TNF-α) was 
purchased from Sigma-Aldrich, South Africa and used at a final concentration of 0.02 µg/ml.  
 
2.3. Plasmids  
The plasmid expressing the human GR, pRS-hGRα, was received as a gift from Prof. R. Evans 
(Havard Hughes Medical Institute, La Jolla, United States of America). Plasmids expressing the 
human AR, pSV-ARo (previously described by Brinkmann et al. 1989), as well as the human PR 
isoforms A and B, pSG5-hPRA and pSG5-hPRB respectively (previously described by Kastner et 
al. 1990), were a kind gift from Prof. Frank Claessens (University of Leuven, Leuven, Belgium). 
The plasmids expressing the human ERα (pSG5-ERα) and β (pSG5-ERα) isoforms, respectively, 






while the pCMV4-3HA.Vpr plasmid, previously described by Sherman et al., 2000, was received 
from Dr Warner Greene (University of California, San Francisco). The following promoter-reporter 
constructs were used: the plasmid pTAT-2xGRE-E1b-luciferase, driven by the E1b promoter and 
containing two copies of the rat TAT-GRE (described in (Sui et al., 1999) was a kind gift from Dr. 
G. Jenster (Erasmus University of Rotterdam, Netherlands) and 5x NFκB-luciferase was purchased 
from Strategene (Houston, Texas, USA). Depending on which steroid receptor was transfected, two 
different β-galactosidase (β-gal) plasmids were used to correct for the transfection efficiencies: the 
cytomegalovirus (CMV)-driven β-gal (received from Prof Guy Haegeman) and pSV-driven β-gal 
(Promega, Madison, USA). The pGL2basic vector (Promega, Madison, USA) was used as a filler 
plasmid. Plasmid DNA was purified using either the EndoFree® Plasmid Maxi Kit (Qiagen GmbH, 
Germany) or the PureYieldTM Plasmid Maxiprep System kit (Promega, Madison, USA) according 
to the manufacturer’s instructions. Except for the pRS-hGRα and pCMV4-3HA.Vpr plasmids, all 
other plasmids were only used in Addendum C. 
 
2.4. Promoter-reporter assays 
For transactivation assays, the Ect1/E6E7 cell line was maintained as above and seeded into 24-well 
tissue culture plates (Greiner Bio-One International, Austria) at 5 x 104 cells per well. On day 2, the 
cells were transiently transfected with 300 ng of the promoter-reporter construct pTAT-2xGRE-
E1b-luc, 30 ng of the expression vector for the hGR, hAR or the filler plasmid pGL2basic, and 30 
ng β-gal, using FuGENE 6 transfection reagent (Roche Molecular Biochemicals, South Africa) 
according to the manufacturer’s instructions. pSV-β-gal was co-transfected with the hGR, while 
pCMV-β-gal was co-transfected with the hAR. On day 3, the cells were incubated with 0.1% 






For transrepression assays, the human Ect1/E6E7 cell line was maintained as above and seeded into 
24-well tissue culture plates at 5 x 104 cells per well. On day 2, the cells were transiently transfected 
using FuGENE 6 transfection reagent (Roche Molecular Biochemicals, South Africa) according to 
the manufacturer’s instructions as follows: For the GR: 100 ng NFĸB-luc, 50 ng pGL2basic and 25 
ng pSV-βgal. For the AR: 400 ng NFĸB-luc, 70 ng pGL2basic and 70 ng pCMV-βgal. On day 3, 
the cells were incubated with 0.02 µg/ml TNF-α in the absence (0.1% ethanol) and presence of 10 
µM Dex (GR) or Mib (AR), respectively, for 24 hours.  
 
The cells were subsequently washed once with 1x PBS, harvested in 50 µl passive lysis buffer 
(0.2% (v/v) Triton, 10% (v/v) glycerol, 2.8% (v/v) TRIS-phosphate-EDTA and 1.44 mM EDTA) 
per well and then incubated for 15 minutes at room temperature, while shaking. The lysed cells 
were subsequently thawed and 10 µl of each lysate was used to determine the luciferase and β-
galactosidase activities in black 96-well cliniplates (Thermo Scientific, Finland). The luciferase 
(Promega Luciferase Assay System, Madison, USA) as well as the β-gal assays (Galacto-StarTM 
assay system, Applied Biosystems, USA) were performed in a Veritas microplate luminometer. The 
amount of luciferase and β-gal present in each sample are expressed as relative light units (RLU). 
To correct for variances in transfection efficiencies the luciferase activity was normalised to the 
constitutively expressed β-gal activity. See Addendum C for promoter-reporter assay results. 
 
2.5. Whole cell binding assays  
Competitive whole cell binding assays were performed essentially as described by Bamberger et al. 
(1995), with the following modifications (Koubovec et al., 2005). To confirm binding of the test 
compounds used in this study to the endogenously expressed GR in the human Ect/E6E7 cell line, 






density of 1 x 105 cells per well. On day 3, the cells were washed three times with 1xPBS, pre-
warmed to 37 °C, and incubated for 6 hours at 37°C with 10 nM 3[H]-Dex (82.8 Ci/mmol) (AEC-
Amersham, South Africa), in the absence (total binding) and presence of 1 µM unlabelled (non-
specific binding) Dex, Prog, MPA, NET-A or cortisol, respectively. To determine the endogenous 
ER levels in the human Ect1/E6E7 cell line, cells were seeded into 12-well tissue culture plates 
(Greiner Bio-One International, Austria) at a density of 2 x 105 cells per well. On day 3, the cells 
were washed three times with 1x PBS, pre-warmed to 37°C, and incubated for 2 hours at 37°C with 
10 nM 3[H]-E2 (110 Ci/mmol) (AEC-Amersham, South Africa), in the absence (total binding) and 
presence of 10 µM unlabelled E2 (non-specific binding). Working on ice at 4°C, all cells were 
washed three times, for 15 minutes, with ice-cold 1x PBS containing 0.2% (w/v) bovine serum 
albumin (BSA) to remove any unbound ligand. For the GR, cells were lysed with 100 µl reporter 
lysis buffer (Promega, Madison, USA) at room temperature for 15 minutes with agitation, while 
200 µl reporter lysis buffer was used for the ER. Thereafter, the lysate was transferred to 
scintillation vials containing 1.5 ml scintillation fluid (Quickszint FLOW 2, Zinsser Analytic, South 
Africa) and the total binding measured by scintillation counting as counts per minute (cpm) using a 
Tri-Carb 2810 scintillation counter. Specific binding (total binding minus non-specific binding) was 
normalised to the protein concentration, determined by using the Bradford protein assay method 
(Bradford, 1976). The reported values are averages of three independent assays, with each condition 
performed in triplicate.  
 
The ER numbers in ƒmol/mg protein were determined as follows: 
The specific activity of the 3[H]-E2 (Ci/mmol) was converted to disintegrations per minute (dpm) 
per mmol, by multiplying the Ci/mmol by a factor of 2.22 x 1012 (1 Curie equals 2.22 x 1012 dpm). 






and then divided by 1012 to get specific activity in cpm/ƒmol. The specific binding cpm value was 
then divided by this value to give the specific binding in ƒmol. To yield the number of binding sites 
in ƒmol/mg protein, the specific binding (ƒmol) was divided by the protein content of the sample in 
mg. The ER binding data are shown in Addendum C. 
 
2.6. Western blotting 
The human Ect1/E6E7 cell line was maintained as above and plated into either 24-well- (1.5 x 105 
cells per well), 12-well- (1 x 105 cells per well) or 6-well tissue culture plates (Greiner Bio-One 
International, Austria) (2.5 x 105 cells per well). For positive controls, COS-1 cells (1 x 105 cells per 
well in a 12-well plate) were transiently transfected with 250 ng DNA of a particular steroid 
receptor expression vector, while untransfected COS-1 cells were used as a negative control. The 
cells were washed with ice cold 1x PBS and lysed with 2x SDS-polyacrylamide gel by 
electrophoresis (PAGE) loading buffer (100 mM TRIS-HCl, pH6.8, 20% (v/v) glycerol, 5% (w/v) 
SDS, 0.1% (w/v) bromphenol blue, and 2% (v/v) β-mercaptoethanol) (Sambrook et al., 1989). All 
lysates were denatured by boiling for 10 minutes at 97°C. Protein samples were separated on a 10% 
SDS-PAGE at 200 V for 45 minutes using a 1xSDS-PAGE buffer (35 mM SDS, 250 mM TRIS, 
1.92 M glycine). Following electrophoresis, the proteins were electroblotted at 180 mA for 1 hour 
onto an Immobilon®-P transfer polyvinylidene fluoride (PVDF) membrane (Millipore Corporation, 
USA) using ice-cold 1x transfer buffer (25 mM TRIS, 192 mM glycine, 10% (v/v) methanol). The 
membranes were then blocked for 90 minutes in 10% (w/v) fat-free milk powder in 1x TRIS 
buffered saline (TBS) containing 0.1% (v/v) Tween-20 (TBST). Thereafter the membranes were 
probed with the antibodies specific for the GR (H-300), AR (441), PR-A/B (AB-52), PR-B (B-30), 
MR (H-300), ERα (M-20), ERβ (H-150), C/EBPβ (C-19), STAT-3 (C-20), GAPDH (0411), 






influenza virus (12CA5, Roche Applied Biotechnology Inc., USA), or β-actin (4967, Cell 
Signalling Technology, Massachusetts, USA) (Table 2.1) for 16 hours at 4°C. GAPDH, Hsp90 and 
β-actin were used as loading controls. The membranes were subsequently washed with TBST, once 
for 15 minutes and three 5 minute washes before incubating with HRP-conjugated secondary 
antibodies (goat anti-rabbit or anti-mouse) (Santa Cruz Biotechnology Inc., CA, USA) for 90 
minutes at room temperature. The membranes were washed again as indicated above, and then 
visualised using Pierce® ECL Western blotting substrate (Thermo Scientific Inc., USA) and ECL 
Hyperfilm (GE Healthcare Amersham, USA) or medical X-ray film (Africa X-Ray Industrial and 
Medical (Pty) LTD., South Africa). All the antibody dilutions used in this study are summarised in 
Table 2.1. Western Blots showing the expression of steroid receptors in the human ectocervical 
epithelial cell line, Ect1/E6E7, are shown in Addendum C. 
 
2.7. Isolation of total RNA and complementary DNA (cDNA) synthesis 
The human Ect1/E6E7 cell line was plated in 12-well tissue culture plates (Greiner Bio-One 
International, Austria) at a density of 1 x 105 cells per well. Cells were incubated with test 
compounds as described in the figure legends and the total RNA was isolated from the cells using 
Tri-reagent (Sigma-Aldrich, South Africa). Briefly, the cells were lysed by adding 400 µl Tri-
reagent to the cells, transferring the lysates to 1.5 ml microcentrifuge tubes and incubating for 5 
minutes at room temperature. Thereafter, 80 µl chloroform was added and the mixture was vortexed 
for 1 minute. Samples were incubated for 2-3 minutes at room temperature before centrifugation at 
12 200 g for 15 minutes at 4°C. The aqueous phase was transferred to a new tube and an equal 
volume of ice-cold isopropanol was added. Samples were vortexed for 15 seconds and incubated for 







Table 2.1. Primary and secondary antibody dilutions used for Western blotting. 




GR 1:4 000 goat anti-rabbit 1:10 000 
AR 1:1 000 goat anti-mouse 1:5 000 
PR-A/B 1:500 goat anti-mouse 1:2 000 
PR-B 1:500 goat anti-mouse 1:2 000 
MR 1:200 goat anti-rabbit 1:2 000 
ERα 1:200 goat anti-rabbit 1:5 000 
ERβ 1:1 000 goat anti-rabbit 1:1 000 
HA 1:400 goat anti-mouse 1:1 000 
C/EBPβ 1:1 000 goat anti-rabbit 1:2 000 
STAT-3 1:1 000 goat anti-rabbit 1:4 000 
GAPDH 1:2 000 goat anti-mouse 1:4 000 
Hsp90 1:5 000 goat anti-rabbit 1:2 000 
β-Actin 1:1 490 goat anti-rabbit 1:10 000 
 
 
pellet the RNA. The pellets were washed with 500 µl 75% (v/v) ethanol (100% ethanol diluted in 
diethyl pyrocarbonate (DEPC) water). Samples were vortexed (±1 min) and centrifuged at 8 000 g 
for 5 min at 4°C. The supernatant was aspirated and the RNA pellets were allowed to air dry for 5-
10 minutes on ice. RNA was dissolved in 15 µl DEPC-treated water. The RNA concentration was 






determined. The integrity of the 28S and 18S ribosomal bands was confirmed on 1% denaturing 
formaldehyde agarose gels. A representative gel picture is shown in addendum B (figure B.1.1). 
RNA samples were stored at -80°C.  
 
Total RNA extracted from the Ect1/E6E7 cell line was reverse transcribed using the transcriptor 
first strand cDNA synthesis Kit (Roche Applied Science, South Africa) according to the 
manufacturer’s instructions. Briefly, 1 µg total RNA, 2.5 µM anchored-oligo(dT)18-primer and 
PCR-grade water, if needed, was added to a final volume of 13 µl. This template-primer mixture 
was incubated for 10 minutes at 65°C to denature the RNA secondary structures and immediately 
placed on ice. Then, 1x transcriptor reverse transcriptase reaction buffer, 20 U protector RNase 
inhibitor, 1 mM deoxynucleotide (dNTP) mix and 10 U transcriptor reverse transcriptase was 
added. The samples were subsequently incubated for 1 hour at 50°C, after which the reaction was 
stopped by placing the samples at 85°C for 5 minutes to inactivate the transcriptor reverse 
transcriptase. The cDNA samples were stored at -20°C until needed. 
 
2.8. Realtime quantitative polymerase chain reaction (qPCR) 
Realtime qPCR was performed by using a Light-Cycler, rapid thermal cycler system (Roche 
Applied Science, South Africa) according to the manufacturer’s instructions. Reagents in the 
LightCycler-FastStart DNA Masternon-plus SYBR Green I system (Roche Diagnostics, South Africa) 
were used. The PCR reaction mixture was prepared by adding the forward and reverse primers 
(final concentration of 0.5 µM each), MgCl2 (final concentration of 3 mM for both IL-12p40 and 
IL-10, 2 mM for IL-12p35 or 4 mM for GAPDH), LightCycler SYBR green I non-plus master mix 
and PCR-grade water to a final volume of 9 µl per sample. Thereafter, 1 µl cDNA template or PCR 






the Roche FastStart Taq polymerase, followed by denaturation at 95°C for 10 seconds. The 
annealing temperatures for 10 seconds are indicated in Table 2.2, and this was followed by 
extension at 72°C for 10 seconds (for all genes except GAPDH). For GAPDH, the thermal profile 
was denaturation at 95°C for 10 seconds, annealing at 59°C (Table 2.2) for 10 seconds and 
extension at 72°C for 12 seconds. Typically 45 repeats of the three PCR steps were used. Agarose 
gel electrophoresis and melting curve analysis were performed to confirm the presence of a single 
amplicon, as well as the amplicon size. A cDNA dilution series was used to generate a standard 
curve so as to determine the amplification efficiency of each primer set (Table 2.2). The relative 
transcript levels of the target genes were calculated using the mathematical model described by 






Table 2.2. Primer sequences and annealing temperatures for all genes investigated. 
Gene Primers 










































307 59 1.86 








2.9. Small interference RNA (siRNA) transfection 
The human Ect1/E6E7 cell line was plated in 12-well tissue culture plates at a density of 1 x 105 
cells per well. On day 2, the cells were transfected with 10 nM validated non-silencing scrambled 
sequence control (NSC) siRNA (Qiagen, USA) or GR HS_NR3C1_6 siRNA (cat # S102654764, 
Qiagen, USA) or GR_HS_NR3C1_5 siRNA (cat# S102654757, Qiagen, USA) directed against 
human GR, or C/EBPβ siRNA (sc-29229; Santa Cruz Biotechnology, USA) directed against human 
C/EBPβ, or STAT-3 siRNA (sc-29493; Santa Cruz Biotechnology, USA) directed against human 
STAT-3, using HiPerfect transfection reagent (Qiagen, USA) according to the manufacturer’s 
instructions. Briefly, GR, C/EBPβ, STAT-3 or NSC siRNA was diluted in pre-warmed Optimem 
medium with GlutaMAXTM (GibcoBRL, Paisley, UK), to which 2.95 µl transfection reagent was 
added. The transfection mixture was incubated at room temperature for 10 minutes and then added 
drop-wise directly to the cells. After 24 hours, the cells were treated with 0.02 µg/ml TNF-α and 
either 0.1% ethanol (control) or 1 µM test compound for 6 hours. For experiments determining the 
role of the GR in mediating effects of Vpr, cells were transiently transfected with 1 µg pCMV4-
3HA.Vpr, 24 hours later, using FuGENE 6 transfection reagent (Roche Molecular Biochemicals, 
South Africa) according to the manufacturer’s instructions. RNA was harvested, cDNA synthesised 
and IL-12p40, IL-12p35 and IL-10 gene expression was quantified by realtime qPCR as described 
in Sections 2.7 and 2.8, respectively. Reduction in the protein levels were confirmed by Western 
blot analysis, as described in Section 2.6. 
 
2.10. Multiplex bead array and ELISA 
The human Ect1/E6E7 cell line was plated in 12-well tissue culture plates (Greiner Bio-One 
International, Austria) at a density of 1 x 105 cells per well for the Multiplex bead array, and in 6-






were transfected with 10 nM GR6 or NSC siRNA, respectively, and after 24 hours either left 
untreated (–Vpr) or transiently transfected with 1 µg pCMV4-3HA.Vpr (+Vpr), and incubated for a 
further 24 hours. The cells were subsequently treated with 0.02 µg/ml TNF-α and 0.1% EtOH 
(control) or 1 µM Prog, MPA, NET-A or cortisol for 24, 48 or 96 hours. The supernatants were 
collected, and protease inhibitors (1x Complete Mini Protease Inhibitor Cocktail; Roche Applied 
Science, South Africa) were added.  
 
The human 8-plex luminex assay (Millipore, Missouri, USA) was used to simultaneously quantify 
the protein levels of IL-6, IL-8, IL-10, IL-12p40, IL-12p70, macrophage inflammatory protein 
(MIP)-1α, MIP-1β and RANTES in the Ect1/E6E7 cell culture supernatants according to the 
manufacturer’s instructions. All samples, as well as two quality controls included in the kit, were 
analysed in duplicate. The levels of all the analytes in the quality controls were within the expected 
ranges. A standard curve ranging from 3.2 pg/ml to 10 000 pg/ml was used for all the cytokines, 
and Bio-Plex Manager Software, version 4.1.1., was used to analyse the data.  
 
The protein levels of IL-12p40 and IL-10 in the cell culture supernatants were quantified by ELISA, 
using the human IL-12/IL-23 (p40) ELISA Max Deluxe set (Biolegend, USA) and human IL-10 
ready-set-go kit (eBioscience, USA), respectively, according to the manufacturer’s instructions. All 
samples were analysed in duplicate. The standard curve ranged from 62.5 pg/ml to 4 000 pg/ml for 
IL-12p40, and 2 pg/ml to 300 pg/ml for IL-10. All standards were analysed in triplicate. 
 
2.11. Co-immunoprecipitation (Co-IP) assay 
Co-IP assays were performed as described by Avenant et al. (2010), with the following 






density of 2 x 106 cells. After 48 hours, the cells were incubated with 0.02 µg/ml TNF-α and 0.1% 
EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 1 hour. The cells were washed twice 
with cold PBS and harvested in 500 µl radio-immunoprecipitation (RIPA) buffer (50 mM TRIS-
HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing 
protease inhibitors (1x Complete Mini Protease Inhibitor Cocktail; Roche Applied Science, South 
Africa). After two cycles of freeze-thaw, the cells were collected, centrifuged at 16 000 g for 10 
minutes at 4°C, and the supernatants collected. The input samples were prepared by adding 10 µl 
2xSDS-PAGE loading buffer (Sambrook et al., 1989) to 20 µl of the supernatant, and samples 
stored at – 20°C. The remaining lysate was pre-blocked to reduce the non-specific binding of 
proteins to the protein A/G PLUS beads. This was done by adding 5 µg anti-IgG and 20 µl 50:50 
(v/v) pre-blocked protein A/G PLUS beads (sc-2003, Santa Cruz Biotechnology, USA) to the 
supernatant and incubating for 1 hour at 4°C on a rotating wheel. These pre-blocked protein A/G 
PLUS beads were prepared by incubating 500 µl of the beads with 2 ml IP dilution buffer (see 
above), salmon sperm DNA (final concentration 0.2 mg/ml) and bovine serum albumin (BSA) 
(final concentration 1 mg/ml) for 1 hour at 4°C on a rotating wheel. This was followed by 
centrifugation at 1 500 g for 5 minutes at 4°C, and the beads were subsequently resuspended as a 
50% slurry in IP dilution buffer containing protease inhibitors (see above). The pre-blocked samples 
were centrifuged at 14 000 g for 10 minutes at 4°C and the supernatant collected for 
immunoprecipitation. The Co-IP samples were prepared by adding 2 µg anti-GR antibody (H-300, 
Santa Cruz Biotechnology Inc., USA) to the pre-cleared supernatants, followed by incubation 
overnight at 4°C on a rotating wheel. The following day, 20 µl 50:50 (v/v) pre-blocked protein A/G 
PLUS beads were added to the mixture and incubated for 2 hours at 4°C on a rotating wheel. The 
samples were then centrifuged at 1 000 g for 1 minute at 4°C and the beads were washed twice with 






boiled for 5 minutes, before centrifugation at 16 000 g for 10 minutes at room temperature to collect 
the supernatant. The immuneprecipitates were subjected to electrophoresis on a 10% SDS 
polyacrylamide gel Western blot analysis was performed as described in Section 2.6. 
 
2.12. Chromatin immunoprecipitation (ChIP) and re-ChIP assays  
2.12.1. Treatment of Ect1/E6E7 cells 
To determine whether the GR is recruited to the endogenous IL-12p40 and IL-10 promoters in the 
human Ect1/E6E7 cell line, the basic method described by Ma and co-workers (2003) was followed 
with a few modifications (Avenant et al., 2010a, Verhoog et al., 2011). The human Ect1/E6E7 cell 
line was seeded in 14 cm2 tissue culture dishes at a density of 1 x 107 cells per dish. After 72 hours, 
the supplemented KSFM was aspirated and replaced with unsupplemented KSFM. Following 24 
hours, the cells were treated with 0.02 µg/ml TNF-α and 0.1% ethanol (control) or 1 µM Prog, 
MPA, NET-A or cortisol for 2 hours.  
 
2.12.2. Formaldehyde cross-linking, lysing of cells and DNA fragmentation 
Following the 2 hour incubation period, 37% formaldehyde was added directly to the medium to a 
final concentration of 1%, and incubated for 10 minutes at 37°C to allow for cross-linking of the 
proteins and the chromatin. To stop the cross-link, glycine to a final concentration of 0.125 M was 
added to the mixture, while shaking and incubated, for 5 minutes at room temperature. The cells 
were subsequently washed twice with ice-cold PBS, scraped and harvested in PBS containing 
protease inhibitors (1x Complete Mini Protease Inhibitor Cocktail tablet; Roche Applied Science, 
South Africa), followed by centrifugation at 1 200 g for 10 minutes at 4°C.  The cell pellets were 
resuspended in 500 µl nuclear lysis buffer (1% (w/v) SDS, 50 mM TRIS-HCl (pH 8.0), 10 mM 






sonicator (Qsonica, South Africa), the cell lysates were sonicated on 75% power for 50 cycles at 30 
seconds per cycle, with 30 second intervals between pulses, causing fragmentation of the DNA to 
sizes of between 100 and 500 bp. A representative gel picture is shown in addendum A (figure 
B.2.1). The sonicated chromatin was centrifuged at 15 000 g for 10 min at 4°C to pellet the cell 
debris. The supernatant was transferred to a clean microcentrifuge tube and the amount of A260 
units/µl in the sonicated lysate was measured on a NanoDrop (ND-100 Spectrophotometer). 
Nuclear lysis buffer was used to dilute samples to equal chromatin concentration. For the input 
samples, ~30 µg of the diluted sonicated chromatin was made up to a volume of 30 µl with nuclear 
lysis buffer, and further diluted with 90 µl IP dilution buffer (0.01% (w/v) SDS, 20 mM TRIS-HCl 
(pH 8.0), 1.1% (v/v) Triton-X-100, 167 mM NaCl, 1.2 mM EDTA and 1x Complete Mini Protease 
Inhibitor Cocktail tablet per 10 ml). The input samples were stored at -80°C, whilst remaining 
sonicated chromatin was immediately prepared for immunoprecipitation.  
 
2.12.3. Preparation of the sonicated cell lysate for immunoprecipitation 
A total of ~100 µg sonicated chromatin in 100 µl  nuclear lysis buffer containing protease inhibitors 
(1x Complete Mini Protease Inhibitor Cocktail tablet per 10 ml) was diluted with 900 µl IP dilution 
buffer containing protease inhibitors (see above). To reduce the non-specific binding, the chromatin 
was pre-blocked by adding 20 µl 50:50 (v/v) pre-blocked protein A/G PLUS beads (sc-2003, Santa 
Cruz Biotechnology, USA) and incubating for 1 hour at 4°C on a rotating wheel. These pre-blocked 
protein A/G PLUS beads were prepared as described above. The pre-cleared chromatin was 
centrifuged at 15 000 g for 10 minutes at 4°C, and the supernatants were transferred to a new 
microcentrifuge tube, and 5 µg primary antibody (anti-GR or anti-IgG) added. This mixture was 
incubated overnight at 4°C on a rotating wheel. The following day, 40 µl pre-cleared protein A/G 






before centrifugation at 5 000 g for 1 minute at 4°C. To remove DNA and proteins non-specifically 
associated with the protein A/G PLUS beads, the pellet was washed sequentially with 1 ml of each 
of the wash buffers I, II and III: wash buffer I (0.1% SDS, 1% (v/v) Triton-X-100, 2 mM EDTA, 20 
mM TRIS-HCl (pH 8.0) and 150 mM NaCl), wash buffer II (0.1% SDS, 1% (v/v) Triton-X-100, 2 
mM EDTA, 20 mM TRIS-HCl (pH 8.0) and 500 mM NaCl) and wash buffer III (1% (v/v) NP-40, 
1% (w/v) sodium deoxycholate, 500 mM LiCl, 1 mM EDTA and 10 mM TRIS-HCl (pH 8.0). This 
was followed by a further three washes with 1 ml TE buffer (10 mM TRIS-HCl (pH 8.0) and 0.1 
mM EDTA). The immunoprecipitated DNA-protein complexes were eluted from the protein A/G 
PLUS beads twice with 150 µl elution buffer (1% (w/v) SDS and 100 mM NaHCO3) at room 
temperature, while on a rotating wheel for 15 minutes. 
 
2.12.4. Isolation and purification of DNA associated with the immunoprecipitated protein 
To reverse the cross-linking, NaCl to a final concentration of 300 nM, was added to the eluted 
DNA-protein complexes, as well as the input samples, and incubated overnight at 65°C. The next 
day, EDTA (final concentration of 15 nM), TRIS-HCl (final concentration of 125 nM) and 60 ng/ml 
proteinase K (Roche Applied Science, South Africa) were added to the samples, prior to a further 
incubation for 1 hour at 45°C to digest the proteins. Both immunoprecipitated- and input DNA were 
purified using the NucleoSpin® Extract II kit (Thermo Scientific Inc., USA) according to the 
manufacturer’s instructions.  
 
2.12.5. Analysis of DNA coupled with the immunoprecipitated protein 
The purified immunoprecipitated- and input DNA were analysed using realtime qPCR using 
primers specific for cis-elements of the IL-12p40 and IL-10 promoters (see Table 2.3). For the IL-






while AP-1, Sp1 and STAT-3 regulatory elements were investigated for the IL-10 promoter. It is 
important to note that some primers span more than one regulatory element, as certain cis-elements 
are located in close proximity to each other. All primers used for the ChIP and re-ChIP assays were 
designed by the candidate. As a positive control, to verify that the GR ChIP assay is working the 
recruitment of the GR to the GRE-containing glucocorticoid-induced leucine zipper (GILZ) 
promoter using the following primer set: (forward) 5’-AGTTAAGCTCCTGATTTAAGAAG-3’, 






Table 2.3. Primers specific for cis-elements of the IL-12p40 and IL-10 promoters used in ChIP and re-ChIP assays. 
Cis-element Position relative to 
transcription start site 
Primers 
(5’ - 3’) 





HUMAN IL-12p40 PROMOTER 


















HUMAN IL-10 PROMOTER 
















All samples were incubated at 95°C for 10 minutes to activate the Roche FastStart Taq polymerase, 
followed by the denaturation at 95°C for 10 seconds, annealing for 10 seconds (see temperature in 
Table 2.3), followed by extension at 72°C for 10 seconds. Typically 40 repeats of the three PCR 
steps were used for all primer pairs. Agarose gel electrophoresis and melting curve analysis were 
performed to confirm the presence of a single amplicon, as well as the amplicon size. The relative 
protein recruitment was calculated by the method described by Pfaffl with slight modifications 
(Pfaffl, 2001) as the primer efficiency was assumed to be 2 and normalised relative to input, which 
was set as one. 
 
For the chromatin reimmunoprecipitation (re-ChIP) assay (a few modifications were made to the 
protocol received from Prof Susanne Mandrup, Department of Biochemistry and Molecular 
Biology, University of Southern Denmark), the immunoprecipitated DNA-protein complexes were 
eluted at 37°C by incubation for 30 minutes in 100 µl elution buffer (1% (w/v) SDS and 10 mM 
dithiothreitol (DTT)), while on a rotating wheel. The supernatants were diluted 10 times with the 
ChIP dilution buffer without SDS (20 mM TRIS-HCl (pH 8.0), 1.1% (v/v) Triton-X-100, 167 mM 
NaCl, 1.2 mM EDTA and 1x Complete Mini Protease Inhibitor Cocktail tablet per 10 ml), and 100 
µl of the diluted chromatin was stored at -80°C as control for the first immunoprecipitation. The 
remaining sonicated chromatin was diluted with 1 ml IP dilution buffer and reimmunoprecipitated 
with an antibody specific for either C/EBPβ or STAT-3 before analysing as above.  
 
2.13. Data manipulation and statistical analysis 
GraphPad Prism® version 5 (GraphPad Software, Inc., San Diego, CA) was used for data 
manipulation, graphical presentations and statistical analysis. Unless otherwise stated in the figure 
legends, one-way ANOVA analysis of variance, with Dunnett’s (compares all columns vs. control 





column graphs. For grouped analysis (response is affect by two factors), two-way ANOVA analysis 
of variance with Bonferroni’s (compares all pairs of columns) post–test was used. Statistically 
significant differences are indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001, 
respectively, whereas no statistical significance (p>0.05) is indicated by ns. The letters a,b,c etc. are 
also used to denote statistically significant differences, where all those values which differ 
significantly from others, are assigned a different letter. Unless otherwise indicated, the error bars 












BRIEF INTRODUCTION, RESULTS AND DISCUSSION 
 
THE MOLECULAR MECHANISM OF PROGESTIN-INDUCED 
REGULATION OF INTERLEUKIN (IL)-12p40 AND IL-10 IN A 












3.1. Brief Introduction 
The female genital tract (cervicovaginal environment) consist of the vagina and ectocervix, which 
are both considered to be non-sterile environments, as well as the endocervix, a more sterile 
environment. Epithelial cells lining the female genital tract are capable of eliciting both innate and 
acquired local immune responses at the mucosal surface against invading pathogens. These 
epithelial cells have properties enabling them to fight infections, such as the production of cytokines 
and chemokines (Shrier et al., 2003, Ochiel et al., 2008, Dubicke et al., 2010). Although the vagina 
is the first compartment exposed to potential pathogens, the ectocervix is proposed to be the first 
target site to become infected with sexually transmitted HIV-1 (Howell et al., 2005, Hladik and 
Hope, 2009, Kaushic et al., 2010). It is suggested that this is mainly due to HIV-1 target cells such 
as CD4+ T cells and macrophages being prevalent in this region (Pudney et al., 2005). 
 
Contraceptive use of MPA has been shown associated with increased cervical shedding of HIV 
DNA (Clemetson et al., 1993, Mostad et al., 1997, Wang, 2004). Although the precise mechanism 
is not known, it has been suggested that it may be due to altered physiology of the local genital tract 
or modulating cervical immunity. Whether NET-A has similar effects is not known. Thus, 
investigating the effects of MPA, as well as NET-A on immune responses in the female genital 
tract, particularly the mechanisms of immune gene regulation in the cervicovaginal environment 
may further our understanding of the factors affecting mucosal immunity and hence shed light on 
determinants of susceptibility. In light of the above, this study investigated the effects, and the 
underlying molecular mechanisms, of MPA and NET-A, relative to Prog, on mucosal immunity, by 
comparing their regulation of the endogenous cytokine genes, IL-12p40 and IL-10. The human 
Ect1/E6E7 epithelial cell line, generated from normal human ectocervical cells and immortalized by 
expression of the E6 and E7 genes of HPV 16 (Fichorova et al., 1997), was used as an in vitro cell 






3.2.1. Prog, MPA and NET-A upregulate IL-12p40 mRNA expression, while IL-10 mRNA 
expression is downregulated 
The human Ect1/E6E7 cell line was treated with 0.02 µg/ml TNF-α and 0.1% EtOH (control) or 1 
µM Prog, MPA or NET-A for 6 hours, followed by qPCR analysis for the mRNA expression of IL-
12p40 and IL-10, respectively. Figures 3.1A and 3.1B shows the TNF-α induction of IL-12p40 and 
IL-10 mRNA expression, while figures 3.1C and 3.1D show the effects of the ligands on the mRNA 
expression of the cytokine genes. Surprisingly, Prog, MPA and NET-A significantly (p<0.001) 
upregulated IL-12p40 gene expression (figure 3.1C). Conversely, all the ligands significantly 
(p<0.001) downregulated the mRNA expression of the IL-10 gene (figure 3.1D). Interestingly, no 
significant differences were detected between any of the ligands in the regulation of IL-12p40 or 
IL-10. The effects of Prog, MPA and NET-A on IL-12p40 and IL-10 protein levels were also 
investigated, using a combination of Multiplex bead array and ELISA. The Ect1/E6E7 cell line was 
treated with 0.02 µg/ml TNF-α and 0.1% EtOH (control) or 1 µM Prog, MPA or NET-A for 24, 48 
and 96 hours, respectively. No conclusions could be drawn from these results, as negligible IL-







































































































































































Figure 3.1. Effect of Prog, MPA and NET-A on the TNF-α induced expression of IL-12p40 and IL-10 
in the human ectocervical cell line. The human Ect1/E6E7 cell line was incubated with 0.02 µg/ml TNF-α 
in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA or NET-A for 6 hours. Total RNA was isolated 
and reversed transcribed to cDNA. Realtime qPCR was performed to determine the mRNA expression levels 
of IL-12p40 (A and C) and IL-10 (B and D), using GAPDH as the internal standard. Results shown are the 
averages (± SEM) of at least four independent experiments. Relative IL-12p40 and IL-10 mRNA expression 
of treated samples were calculated relative to vehicle control (EtOH), which was set as one. One-way 
ANOVA analysis of variance and Bonferroni (compares all pairs of columns) post-tests were used for 













3.2.2. A role for the GR in the regulation of IL-12p40 and IL-10 mRNA expression by Prog, 
MPA and NET-A  
As we have previously shown that the endogenously expressed GR in the Ect1/E6E7 cell line is the 
only endogenous steroid receptor transcriptionally active in both a transactivation and 
transrepression assay (Africander et al., 2011a), and it is known that both MPA and NET-A bind to 
the GR (Koubovec et al., 2005), we hypothesised that the regulation of the IL-12p40 and IL-10 
genes by Prog, MPA and NET-A is mediated via the GR. Using competitive whole cell binding 
assays we confirmed binding of Prog, MPA and NET-A to the endogenously expressed GR in the 
human Ect1/E6E7 cell line (figure 3.2A). We show that at 1 µM, there is no statistical difference in 
the total specific binding of the synthetic glucocorticoid Dex, the natural glucocorticoid cortisol, 
Prog or MPA to the endogenous GR. In agreement with a previous study, NET-A has a lower 
binding affinity for the GR, than Prog and MPA. Next, we used Western blotting to determine 
whether Prog, MPA and NET-A, in the presence of TNF-α, have an effect on the endogenous GR 
protein levels. Ect1/E6E7 cells treated with the ligands in the presence of TNF-α for 6 hours were 
analysed by means of Western blotting using antibodies specific for the GR and GAPDH (loading 
control). The results showed that none of the ligands had any effect on the GR protein levels after 6 





























































         







































Figure 3.2. Prog, MPA and NET-A bind to the endogenous GR in the Ect1/E6E7 cell line, but do not 
modulate GR protein levels. (A) The human Ect1/E6E7 cell line was incubated with 10 nM [3H]-Dex in the 
absence (total binding) and presence of 1 µM unlabelled (non-specific binding) Dex, Prog, MPA, NET-A or 
cortisol for 6 hours. Percentage specific binding (total binding minus non-specific binding) is plotted. 
Binding of the test compounds to the GR is shown relative to binding of Dex set as 100%. One-way 
ANOVA analysis of variance and Dunnett (compare all columns versus control (Dex) column) was 
performed as post-test (B) Whole cell extracts were prepared from the human Ect1/E6E7 cell line treated 
with 0.02 µg/ml  TNF-α in the presence of  0.1% EtOH or 1 µM Prog, MPA, NET-A or cortisol for 6 hours 
to harvest total protein. Protein lysates were subjected to electrophoresis on a 10% SDS polyacrylamide gel. 
The GR protein levels were analysed using a GR-specific antibody. GAPDH was used as a loading control. 
A single representative gel of at least three independent experiments is shown. (C) GR protein levels were 
quantified using UN-SCAN-IT and normalised to the quantified GAPDH levels. The effect of the test 
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To further investigate the role of the GR in mediating the regulation of Prog, MPA and NET-A on 
the IL-12p40 and IL-10 genes the GR was silenced using siRNA transfections. The Ect1/E6E7 cell 
line was transfected with validated GR-specific siRNA oligonucleotides or non-silencing RNA 
oligonucleotides (control) for 48 hours, followed by treatment with 0.02 µg/ml TNF-α in the 
presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. To confirm 
GR knockdown, Western blot analysis confirmed reduction of GR protein levels of approximately 
83% (figure 3.3A and 3.3B). Similar results were obtained when transfecting the GR-specific GR5 
siRNA oligonucleotides. Gene expression analysis by qPCR showed that, as expected, cortisol 
induced upregulation of IL-12p40 and downregulation of IL-10, was significantly reduced by the 
decrease in GR protein levels (figure 3.3C and 3.3D). Similarly, the decreased GR levels 
significantly inhibited the upregulation of IL-12p40 and downregulation of IL-10 by Prog, MPA 
and NET-A, indicating that the effect of these ligands on IL-12p40 and IL-10 genes is mediated via 
the GR. 
 
3.2.3. The GR is recruited to the endogenous IL-12p40 and IL-10 promoters in response to 
Prog, MPA and NET-A 
Having established that the GR is required for the Prog, MPA and NET-A induced regulation of 
both IL-12p40 and IL-10 gene expression, it was next investigated whether the GR could be 
recruited to the endogenous IL-12p40 and IL-10 promoters in the Ect1/E6E7 cells. This was done 
by chromatin immunoprecipitation (ChIP) assays, using a GR specific antibody for 
immunoprecipitation and primers spanning 190 bp of the IL-12p40 promoter containing both the 









































































































































































Figure 3.3. Decreasing GR protein levels by siRNA indicates a role for the GR in mediating the effects 
of Prog, MPA and NET-A on IL-12p40 and IL-10 mRNA expression in the Ect1/E6E7 cell line. 
Untransfected human Ect1/E6E7 cells, as well as cells transfected with 10 nM NSC or GR siRNA 
oligonucleotides, were either left untreated or treated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH 
(control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. (A) For verification of GR knockdown, total 
protein from the untreated cells were harvested to perform Western blotting, using antibodies specific for the 
GR and GAPDH. The latter was used as a loading control. A representative blot is shown. (B) GR expression 
levels relative to GAPDH were quantified using UN-SCAN-IT. Western blots of at least two independent 
experiments were quantified to determine the percentage GR protein knockdown. One-way ANOVA 
analysis of variance and Dunnett (compares all columns vs. control (NSC siRNA) column) post-test was 
used for statistical analysis. (C-D) Total RNA was isolated and reversed transcribed to cDNA. Thereafter 
realtime qPCR was performed to determine the mRNA expression levels of (C) IL-12p40 and (D) IL-10, 
using GAPDH as the internal standard. Relative IL-12p40 and IL-10 gene expression of treated samples was 
calculated relative to vehicle control (EtOH) of the NSC siRNA, which was set as one. Results shown are the 
average (± SEM) of at least three independent experiments. Two-way ANOVA analysis of variance and 
Bonferroni (compares all pairs of columns) post-tests were used for statistical analysis.  
 
elements, and 84 bp of the IL-10 promoter region containing both a specific protein (Sp)-1 and 
signal transducer and activator of transcription (STAT)-3 regulatory element. 
 
As there are no GRE sequences defined within the IL-12p40 promoter, other regulatory elements 
known to regulate IL-12p40 promoter activity were investigated. These include C/EBPβ and Sp1. 
Similarly, for the IL-10 promoter, cis-regulatory elements previously shown to be involved in the 
downregulation of IL-10 gene expression, such as Sp1 and STAT-3 (Steinke et al., 2004, Lee et al., 
2010) were investigated. Intact Ect1/E6E7 cells were treated with 0.02 µg/ml TNF-α in the presence 
of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 2 hours. As shown in figure 
3.4B and 3.5B, and as expected, the natural glucocorticoid cortisol caused significant recruitment of 
the GR to the NFkB-C/EBPβ region of the endogenous IL-12p40 and Sp1/STAT-3 region of the IL-
10 promoters, respectively. Similarly, the GR was also recruited to these sites on the endogenous 
IL-12p40 (figure 3.4B) and IL-10 (figure 3.5B) promoters in the presence of Prog, MPA and NET-
A. In contrast, we show no recruitment in the presence of all ligands to an AP-1 or Sp1 regulatory 





3.5C) in the IL-10 promoter. Interestingly, significant recruitment of the GR to the Sp1 binding site 
of the endogenous IL-12p40 promoter was observed with cortisol treatment. The IgG negative 
control confirmed the specificity of the GR antibody used for immunoprecipitation (figure 3.4 and 
3.5). For verification and validation of the ChIP assay, the recruitment of the GR, in response to all 
ligands, to the endogenous GRE-containing glucocorticoid-induced leucine zipper (GILZ) promoter 
was investigated in the Ect1/E6E7 cell line (figure 3.5D). We show recruitment of the GR to the 
GILZ promoter in response to all the ligands, except NET-A. These results suggest that the ligand 
(cortisol, Prog, MPA or NET-A) bound GR interacts with the NFkB-C/EBPβ cis-elements of the 
IL-12p40 promoter to enhance transcription of this gene, whereas recruitment of the liganded GR to 














































































































































































































































Figure 3.4. The GR is recruited to the NFkB-C/EBPβ region of the IL-12p40 promoter in response to 
cortisol, Prog, MPA and NET-A. Human Ect1/E6E7 cells were incubated with 0.02 µg/ml TNF-α in the 
presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 2 hours, followed by the ChIP 
assay. (A) A schematic illustration of the IL-12p40 promoter indicating the positions of the primer pairs. 
Immunoprecipitated GR protein bound to the endogenous IL-12p40 promoter was detected using primers 
encompassing (B) the NFkB-C/EBPβ, (C) AP-1 and (D) Sp1 regulatory elements. Immunoprecipitation with 
anti-IgG served as negative control. The co-immunoprecipitated DNA fragments and input DNA were 
analysed by realtime qPCR. Data shown are normalised to input and expressed as the fold-response relative 
to EtOH (control), which was set as one. Results shown are the average (± SEM) of at least three 
independent experiments. One-way ANOVA analysis of variance and both Bonferroni (compares all pairs of 





























































































































































































































































Figure 3.5. The GR is recruited to the Sp1/STAT-3 region of the IL-10 promoter in response to 
cortisol, Prog, MPA and NET-A. Human Ect1/E6E7 cells were incubated with 0.02 µg/ml TNF-α in the 
presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 2 hours, followed by the ChIP 
assay. (A) A schematic illustration of the IL-10 promoter indicating the positions of the primer pairs. 
Immunoprecipitated GR protein bound to the endogenous IL-10 promoter was detected using primers 
encompassing (B) the Sp1/STAT-3 and (C) GRE/Sp1 regulatory elements of IL-10, and (D) the GILZ 
promoter using primers spanning the equivalent of GREs 3-6. Immunoprecipitation with anti-IgG served as 
negative control. The co-immunoprecipitated DNA fragments and input DNA were analysed by realtime 
qPCR. Data shown are normalised to input and expressed as the fold-response relative to EtOH (control), 
which was set as one. Results shown are the average (± SEM) of at least three independent experiments. 
One-way ANOVA analysis of variance and both Bonferroni (compares all pairs of columns) and Dunnett 
(compares all columns vs. control (EtOH) column) post-tests were used for statistical analysis.  
 
3.2.4. C/EBPβ is required for the GR-mediated upregulation of the IL-12p40 gene in 
response to TNF-α and Prog, MPA or NET-A  
The finding that the GR is recruited to the region of the endogenous IL-12p40 promoter 
encompassing the NFkB and C/EBPβ cis-elements suggests that C/EBPβ, rather than NFkB, is 
involved in the transcriptional activation of the IL-12p40 gene, as tethering of the GR to NFkB is 
generally associated with the downreglation of pro-inflammatory cytokine genes (Smoak and 







role in the activation of the IL-12p40 promoter (Plevy et al., 1997, Becker et al., 2001). For this 
reason, the involvement of C/EBPβ in the ligand-dependent GR-mediated upregulation of IL-12p40 
mRNA expression was thus further investigated, by siRNA. The Ect1/E6E7 cell line was 
transfected with 10 nM validated C/EBPβ- or NSC-specific siRNA oligonucleotides, followed by 
treatment with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, 
NET-A or cortisol for 6 hours. Western blot analysis showed 54% reduction in the expression of 
endogenous C/EBPβ protein levels as compared to the NSC (figure 3.6A and 3.6B). Reduced 
C/EBPβ levels significantly reversed the cortisol-induced upregulation of IL-12p40 gene expression 
(figure 3.6C). Similarly, knockdown of C/EBPβ abrogated the upregulation of IL-12p40 by Prog, 
MPA and NET-A, indicating that C/EBPβ is required for the GR-mediated upregulation of IL-
12p40 gene expression in response to these ligands. 
 
Taken together, these results suggest that C/EBPβ is needed for the upregulation of IL-12p40 gene 
expression by Prog-, MPA- or NET-A- bound GR, suggesting that the GR and C/EBPβ are co-
recruited to the IL-12p40 promoter. Co-immunoprecipitation assays were thus used to investigate 
whether these two proteins interact with each other. The Ect1/E6E7 cell line was treated with 0.02 
µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 
an hour, and immunoprecipitated using a GR-specific antibody. Western Blot analysis confirmed 
the presence of the GR and C/EBPβ in the input samples (figure 3.7A). Figure 3.7B shows that the 
GR is present in all the immunoprecipitated samples, independent of the presence of ligand. When 
the same membrane was stripped to remove the anti-GR antibody, and reprobed with a C/EBPβ-
specific antibody, the results show that C/EBPβ co-immunoprecipitated with the GR in the presence 
of TNF-α, and that the presence of ligand does not disrupt this interaction. These results suggest 
that the liganded GR and C/EBPβ can occur in a complex in the Ect1/E6E7 cell line. However, due 





should be repeated by firstly probing with a C/EBPβ-specific antibody, followed by reprobing with 
a GR-specific antibody.  
  
























































































Figure 3.6. Reducing C/EBPβ protein by siRNA indicates a role for C/EBPβ in the GR-mediated 
upregulation of IL-12p40 gene expression in the Ect1/E6E7 cell line. Human Ect1/E6E7 cells were 
transfected with 10 nM NSC or C/EBPβ siRNA oligonucleotides and after 24 hours treated with 0.02 µg/ml 
TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. (A) For 
verification of C/EBPβ knockdown, total protein from the untreated cells were harvested to perform Western 
blotting using antibodies specific for C/EBPβ and Hsp90. The latter was used as a loading control. A 
representative blot is shown. (B) C/EBPβ expression levels relative to Hsp90 were quantified using UN-
SCAN-IT. Western blots of at least four independent experiments were quantified to determine the 
percentage C/EBPβ protein knockdown. (C) Total RNA was isolated and reversed transcribed to cDNA. 
Thereafter realtime qPCR was performed to determine the mRNA expression levels of IL-12p40, using 
GAPDH as the internal standard. Relative IL-12p40 gene expression of treated samples was calculated 
relative to vehicle control (EtOH) of the NSC siRNA, which was set as one. Results shown are the average 
(± SEM) of at least three independent experiments. Two-way ANOVA analysis of variance and Bonferroni 











Figure 3.7. The liganded GR and C/EBPβ occurs in a complex in the Ect1/E6E7 cell line. Human 
Ect1/E6E7 cells were incubated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM 
Prog, MPA, NET-A or cortisol for an hour. Cellular extracts were immunoprecipitated with a GR-specific 
antibody, and Western blots were probed firstly GR-specific antibody and then stripped and reporbed with 
the C/EBPβ antibody. A representative blot of three independent experiments is shown. (A) Both the GR and 
C/EBPβ are present in the input samples. (B) C/EBPβ co-immunoprecipitated with the GR only in the 
presence of ligand, indicating that the liganded GR and C/EBPβ can occur in a complex in the Ect1/E6E7 
cell line. 
 
Having shown that C/EBPβ is required for the upregulation of IL-12p40 gene expression by Prog, 
MPA and NET-A via the GR, and that the GR and C/EBPβ can occur as a complex, the co-
localisation of the GR-C/EBPβ protein complex on the endogenous IL-12p40 promoter was next 
investigated by using a re-ChIP assay. Intact Ect1/E6E7 cells were treated with 0.02 µg/ml TNF-α 
in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 2 hours. The 
immunoprecipitated GR-C/EBPβ proteins bound to the endogenous IL-12p40 promoter were 
detected using primers spanning 190 bp of the IL-12p40 promoter, which comprises the C/EBPβ 
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realtime qPCR. Similar results were obtained for the re-ChIP assay (figure 3.8A) when compared to 
that of the ChIP assay (figure 3.4B). Figure 3.8A shows that only the Prog, MPA and cortisol 
treatment resulted in significant recruitment. Although NET-A shows a possible recruitment of the 
GR-C/EBPβ complex to the C/EBPβ binding site in the IL-12p40 promoter, significance could not 
be established. Significance for NET-A could possibly be obtained by performing more 
experiments (increasing the “n” value), thereby increasing the statistical power of the experiments. 
The IgG negative control confirmed the specificity of this GR-C/EBPβ co-localisation on the IL-
12p40 promoter, as no recruitment of this complex was observed in the presence of an anti-IgG 
antibody (figure 3.8B). Taken together, our results show that, in response to Prog, MPA and 
possibly NET-A, the GR interacts with C/EBPβ, and that endogenous GR and C/EBPβ are in a 





























































































































Figure 3.8. The endogenous GR and C/EBPβ are in a complex recruited to the endogenous IL-12p40 
promoter in the Ect1/E6E7 cell line in response to Prog, MPA and NET-A. Human Ect1/E6E7 cells were 
incubated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or 
cortisol for 2 hours. Cell lysates were subjected to immunoprecipitation first with (A) the GR-specific 
antibody (ChIP) and then with the C/EBPβ antibody (re-ChIP) or (B) IgG. The immunoprecipitation DNA 
fragments and input DNA were analysed by realtime qPCR. Data shown are normalised to input and 
expressed as the fold-response relative to EtOH (control) in A, which was set as one. Results shown are the 
average (± SEM) of at least three independent experiments. One-way ANOVA analysis of variance and both 
Bonferroni (compares all pairs of columns) and Dunnett (compares all columns vs. control (EtOH) column) 











3.2.5. STAT-3 is required for the GR-mediated downregulation of IL-10 gene expression in 
response to MPA and NET-A  
The results indicating that the GR is recruited to the Sp1/STAT-3 regulatory elements of the 
endogenous IL-10 promoter, but not to Sp1/GRE regulatory elements, suggest that the STAT-3 
regulatory element is important for the transcriptional suppression of IL-10 gene expression. The 
involvement of the transcription factor STAT-3 in the ligand dependent GR-mediated 
downregulation of IL-10 mRNA expression was thus further investigated by siRNA. The 
Ect1/E6E7 cell line was transfected with 10 nM validated NSC siRNA or STAT-3-specific siRNA 
oligonucleotides, followed by treatment with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH 
(control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. Western blot analysis showed 55% 
reduction in the expression of endogenous STAT-3 protein levels as compared to the NSC (figure 
3.9A and 3.9B). Reduced STAT-3 levels significantly reversed the cortisol-induced downregulation 
of IL-10 (figure 3.9C). Similarly, the Prog, MPA and NET-A induced downregulation of IL-10 
gene expression was significantly attenuated by the decrease in STAT-3 levels, suggesting a role for 
STAT-3 in the GR-mediated downregulation of IL-10 gene in response to these ligands. 










   






















































































Figure 3.9. Reduced STAT-3 protein by siRNA indicates a role for STAT-3 in the GR mediated 
downregulation of IL-10 gene expression in the Ect1/E6E7 cell line. Human Ect1/E6E7 cells were 
transfected with 10 nM NSC or STAT-3 siRNA oligonucleotides and after 24 hours stimulated with 0.02 
µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. 
(A) For verification of STAT-3 knockdown, total protein from the untreated cells was harvested to perform 
Western blotting using antibodies specific for STAT-3 and GAPDH. The latter was used as a loading 
control. A representative blot is shown. (B) STAT-3 expression levels relative to GAPDH were quantified 
using UN-SCAN-IT. Western blots of at least four independent experiments were quantified to determine the 
percentage STAT-3 protein knockdown. (C) Total RNA was isolated and reversed transcribed to cDNA. 
Thereafter realtime qPCR was performed to determine the mRNA expression levels of IL-10, using GAPDH 
as the internal standard. Relative IL-10 gene expression of treated samples was calculated relative to vehicle 
control (EtOH) of the NSC siRNA, which was set as one. Results shown are the average (± SEM) of at least 
three independent experiments. Two-way ANOVA analysis of variance and Bonferroni (compares all pairs 








Taken together, these results suggest that STAT-3 is needed for the downregulation of IL-10 gene 
expression by Prog-, MPA- or NET-A- bound GR, suggesting that the GR and STAT-3 are co-
recruited to the IL-10 promoter. Co-immunoprecipitation assays were thus used to investigate 
whether these two proteins interact with each other. The Ect1/E6E7 cell line was treated with 0.02 
µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 
an hour, and immunoprecipitated using a GR-specific antibody. Western Blot analysis confirmed 
the presence of the GR and STAT-3 in the input samples (figure 3.10A). Figure 3.10B shows that 
the GR is present in all the immunoprecipitated samples, independent of the presence of ligand. 
When the same membrane was stripped to remove the anti-GR antibody, and reprobed with a 
STAT-3-specific antibody, the results like those observed for C/EBPβ, show that STAT-3 co-
immunoprecipitated with the GR, in the presence of TNF-α, and that the ligands do not disturb the 
interaction. These results suggest that the GR and STAT-3 can occur in a complex in the Ect1/E6E7 
cell line. No interaction between GR and STAT-3 was observed when immunoprecipitated with 
IgG. As for the GR-C/EBPβ co-immunoprecipitation assay (figure 3.7B), high signal background 
was observed for the GR Western blot. Thus, the co-immunoprecipitation assay should be repeated 
by firstly probing with a STAT-3-specific antibody, and then reprobing with a GR-specific 
antibody. 
 
Having shown that STAT-3 is required for the downregulation of IL-10 gene expression by Prog, 
MPA and NET-A via the GR, and that the GR and STAT-3 can occur as a complex, the co-
localisation of the GR-STAT-3 protein complex on the endogenous IL-10 promoter was next 
investigated by using a re-ChIP assay. Intact Ect1/E6E7 cells were treated with 0.02 µg/ml TNF-α 
in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 2 hours. The 
immunoprecipitated GR-STAT-3 proteins bound to the endogenous IL-10 promoter were detected 





element. The immunoprecipitated DNA fragments and input DNA were analysed by realtime 
qPCR. Similar results were obtained for the re-ChIP assay (figure 3.11A) when compared to that of 
the ChIP assay (figure 3.5B). The level of recruitment of the GR-STAT-3 complex to the 
endogenous IL-10 promoter at the STAT-3 binding site by Prog, MPA, NET-A and cortisol 
treatment didn’t significantly differ from each other (figure 3.11A). The IgG negative control 
confirmed the specificity of this GR-STAT-3 co-localisation on the IL-10 promoter, as no 
recruitment of this complex was observed in the presence of an anti-IgG antibody (figure 3.11B). 
Taken together, our results show that, in response to Prog, MPA and possibly NET-A, the GR 
interacts with STAT-3, and that endogenous GR and STAT-3 are in a common complex bound to 






Figure 3.10. The liganded GR and STAT-3 occurs in a complex in the Ect1/E6E7 cell line. Human 
Ect1/E6E7 cells were incubated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM 
Prog, MPA, NET-A or cortisol for an hour. Cellular extracts were immunoprecipitated with a GR-specific 
antibody, and Western blots were probed firstly with the GR-specific antibody and then stripped and 
reporbed with the STAT-3 antibody. A representative blot of three independent experiments is shown. (A) 
Both the GR and STAT-3 are present in the input samples. (B) STAT-3 co-immunoprecipitated with the GR 
only in the presence of ligand, indicating that the liganded GR and STAT-3 can occur in a complex in the 
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Figure 3.11. The endogenous GR and STAT-3 are in a complex recruited to the endogenous IL-10 
promoter in the Ect1/E6E7 cell line in response to Prog, MPA and NET-A. Human Ect1/E6E7 cells were 
incubated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or 
cortisol for 2 hours. Cell lysates were subjected to immunoprecipitation first with (A) the GR-specific 
antibody (ChIP) and then with the STAT-3 antibody (re-ChIP) or (B) IgG (re-ChIP). The 
immunoprecipitation DNA fragments and input DNA were analysed by realtime qPCR. Data shown are 
normalised to input and expressed as the fold-response relative to EtOH (control) in A, which was set as one. 
Results shown are the average (± SEM) of at least three independent experiments. One-way ANOVA 
analysis of variance and both Bonferroni (compares all pairs of columns) and Dunnett (compares all columns 














Inflammation in the female genital tract is influenced by immune mediators produced by epithelial 
cells (Givan et al., 1997, Ochiel et al., 2008), and may modulate the mucosal immune function 
(Alfano and Poli, 2005). For example, pro-inflammatory cytokines attract and stimulate immune 
cells, thereby promoting inflammation (Dinarello, 2000, Wira et al., 2005b, Ochiel et al., 2008), 
while anti-inflammatory cytokines reduce inflammation by suppressing the activity of pro-
inflammatory cytokines (Opal and DePalo, 2000). Correlation analysis suggest that an increase in 
inflammation of the human female genital tract may increase susceptibility to infections such as 
HIV-1 (reviewed in (Kaushic et al., 2010, Blish and Beaten, 2011, Roberts et al., 2012a), (Kreiss et 
al., 1994, Gumbi et al., 2008, Nkwanyana et al., 2009). Thus the cytokine milieu in the female 
genital tract, including the ectocervical mucosa, is thought to be a vital determinant of susceptibility 
to infections such as HIV-1 (reviewed in (Gravitt and Ghanem, 2010, Kaushic et al., 2010). The 
pro-inflammatory cytokine, IL-12, and anti-inflammatory cytokine, IL-10, have been reported to 
play a role in HIV-1 infection (Chehimi et al., 1992, Chehimi et al., 1994, Kelly et al., 1997, Cohen 
et al., 1999, Ma and Montaner, 2000, Little et al., 2006, Gee et al., 2007, Byrnes et al., 2008). A 
decrease in the secretion of IL-12 and an increase in IL-10 production may alter susceptibility of 
HIV-1. Several factors such as the female sex steroid hormones and hormonal contraceptives have 
been shown to modulate mucosal immunity in the female genital tract by modifying the cytokine 
milieu (reviewed in (Gravitt and Ghanem, 2010, Hel et al., 2010, Blish and Beaten, 2011, Wira et 
al., 2011), and thereby influence the balance between pro- and anti-inflammatory immune 
responses. Understanding factors such as endogenous hormones or hormonal contraception that 
may influence the local immune response in the cervicovaginal environment is essential, as it is the 
first portal of entry for HIV-infection. Little is known about the effects of the synthetic progestins 
MPA and NET-A widely used in contraception on local epithelial immune function. Our recent 





immunity, showed that Prog, MPA and NET-A differentially regulate TNF-α induced pro-
inflammatory cytokine (IL-6) and chemokine (IL-8 and RANTES) gene expression, in a ligand-, 
promoter- and cell-specific manner (Africander et al., 2011a). Using the human ectocervical 
epithelial cell line (Ect1/E6E7) as an in vitro cell culture model system for mucosal immunity, the 
present study investigated the effects, and the underlying mechanisms, of Prog, MPA or NET-A on 
the mRNA expression of the cytokines, IL-12 and IL-10. The Ect1/E6E7 cell line expresses 
characteristics of multiple layers of stratified squamous non-keratinising epithelial cells (Fichorova 
et al., 1997, Fichorova and Anderson, 1999, Quayle, 2002, Wira et al., 2005a, Wira et al., 2005b), 
and expresses a number of immune mediators either constitutively or when stimulated with TNF-α 
(Fichorova and Anderson, 1999). For the purpose of this study, the ectocervical cell line was treated 
with TNF-α to mimic infection in the non-sterile ectocervical environment.  
 
The general observation was that Prog, MPA and NET-A significantly upregulate the expression of 
the pro-inflammatory cytokine gene IL-12p40 (figure 3.1C), while significantly downregulating the 
expression of the anti-inflammatory cytokine gene IL-10 (figure 3.1D). Considering that these 
cytokine genes are known to have opposing roles in the inflammatory response, the results from this 
study showing opposing effects on IL-12p40 and IL-10 gene expression were not unexpected. 
Surprisingly however, was the fact that Prog upregulated IL-12p40 gene expression. Several studies 
have previously shown that Prog inhibits the production of IL-12 or IL-12p40 in other cell types 
(Par et al., 2003, Enomoto et al., 2007, Hughes et al., 2008, Jones et al., 2008). Similarly, the 
contraceptive use of MPA has previously been shown to downregulate the protein expression of IL-
12p40 in human peripheral blood mononuclear cells (PBMCs) (Kleynhans et al., 2011). However, it 
has been reported that IL-12 levels were higher in the vaginal lavage fluid of adolescent female 
Depo-Provera users, than non-users (Barousse et al., 2007). In agreement with this, the protein 





contraceptives (Gravitt et al., 2003). The results showing downregulation of IL-10 by Prog and 
MPA are consistent with other studies. For example, IL-10 produced in PBMCs have been shown to 
be downregulated in MPA users (Kleynhans et al., 2011), while MPA decreased the 
lipopolysaccharide (LPS)-induced IL-10 mRNA and protein levels in the cervix of mice (Elovitz 
and Gonzalez, 2008). Nonetheless, a number of other studies have shown that Prog has no effect on 
the protein production of IL-10 (reviewed in Bouman et al., 2005; (Visser et al., 1998, Shrier et al., 
2003, Jones et al., 2008, Hickey et al., 2012). To the best of our knowledge, our study is the first to 
report on the gene regulation of IL -12p40 and IL10 by NET-A. Attempts to determine the effects 
of these ligands on IL-12p40 and IL-10 protein levels (Addendum A, figure A3) were less 
successful. Although there are some changes in response to certain ligands, these results may not be 
significant as the absolute protein concentration values determined were at the lower end of the 
standard curve. Thus, further optimisation of these experiments need to be performed.  
 
The physiological implications of our results are potentially important and should be considered in 
the light of the fact that a balance between pro- and anti-inflammatory cytokines should be 
maintained in order to mediate homeostasis in the cervicovaginal environment. Our results showing 
upregulation of the pro-inflammatory IL-12 gene and downregulation of the anti-inflammatory IL-
10 gene by the progestins, suggest that the balance is disrupted, favouring a pro-inflammatory 
milieu, and thus promoting chronic inflammation. Initially, the upregulation of IL-12p40 gene 
expression in the ectocervix may be protective, as IL-12 plays an important role in the early events 
of an immune response and is essential in the defense against pathogens (Hasko and Szabo, 1999, 
Barousse et al., 2007, Hamza et al., 2010), for example Chlamydia trachomatis infection (Cummins 
and Doncel, 2009). It has also been shown that the addition of exogenous IL-12 protected thermally 
injured mice against local HSV-1 infection (Matsuo et al., 1996). On the other hand, it has been 





mediators. Thus long term use of MPA or NET-A, as in the case of contraception, may lead to 
chronic inflammation of the ectocervical environment, which may increase a women’s risk of 
susceptibility to viral infections such as HIV-1 and HSV. Consistent with a pro-inflammatory 
environment increasing susceptibility to HIV-1, Naicker and co-workers proposed that a decrease in 
the production of IL-10 in blood may increase susceptibility to HIV-1 and enhance disease 
progression (Naicker et al., 2009). However, a limitation of this study is that only a single cell line 
was used as an in vitro model for mucosal immunity. Based on the results from a recent study 
conducted by our group showing ligand-, promoter- and cell-specific effects of MPA and NET-A, it 
may be that the effects of the progestogens on IL-12p40 and IL-10 gene expression is cell-specific. 
For this reason, it would be ideal to investigate the regulation of the IL-12p40 and IL-10 genes by 
the progestogens using other cell lines. 
 
Considering that our previous study showed that the GR is the only endogenous steroid receptor 
transcriptionally competent in both transactivation and transrepression in the Ect1/E6E7 cell line 
(Africander et al., 2011a), the role of the GR in the regulation of the mRNA expression of IL-12 
and IL-10 by the progestogens was further investigated. Firstly using competitive whole cell 
binding and Western blotting, we showed that Prog, MPA and NET-A bind to the endogenous GR 
in the Ect1/E6E7 cell line (figure 3.2A) and that none of these ligands modulate GR protein levels 
(figure 3.2B and 3.2C). Secondly, using siRNA to reduce the GR protein levels, the progestin-
mediated upregulation of IL-12p40 (figure 3.3C) and downregulation of IL-10 (figure 3.3D) was 
significantly attenuated. As this study showed that the effects of the progestogens on IL-12p40 and 
IL-10 mRNA expression was completely lost when the GR protein levels were reduced, the role of 
other steroid receptors endogenously expressed in this cell line was not investigated. The finding 
that MPA upregulates IL-12p40 gene expression and downregulates IL-10 gene expression via the 





responsible for its anti-inflammatory effects (Bamberger et al., 1999, Kurebayashi et al., 2003, 
Koubovec et al., 2004, Koubovec et al., 2005). Similarly, the lack of anti-inflammatory activity of 
the natural glucocorticoid cortisol was also somewhat unexpected (John et al., 1998, Richards et al., 
2000, Mozo et al., 2003, Peek et al., 2005). Generally GR ligands, including Dex, cortisol and 
MPA, downregulate pro-inflammatory immune mediators and upregulate anti-inflammatory 
immune mediators (reviewed in De Bosscher and Haegeman, 2009). However, our study shows that 
this is not always the case. Consistent with our results (figure 3.3C and 3.3D), GR ligands such as 
Dex have been shown to elicit pro-inflammatory immune responses in other cell types (Visser et al., 
1998, Lannan et al., 2012). In addition, a role for the GR in the Prog-induced downregulation of IL-
12p40 in macrophages (Jones et al., 2008) has been shown. 
 
Considering that Prog, MPA and NET-A have previously been shown to have different relative 
binding affinities (RBAs) and transcriptional activities via the GR (reviewed in Africander et al., 
2011b; (Kontula et al., 1983, Koubovec et al., 2005, Ronacher et al., 2009), it was surprising that, in 
these cells, these progestogens displayed similar effects on IL-12 and IL-10 gene regulation via the 
GR. As it has recently been shown that MPA and NET-A differentially regulate cytokine gene 
expression, in a ligand-, cell- and promoter-specific manner (Africander et al., 2011a), 
discrepancies between the results from this study, showing similar activities of MPA and NET-A on 
IL12p40 and IL-10 gene expression via the GR in the ectocervical epithelial cell line, and those 
showing differing activities on synthetic GRE-containing promoters in COS-1 and human 
embryonic kidney cells (HEK293), may be due to either cell- or promoter-specific effects. The 
hypothesis of a promoter-specific effect is further strengthened by the result in this study showing 
that the GR is recruited to the endogenous GRE-containing GILZ promoter (Chen et al., 2006) in 





recruitment of the GR to this promoter in response to NET-A, it would be of interest to investigate 
whether MPA and NET-A differentially regulate GILZ gene expression in the Ect1/E6E7 cell line. 
 
The classically accepted mechanism of GR function, is transactivation via direct binding of the 
ligand-bound GR to glucocorticoid response elements (GREs) within promoters of target genes, 
while transrepression would occur via direct protein-protein interactions between the liganded GR 
and other transcription factors such as NFĸB, AP-1 or C/EBP (Edwards et al., 1995, Cato and 
Wade, 1996, McKay and Cidlowski, 1999, Webster and Cidlowski, 1999, De Bosscher et al., 2000, 
Newton, 2000, Osborne et al., 2000, Almawi and Melemedjian, 2002, De Bosscher et al., 2003, 
Leonhardt et al., 2003, Zhou and Cidlowski, 2005, Liberman et al., 2007, Kramarova et al., 2009, 
Africander et al., 2011b). The latter protein-protein interaction is referred to as a tethering 
mechanism. However, human IL-12 and IL-10 gene expression can be regulated via several 
inducible transcription factors that bind to specific binding sites, such as NFĸB, activator protein 
(AP)-1, Sp1, STAT and C/EBP and GREs (Jones and Tjian, 1985, Grimm and Baeuerle, 1993, 
Kube et al., 1995, Murphy et al., 1995, Plevy et al., 1997, Gri et al., 1998, Benkhart et al., 2000, 
Becker et al., 2001, Ma et al., 2001, Cao et al., 2002, Ziegler-Heitbrock et al., 2003, Chambers et 
al., 2004, Ma et al., 2004, Kremer et al., 2007, Mosser and Zhang, 2008, Szalmas et al., 2008, 
Unterberger et al., 2008), within the promoters of these cytokine genes. Thus, considering that IL-
12p40 gene expression is upregulated and IL-10 gene expression is downregulated, it is expected 
that the liganded GR binds to a GRE in the IL-12p40 promoter and one of the above-mentioned 
transcription factors in the IL-10 promoter, respectively. Using a combination of siRNA, co-
immunoprecipitation, ChIP and re-ChIP assays, we show that the regulation of IL-12p40 and IL-10 
by these ligands activate distinct signalling pathways, leading to binding of the GR to specific 
regulatory elements. It is important to note, that tethering of the GR to other DNA-bound 





example, glucocorticoids (Dex) have been shown to positively regulate transcription of the MAPK-
phosphatase gene in human epithelial lung carcinoma cells, by recruiting the transcription factor 
C/EBPβ to the promoter, with C/EBPβ tethered to glucocorticoid-bound GR (Johansson-Haque et 
al., 2008). Similarly, the GR has been shown to interact with C/EBPβ to transactivate haptoglobin 
(Hp) gene expression in rats during acute phase responses (Arambasic et al., 2010). The results in 
this study suggest the formation of a cellular complex of progestin-bound GR and C/EBPβ with the 
endogenous IL-12p40 promoter, likely via binding to C/EBPβ regulatory elements to positively 
regulate transcription of the human IL-12p40 gene. C/EBPβ has previously been reported to play a 
crucial role in the transcriptional activation of the mouse IL-12p40 gene (Plevy et al., 1997). In 
terms of the GR-mediated downregulation of the IL-10 gene in response to Prog, MPA and NET-A 
(figure 3.9C), this study shows a requirement for STAT-3. Using Co-IP assays, a protein-protein 
interaction between the GR and STAT-3 has previously been shown (Zhang et al., 1997, Arambasic 
et al., 2010). The results in this study suggest the formation of a cellular complex of progestin-
bound GR and STAT-3 with the endogenous IL-10 promoter, likely via binding to STAT-3 
regulatory elements to negatively regulate transcription of the human IL-10 gene.  
 
To summarise, we propose a model for the molecular mechanism of progestin-induced regulation of 
IL-12p40 (figure 5.1) and progestin-induced regulation of IL-10 (figure 5.2) in the human 
ectocervical epithelial cell line. Upon progestogen binding, the GR undergoes a conformation 
change and translocates to the nucleus. To activate transcription of the human IL-12p40 gene the 
liganded GR tethers to the transcription factor C/EBPβ and forms a cellular complex, with the 
endogenous IL-12p40 promoter, likely via binding to the C/EBPβ cis-regulatory element. To 
repress transcription of the human IL-10 gene the liganded GR tethers to the transcription factor 
STAT-3 to form a protein complex, with the endogenous IL-10 promoter, likely via binding to the 





therapy may have important implications for the ectocervical immune function, as pro-
inflammatory cytokines have been associated with increased levels of HIV-1 shedding in the female 
genital tract (Gumbi et al., 2008). The proposed mechanism may be particularly relevant to 
infections such as HIV-1 in the cervix, as both IL-12 and IL-10 have been shown to be key role 
players in HIV-1 pathogenesis. Considering the results from a recent clinical study indicating an 
association between the usage of MPA and increased risk of HIV-1 acquisition (Heffron et al., 
2012), our results may provide a potential mechanism whereby the injectable contraceptive Depo-
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4.1. Brief Introduction 
HIV-1 is considered a global pandemic with the majority of infections occurring in the female 
population (Heikinheimo and La, 2008, Kaushic et al., 2010, Le Douce et al., 2010). The majority 
of these women acquire HIV infection via the female genital tract during male to female 
transmission (reviewed in (Cummins and Dezzutti, 2000, Pope and Haase, 2003, Hladik and Hope, 
2009, Kaushic et al., 2010). The ectocervix is thought to be the first target site to become infected 
with sexually transmitted HIV-1 (Howell et al., 2005). Although there are studies indicating that 
epithelial cells of the female genital tract can be infected by HIV-1 and may serve as potential 
targets for the initial infection by HIV-1 and its systemic spread (Howell et al., 1997, Maher et al., 
2005, Bobardt et al., 2007)(reviewed in (Hladik and McElrath, 2008), there has been no conclusive 
evidence of HIV-1 infection of the genital epithelium in vivo (reviewed in Shacklett, 2009 and 
Haase, 2010) (Chapter 1, literature review). In addition, evidence suggest that direct exposure of the 
genital epithelial cells to HIV-1 may disrupt the mucosal barrier of the female genital tract and 
increase the permeability of the mucosal epithelium, possibly due to genital tract inflammation 
(Nazli et al., 2010). 
 
In the light of the fact that it has been suggested that steroid receptors such as the GR may facilitate 
successful HIV-1 pathogenesis (Chapter 1, literature review), our strategy was thus to investigate 
whether HIV-1 Vpr protein modulates TNFα-induced IL-12p35, as well as IL-12p40 and IL-10 
gene expression by Prog, MPA and NET-A, and to determine whether the GR plays a role in 
mediating these effects. IL-12p35 was included in this part of the study as Vpr has previously been 









4.2.1. As observed for IL-12p40, Prog, MPA and NET-A also upregulate IL-12p35 mRNA 
expression in the Ect1/E6E7 cell line  
The previous chapter showed that Prog, MPA and NET-A regulated the mNA expression of IL-
12p40 and IL-10. As IL-12 is a heterodimeric glycoprotein consisting of IL-12p40 and IL-12p35 
(Kobayashi et al., 1989, Stern et al., 1990, Aragane et al., 1994, Trinchieri and Scott, 1995b, 
Chizzonite et al., 1998, Trinchieri, 2003, Byrnes et al., 2008), the regulation of IL-12p35 gene 
expression by Prog, MPA and NET-A was also investigated in this chapter. The human Ect1/E6E7 
cell line was treated with 0.02 µg/ml TNF-α and 0.1% EtOH (control) or 1 µM Prog, MPA or NET-
A for 6 hours, followed by qPCR analysis for the mRNA expression of IL-12p40 and IL-12p35, 
respectively. Figure 3.1A and 4.1B shows the effects of the ligands on IL-12p40 and IL-12p35 
mRNA expression in response to Prog, MPA and NET-A. No significant differences were detected 
between any of the ligands in the regulation of IL-12p40 (p>0.05), while IL-12p35 gene expression 
was upregulated to a significantly higher extent by NET-A, than Prog or MPA (p<0.01). These 
results indicate that both IL-12p40 and IL-12p35 gene expression are upregulated by the synthetic 





























































Figure 4.1. Prog, MPA and NET-A upregulate the TNF-α induced expression of IL-12p35 to different 
extents. The human Ect1/E6E7 cell line was incubated with 0.02 µg/ml TNF-α in the presence of 0.1% 
EtOH (control) or 1 µM Prog, MPA or NET-A for 6 hours. Total RNA was isolated and reversed transcribed 
to cDNA. Realtime qPCR was performed to determine the mRNA expression levels of IL-12p35, using 
GAPDH as the internal standard. Results shown are the averages (± SEM) of at least four independent 
experiments. One-way ANOVA analysis of variance and Bonferroni (compares all pairs of columns) post-
tests were used for statistical analysis.  
 
4.2.2. A role for the GR in the regulation of IL-12p35 by Prog and NET-A 
As we have shown a role for the GR in mediating the effects of Prog, MPA and NET-A on IL-
12p40 (figure 3.3C), we hypothesised that the effects of these ligands on IL-12p35 are also 
mediated by the GR. To further investigate the role of the GR in mediating the regulation of Prog, 
MPA and NET-A on IL-12p35 gene expression, the GR was silenced using siRNA transfections. 
The Ect1/E6E7 cell line was transiently transfected with validated GR specific siRNA 
oligonucleotides or NSC siRNA oligonucleotides (control) for 48 hours, followed by treatment with 
0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol 






levels of approximately 83% (figure 3.3A and 3.3B). Consistent with the GR knockdown result for 
IL-12p40 (Chapter 3), reduction of GR protein levels significantly abrogates the upregulation of IL-
12p35 in response to Prog and partially NET-A, indicating a role for the GR. Although not 
statistically significant, the GR also seemed to mediate the effect of MPA on IL-12p35. As 
expected, although not statistically significant, the natural glucocorticoid cortisol decreased IL-
12p35 mRNA expression (figure 4.2), and reducing the GR protein levels significantly abrogated 
this downregulation. Taken together, we show that the GR mediates the effects of Prog, while the 
effects of NET-A and possibly MPA are partially mediated by the GR. 
















































Figure 4.2. Decreasing GR protein levels by siRNA indicates a role for the GR in mediating the effects 
of Prog, and a partial role for mediating the effects of NET-A, and possibly MPA, on IL-12p35 mRNA 
expression in the Ect1/E6E7 cell line. The human Ect1/E6E7 cell line transfected with 10 nM GR or NSC 
siRNA oligonucleotides, was treated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 
µM Prog, MPA, NET-A or cortisol for 6 hours. Total RNA was isolated and reversed transcribed to cDNA. 
Thereafter realtime qPCR was performed to determine the mRNA expression levels of IL-12p35, using 
GAPDH as the internal standard. Relative IL-12p35 gene expression of treated samples was calculated 
relative to vehicle control (EtOH) of the NSC siRNA, which was set as one. Results shown are the average 
(± SEM) of at least three independent experiments. Two-way ANOVA analysis of variance and Bonferroni 






4.2.3. The HIV-1 accessory protein, Vpr, modulates the effects of the progestogens on IL-
12p40, IL-12p35 and IL-10 mRNA expression 
Having shown that the progestogens regulate TNF-α-induced IL-12p40 (figure 3.1C), IL-12p35 
(figure 4.1) and IL-10 (figure 3.1D) gene expression in the Ect1/E6E7 cell line, thereby possibly 
providing an environment prone to HIV infections, and that in vitro evidence suggest that the GR 
interacts with the HIV-1 accessory Vpr protein (Refaeli et al., 1995, Kino et al., 1999, Muthumani 
et al., 2006); reviewed in Hapgood and Tomasicchio, 2010), we investigated whether HIV-1 Vpr 
modulates the regulation of these cytokine genes to Prog, MPA and NET-A. The HA-tagged Vpr 
was overexpressed in the human Ect1/E6E7 cell line and treated with 0.02 µg/ml TNF-α in the 
presence of 0.1% EtOH (control) or 1 µM Prog, MPA or NET-A for 6 hours. Realtime qPCR 
results show that Vpr significantly reversed the effects of Prog, MPA and NET-A on the mRNA 
expression of both IL-12p40 (figure 4.3A) and IL-10 (figure 4.3C), but only the NET-A effect on 
the IL-12p35 gene (figure 4.3B). Although not statistically significant, Vpr inhibited the increase of 





























































































































































































































Figure 4.3. Vpr modulates the effects of Prog, MPA and NET-A on IL-12 and IL-10 gene expression in 
the Ect1/E6E7 cell line. Human Ect1/E6E7 cells, in the absence (-Vpr) and presence of transiently 
transfected with 1 µg pCMV4-3HA.Vpr (+Vpr), were treated with 0.02 µg/ml TNF-α and 0.1% EtOH 
(control) or 1 µM Prog, MPA or NET-A for 6 hours. Total RNA was isolated and reversed transcribed to 
cDNA. Realtime qPCR was performed to determine the mRNA expression levels of (A) IL-12p40, (B) IL-
12p35 and(C) IL-10, using GAPDH as the internal standard. Relative IL-12p40, IL-12p35 and IL-10 gene 
expression of treated samples was calculated relative to vehicle control lacking Vpr (-Vpr) set as one. One-
way ANOVA analysis of variance and Dunnett post-test was peformed to compare each of the treated bars to 
their corresponding condition’s control (i.e. EtOH –Vpr or EtOH +Vpr) bar. This is indicated by *, **, *** 
or ns above bars. Two-way ANOVA and Bonferroni post-test was used for statistical analysis to compare 
between the group lacking Vpr (-Vpr) and the group expressing Vpr (+Vpr). This is indicated by the lines 
above the bars. Results shown are the averages (±SEM) of at least four independent experiments. 
 
4.2.4. HIV-1 Vpr requires the GR for the modulation of cytokine gene regulation in the 
Ect1/E6E7 cell line  
Having shown that HIV-1 Vpr modulates the regulation of the cytokine genes in response to some 
of the progestogens, we investigated whether the GR was involved in mediating these effects of 
Vpr. The human Ect1/E6E7 cell line was transfected with 10 nM validated GR-specific siRNA 
oligonucleotides or NSC siRNA oligonucleotides (control), as well as HA-tagged Vpr, followed by 
treatment with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA, 
NET-A or cortisol for 6 hours. To confirm GR knockdown, Western blot analysis showed reduction 
of GR protein levels of approximately 70% (figure 4.4A and 4.4B). As indicated in figure 4.5A, the 
GR is needed for modulating the effects of Vpr on progestogen-induced IL-12p40 gene expression. 
Surprisingly, when GR protein levels are reduced in the presence of Vpr, cortisol treatment 
significantly increases IL-12p40 mRNA expression compared to when Vpr is absent. Interestingly, 
the GR does not mediate the effect of Vpr on the mRNA expression of IL-12p35 in response to 
NET-A (figure 4.5B). Furthermore, the effect of Vpr on Prog and MPA induced upregulation of IL-
10 mRNA expression was not reversed by the reduction of GR protein levels. Surprisingly, 





were reduced. This study shows that Vpr partially requires the GR to modulate the mRNA 
expression of IL-10 in response to NET-A.  
 










































Figure 4.4. Verification of GR knockdown. Total protein from the untreated human Ect1/E6E7 cell line, 
transiently transfected with 1 µg pCMV4-3HA.Vpr, as well as 10 nM GR or NSC siRNA oligonucleotides, 
were harvested to perform Western blotting, using antibodies specific for the GR and GAPDH. The latter 
was used as a loading control. (A) A representative blot is shown. (B) GR expression levels relative to 
GAPDH were quantified using UN-SCAN-IT. Western blots of at least two independent experiments were 
quantified to determine the percentage GR protein knockdown. One-way ANOVA analysis of variance and 













































































































































































































































































































Figure 4.5. Influence of Vpr on the mRNA expression of cytokine genes in response to progestins in a 
GR-dependent manner in the Ect1/E6E7 cell line. The human Ect1/E6E7 cell line was transfected with 10 
nM GR or NSC siRNA oligonucleotides, and after 24 hours transiently transfected with 1 µg pCMV4-
3HA.Vpr (+Vpr). The cells were treated with 0.02 µg/ml TNF-α in the presence of 0.1% EtOH (control) or 1 
µM Prog, MPA, NET-A or cortisol for 6 hours. Total RNA was isolated and reversed transcribed to cDNA. 
Realtime qPCR was performed to determine the mRNA expression levels of IL-12p40 (A), IL-12p35 (B) and 
IL-10 (C), using GAPDH as the internal standard. Relative IL-12p40, IL-12p35 and IL-10 gene expression 
of treated samples was calculated relative to the control (NSC siRNA EtOH) lacking Vpr, which was set as 
one. Two-way ANOVA and Bonferroni post-test was used for statistical analysis. Results shown are the 
averages (±SEM) of at least four independent experiments. The insert shows the effect of the ligands on the 
cytokine gene expression in the absence of Vpr. 
 
Figure 4.6 shows the replotting of the results from figures 3.3, 4.2 and 4.5, where each different 
transfection condition was normalised to its own EtOH+TNF-α which was set as one. An 
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Figure 4.6. A summary of the effects of Prog, MPA and NET-A, in the absence and presence of Vpr, as 
well as in the absence and presence of GR, on (A) IL-12p40, (B) IL-12p35 and (C) IL-10 mRNA 
expression in the Ect1/E6E7 cell line. The figure is replotted from figures 3.4, 4.2 and 4.6. The effects of 
these progestogens on (A) IL-12p40, (B) IL-12p35 and (C) IL-10 mRNA expression is plotted relative to the 
EtOH+TNF-α of each different transfection condition, which was set as one. Two-way ANOVA analysis of 
variance and Bonferroni (compares all pairs of columns) post-tests were used for statistical analysis. 
 
Interestingly, the qPCR results revealed that, in the presence of Vpr, reduced GR protein levels 
resulted in an increase in TNFα-induced IL-12p40, IL-12p35 and IL-10 gene expression in the 
absence of GR ligand (figure 4.5A-C). Figure 4.7 shows the replotting of the EtOH+TNF-α results 
from figures 4.3 and 4.5 and suggests that Vpr requires the unliganded GR for its effect on these 
cytokine genes. Taken together, these results suggest that upon treatment of the Ect1/E6E7 cells 
with TNF-α, Vpr reduces inflammation by decreasing the gene expression of pro-inflammatory IL-









































































































































Figure 4.7. The GR is needed for Vpr mediated suppression of TNF-α induced mRNA expression of 
IL-12p40 and IL-12p35 in the human ectocervical epithelial cell line. qPCR data for EtOH+TNF-α from 
figures 4.3 and 4.5 were replotted. The Ect1/E6E7 cell line lacking Vpr was set as 1, and all other conditions 
were plotted relevant to that. One-way ANOVA analysis of variance and Bonferroni (compares all pairs of 














4.2.5. GR protein levels are not significantly changed by HIV-1 Vpr in the human 
ectocervical cell line  
Next we determined whether the overexpression of Vpr affected GR protein levels. The human 
Ect/E6E7 cell line was transiently transfected with 1 µg pCMV4-3HA.Vpr and treated with 0.02 
µg/ml TNF-α and 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. 
Western blot analysis in figure 4.8A and 4.8B show that Vpr is indeed overexpressed in the 
Ect1/E6E7 cell line and it does not affect the unliganded GR protein levels. Although not 
statistically significant, in the presence of all the ligands (figure 4.8C and 4.8D), Vpr appeared to 









































































































































































Figure 4.8. Vpr does not modulate endogenous GR protein levels in the Ect1/E6E7 cell line. Whole cell 
extracts were prepared from the human Ect1/E6E7 cell line, lacking Vpr expression (-Vpr) and cells 
transiently transfected with 1 µg pCMV4-3HA.Vpr (+Vpr). Protein lysates were subjected to electrophoresis 
on a 10% SDS polyacrylamide gel. The GR and Vpr protein levels were analysed using GR- and HA-
specific antibodies. GAPDH was used as a loading control. (A-B) A single representative gel of at least two 
independent experiments is shown. (C-D) The cells were treated with 0.02 µg/ml TNF-α and 0.1% EtOH 
(control) or 1 µM Prog, MPA, NET-A or cortisol for 6 hours. (B and D) GR protein levels were quantified 
using UN-SCAN-IT and normalised to the quantified GAPDH levels. The effect of the test compounds on 
the endogenous GR protein levels is shown as fold induction relative to EtOH set as 1. Two-way ANOVA 




Numerous epidemiological studies have investigated the association between the use of hormonal 
contraceptives and HIV-1 acquisition and cervical shedding of the virus (Clemetson et al., 1993, 







+ 0.02 µg/ml TNF-α + 0.02 µg/ml TNF-α 





Morrison et al., 2007, Myer et al., 2007, Kumwenda et al., 2008, Morrison et al., 2010, Heffron et 
al., 2012, Morrison et al., 2012). However, whether hormonal contraceptives are indeed a risk factor 
for HIV-1 acquisition remains controversial. Results from Chapter 3 suggest that the synthetic 
progestins used in contraception, MPA and NET-A, modulate the inflammatory process in the 
female genital tract by affecting the gene expression of IL-12p40 and IL-10. Similar effects were 
seen for IL-12p35 (figure 4.1). Taken together, these results suggest that MPA and NET-A used in 
hormonal therapy may lead to chronic inflammation in the ectocervical environment, thereby 
providing a potential environment conducive to infections such as HIV-1. 
 
In Chapter 3 we also showed that the GR mediates the effects of the progestins on IL-12p40 (figure 
3.3C) and IL-10 (figure 3.3D), while in this chapter the same is shown for IL-12p35 (figure 4.2). 
Moreover, there is evidence to suggest that the GR may play a role in HIV-1 pathogenesis and that 
its activity and function becomes enhanced during HIV-1 infection (Kino et al., 2003)(reviewed in 
(Hapgood and Tomasicchio, 2010). It has been suggested that the HIV-1 accessory Vpr is in part 
responsible for the observed increase in the GR transcriptional activity, as Vpr has been shown to 
act as a co-activator for the GR (Kino et al., 1999, Sherman et al., 2000, Kino et al., 2002, Mirani et 
al., 2002, Muthumani et al., 2004). The main aim of the study in this chapter, was thus to 
investigate whether Vpr could modulate the effects of the progestins on the mRNA expression of 
these cytokine genes. The Ect1/E6E7 cell line was transiently transfected with 1 µg of the pCMV4-
3HA.Vpr plasmid. This concentration was suggested by the laboratory of Prof Janet Hapgood at the 
University of Cape Town (personal communication).  
 
The general trend observed was that Vpr significantly modulated the effects of Prog, MPA and 
NET-A on the mRNA expression of IL-12p40 (figure 4.3A) and IL-10 (figure 4.3C), respectively. 





4.3B). Moreover, this study shows that Vpr downregulates IL-12p40 and IL-12p35 gene expression 
in the absence of ligands (figure 4.7). Collectively, these results suggest that Vpr has anti-
inflammatory activities and immunsuppressive properties, i.e. Vpr downregulates the pro-
inflammatory cytokine IL-12 and upregulates the anti-inflammatory cytokine IL-10. Consistent 
with this results, Vpr has been reported to downregulate the production of pro-inflammatory 
cytokines and chemokines (reviewed in (Muthumani et al., 2004). Results suggest that in the 
presence of Vpr, these progestins may increase susceptibility to other genital infections due to an 
increase in the IL-10/IL-12 ratio, which is thought to weaken the hosts defense mechanisms against 
infections (Kelly et al., 1997). It should be noted that the effect of the progestogens on these 
cytokine genes in the absence of Vpr, was investigated without transfecting the cells with an empty 
vector. A more appropriate control for these experiments may be transfection with a pCMV-driven 
empty plasmid. 
 
Having shown that Vpr can modulate the effects of the GR ligands Prog, MPA and NET-A 
(Koubovec et al., 2005, Ronacher et al., 2009, Avenant et al., 2010a) on IL-12 and IL-10 gene 
expression, we next investigated whether the GR was involved in mediating these effects using GR 
knockdown experiments. Reduction of the GR protein levels showed that Vpr significantly alters 
the cortisol induced regulation of IL-12p40 (figure 4.5A), IL-12p35 (figure 4.5B) and IL-10 (figure 
4.5C) mRNA expression in a GR-dependent manner. Unexpectedly, when the GR protein levels 
were reduced in the presence of Vpr, cortisol treatment significantly increased IL-12p40 mRNA 
expression compared to when Vpr is absent (figure 4.5A). The reason for this observation is not 
clear, but we speculate that it may be due to non-genomic effects of cortisol. Furthermore, although 
Vpr modulated the NET-A induced mRNA expression of IL-12p35 (figure 4.5B or figure 4.6B), 
this response did not require the GR. One can postulate that in the presence of Vpr, NET-A elicits 





receptor, as Vpr have previously been shown to also interact with the PR and ER (Kino et al., 
1999). A similar explanation could account for why the GR is not needed for the Vpr modulation of 
Prog- and MPA-induced IL-10 expression (figure 4.5C or figure 4.6C). 
 
Furthermore, our results in the human ectocervical epithelial cell line showed that Vpr, independent 
of ligand, significantly suppresses the TNF-α induced mRNA expression of both IL-12p40 and IL-
12p35 (figure 4.7A and figure 4.7B), but not that of IL-10 (figure 4.7C), in a GR-dependent 
manner. This result is inconsistent with the study of Mirani and co-workers who found that Vpr 
suppressed the mRNA expression of IL-12p35, but not that of IL-12p40 in human peripheral 
monocytes stimulated with LPS (Mirani et al., 2002). This thesis suggests that Vpr may reduce 
inflammation in the ectocervical environment by decreasing the expression of pro-inflammatory 
cytokines via the GR.  
 
As ligand binding has been shown to destabilise the GR, by degradation via the ubiquitination-
proteasome pathway (Webster et al. 1997, Wallace & Cidlowski 2001, Ismaili & Garabedian 2004, 
Kinyamu et al 2005), it could be argued that these progestogens could have altered the endogenous 
GR levels, or that Vpr could have (i) stabilised the GR against degradation and thereby increased 
the GR levels prior to stimulation or (ii) acted like the GR ligands and reduced GR levels. However, 
using Western blotting (figure 4.8C and 4.8D), we showed that Vpr did not significantly alter ligand 
bound GR levels. After the initial Western blot showing that Vpr could be overexpressed in the 
Ect1/E6E7 cell line, we subsequently were unable to detect Vpr using the same commercial 
antibody for detection of HA as before. Thus, it could not be determined whether ligand treatment 
affected Vpr expression levels. These experiments should thus be repeated as soon as the conditions 
for the currently available antibody are optimised or by using a different HA-tagged antibody or one 





be crucial to show that silencing of the GR protein levels do not affect the expression of Vpr. 
Furthermore, once the experimental conditions for the Multiplex bead array and/or the ELISA 
(Chapter 3; Addendum A, figure A3) has been finalised, the effects of Vpr should be investigated at 
the protein level. 
 
In conclusion, although the results from this study suggest that Vpr influences the regulation of IL-
12 and IL-10 mRNA expression by the progestogens Prog, MPA and NET-A, and in most part via 
the GR, these results should be interpreted with caution considering the trend of decreasing GR 
protein levels in the presence of Vpr. Nonetheless, the results may suggest that in the presence of 
Vpr (HIV-1 infection) inflammation in the ectocervical environment is reduced, which may be 
beneficial in terms of HIV-1, but may increase women’s susceptibility to other genital infections 





























Although MPA, and also NET, are widely used in female reproductive therapy, little is known 
about their effects on local immune function, and the implications on susceptibility to infections 
such as HIV-1. In the first part of this thesis (Chapter 3), using the Ect1/E6E7 immortalised 
ectocervical epithelial cell line, the regulation of two cytokine genes by MPA and NET-A, as 
compared to the endogenous hormone Prog, and the underlying molecular mechanism was 
investigated. Although immortalised, the Ect/E6E7 cell line has been reported to have similar 
morphological and immunocytochemical features to that of their tissue of origin as well as primary 
cultures (Fichorova et al., 1997, Fichorova and Anderson, 1999). In the second part of the thesis 
(Chapter 4), the influence of the HIV-1 Vpr on the regulation of cytokine genes by the 
progestogens, was examined.  
 
5.1. Comparing the regulation of a pro- and anti-inflammatory cytokine gene 
in the human Ect1/E6E7 cell line 
Inflammation is characterised by an increase in the production of pro-inflammatory cytokines which 
attracts and stimulates immune cells. In Chapter 3, the regulation of IL-12 and IL-10 by Prog, MPA 
and NET-A was investigated. These specific cytokines were selected based on their 
immuneregulatory role during infections (Trinchieri and Scott, 1995b, Trinchieri and Gerosa, 1996, 
Trinchieri, 1998, Schottelius et al., 1999, Leifeld et al., 2002, Pestka et al., 2004, Nemeth et al., 
2005, Couper et al., 2008), as well as having distinct roles in HIV-1 pathogenesis (Chehimi et al., 
1992, Chehimi et al., 1994, Kelly et al., 1997, Cohen et al., 1999, Ma and Montaner, 2000, Little et 






The results presented in Chapter 3 showed that Prog, MPA and NET-A significantly upregulated 
the TNF-α stimulated IL-12p40 (figure 3.1C) gene expression to similar extents, while the mRNA 
expression of IL-10 was significantly downregulated (figure 3.1D). The results from this study 
showing upregulation of the pro-inflammatory cytokine IL-12p40 by Prog is inconsistent with 
previous studies showing inhibition of protein levels in mouse bone-marrow derived macrophages 
(Jones et al., 2008) and mouse spleen dendritic cells (Hughes et al., 2008). Consistent with the 
results from this study, MPA has been shown to increase the concentration of IL-12 in vaginal 
lavage fluid of DMPA adolescent female users (Barousse et al., 2007). Furthermore, as seen for IL-
12p40, the results for this study showing downregulation of the anti-inflammatory cytokine IL-10 
by Prog is inconsistent with previous reports, while that of MPA correlates to the literature. 
Previous studies reported that Prog has no effect on the production of IL-10 (Visser et al., 1998, 
Shrier et al., 2003, Bouman et al., 2005), while a decrease in the LPS-induced IL-10 mRNA and 
protein levels in the cervix of mice was observed for MPA (Elovitz and Gonzalez, 2008). 
Addressing the discrepancies between results of this study and that of previous studies is not easy. 
However, it is likely that the differences could be ascribed to factors such as cell-specific effects or 
differences at the transcript (mRNA) vs protein level. Indeed, the immune responses of cervical 
lymphocytes have been reported to differ from that observed in PBMCs (Vats et al., 2007). In 
addition, it is well-known that protein levels do not always correlate to the transcript levels as the 
production of proteins is regulated not only at the transcriptional level, but also other processes such 
as mRNA degradation, translation, post-transcriptional modifications and protein degradation 
(Vogel and Marcotte, 2012). Results from the present study indicate that progestins are pro-
inflammatory in the ectocervical epithelial cells of the female genital tract. Interestingly clinical 
(Barousse et al., 2007) and animal (Elovitz and Gonzalez, 2008) evidence, for IL-12 and IL-10, 






Chapter 3 also investigated the effects of these ligands on IL-12p40 and IL-10 (Addendum A, figure 
A3) protein levels using both a Multiplex bead array and ELISA. Firstly, the IL-12p40 and IL-10 
protein levels were measured in the cell culture supernatant after 24 hours using the Multiplex bead 
array. Although, the results obtained for the IL-12p40 and IL-10 protein levels were below the 
detectable (linear) range, 0.24 – 1.79 pg/ml and ~ 0.90 pg/ml, respectively, we were able to quantify 
the protein levels of other immune mediators such as IL-6, IL-8 and RANTES (Addendum A, 
figure A4). Interestingly, the general trends observed for the effects of progestogens on the protein 
expression of these pro-inflammatory cytokines/chemokines correlates with the recently reported 
mRNA expression (Africander et al., 2011a). Subsequently, we found a study showing that IL-12 
and IL-10 are time-dependently increased in the vaginal epithelial cell line, Vk2/E6E7, from 24 to 
96 hours (Steele and Fidel, 2002). Our next strategy was thus to measure IL-12p40 and IL-10 
protein levels in response to Prog, MPA and NET-A after 48 and 96 hours, using ELISA due to the 
expense of the Multiplex bead array. The protein levels of IL-12p40 and IL-10 were still below the 
detectable range. Thus, the optimal time for detecting IL-12 and IL-10 protein in the ectocervical 
epithelial cell line should be determined by performing a more in-depth time course experiment. In 
addition, the media could be concentrated to improve detection of these cytokines. However, the 
possibility that the protein levels of these cytokines are too low to be detected in this cell line cannot 
be excluded. It may also be useful to use fluorescence activated cell-sorting (FACS) as an 
alternative method.  
 
Taken together, the results suggest that Prog, MPA and NET-A promote inflammation in the 
ectocervical environment. This may increase susceptibility to viral infections such as HIV, HSV 
and HPV since several lines of evidence suggest that an increase in inflammation of the human 
female genital tract may increase susceptibility to infections. The physiological implication of this 





10 mRNA expression may be beneficial. The concentrations of Prog fluctuates due to reproductive 
processes such as pregnancy and menstruation (Bouman et al., 2005, Wira et al., 2005a, Gravitt and 
Ghanem, 2010), thus Prog will not induce chronic inflammation, but rather acute inflammation 
during times of high Prog concentrations such as during the luteal phase of the menstrual cycle, 
thereby providing protection for the development of a potential fetus (Fleischman and Fessler, 
2010). In contrast, the long term use of MPA or NET-A as contraceptives, may lead to chronic 
inflammation of the ectocervical environment. This chronic inflammation may lead to an increase in 
the recruitment of HIV-1 target cells into the site of infection, and potentially increase susceptibility 
to HIV-1 (Bebell et al., 2008, Gumbi et al., 2008, Nkwanyana et al., 2009), reviewed in (Roberts et 
al., 2012a). However, the effects on the expression levels of IL-12 and IL-10 in the ectocervical 
epithelial cells cannot be considered in isolation as there is a constant release of various pro- and 
anti-inflammatory mediators during an immune response. Furthermore, the defense mechanisms in 
the female genital tract are dependent on a number of different factors in different anatomical sites. 
It would thus be critical to investigate the pro- and anti-inflammatory cytokine profiles ex vivo, 
using explants from the ectocervix, and possibly endocervix and vagina, from healthy versus HIV 
infected women using MPA and NET-A as injectable contraceptives, to those not using these 
contraceptives. Although the concentrations of MPA and NET-A used in this study were much 
higher than the serum concentrations reported in the literature (Chapter 1, literature review), the 
possibility that higher concentrations are present in ectocervical tissues in vivo compared with the 
concentrations usually measured in the blood, should not be excluded. There is evidence that MPA 
at low and high concentrations elicit similar effects on AR responsive genes (Ghatge, 2005). 
However, future studies should include a dose response analysis for MPA and NET-A on IL-12p40 






Progestogens mediate their biological effects by binding to steroid receptors, including the PR, AR, 
GR and possibly the ER. Although all these steroid receptors are endogenously expressed in the 
Ect1/E6E7 cell line, only the GR is transcriptionally active for both transactivation and 
transrepression in this cell line (Africander et al., 2011a). In the current study is was hypothesised 
that the effects of the progestogens on the cytokine genes are due to those ligands acting via the GR. 
Using a combination of whole cell binding assays (figure 3.2A) and Western blotting (figure 3.2B 
and 3.2C), the present study shows that these ligands bind to the endogenous GR and do not affect 
the levels of the protein. This is consistent with previous studies in human lung carcinoma cells 
(A549) endogenously expressing the GR or COS-1 cells with overexpressed human GR (Koubovec 
et al., 2005, Ronacher et al., 2009). Furthermore, as it has previously been shown that the GR bound 
to Prog, MPA and NET-A has a half-life of 28, 17 and 37 hours, respectively (Avenant et al., 
2010b), we did not expect these progestogens to modulate the endogenous GR protein levels in the 
Ect1/E6E7 cell line at 6 hours. We next determined whether the GR is involved in the response of 
these progestogens on the IL-12p40 and IL-10 genes by reducing the GR protein levels using 
siRNA. The results suggest that the induction of IL-12p40 (figure 3.3C) and inhibition of IL-10 
(figure 3.3D) by Prog, MPA and NET-A is via the GR, since complete abrogation of the effects on 
these cytokine genes were seen when the GR protein levels were reduced. Interestingly, IL-10 
mRNA expression (figure 3.3D) was upregulated by NET-A in the presence of GR siRNA. This 
suggests that when GR levels are reduced, NET-A, or one of its metabolites, act via another steroid 
receptor, as it is known that the PR, AR and ER are endogenously expressed in this cell line 
(Africander et al., 2011a). Considering that similar effects are not seen for MPA, it is speculated 
that this effect is likely due to the activity of metabolites of NET, rather than NET itself, via the ER. 
Future studies should thus investigate the role of the ER in the NET-A induced regulation of IL-10, 





metabolites such 3α-hydroxy-5α-hydrogen-NET (Schoonen et al., 2000) on IL-10 gene expression 
could also be investigated.  
 
It was rather surprising that MPA and the natural glucocorticoid cortisol, previously shown to elicit 
anti-inflammatory activity via the GR (Bamberger et al., 1999, Kurebayashi et al., 2003, Koubovec 
et al., 2004, Koubovec et al., 2005)(reviewed in (Griekspoor et al., 2007), exhibited pro-
inflammatory activity in the ectocervical epithelial cell line. However, both anti-inflammatory (De 
Bosscher and Haegeman, 2009) and pro-inflammatory activities (Lannan et al., 2012) have 
previously been reported for the potent synthetic GR ligand, Dex. 
The fact that MPA and NET-A displayed similar effects on IL-12p40 and IL-10 gene regulation via 
the GR was also unexpected, as these progestogens are known to have different binding affinities 
for the GR, as well as potencies and efficacies for transactivation and transrepression via the GR 
(Koubovec et al., 2005, Ronacher et al., 2009). Thus, the results from this study showing similar 
activities of 1 µM MPA and NET-A via the GR in the Ect1/E6E7 cell line are difficult to explain. It 
may be that the amount of activated GR is sufficient for mediating similar effects of these 
progestins on these genes, as demonstrated by the ChIP results in Chapter 3, even though the 
fractional occupancy of the GR is different for MPA and NET-A. Alternatively, the relative 
affinities of these ligands for the GR may be different in this cell line compared to other cell lines, 
as it has previously been shown that the concentration of GR determines the binding affinity of a 
ligand for the receptor (Robertson, 2011). To address this possibility, the relative binding affinities 
of these progestins for the endogenous GR in the Ect1/E6E7 cell line could be determined.  
 
Having shown that Prog, MPA and NET-A regulate the gene expression of both IL-12p40 and IL-
10 via the GR, a detailed investigation was followed into the molecular mechanism involved. 
Whether the progestogen-bound GR could be recruited to the endogenous IL-12p40 and IL-10 





showed that the GR was recruited to the endogenous IL-12p40 promoter region encompassing the 
NFkB and C/EBPβ cis-elements (figure 3.4B) in the presence of TNF-α and Prog, MPA, NET-A or 
cortisol. TNF-α is known to activate both the transcription factors NFkB (Smoak and Cidlowski, 
2004) and C/EBPβ (Cardinaux et al., 2000, Kim et al., 2009). Tethering of the GR to NFkB is 
mostly seen when pro-inflammatory genes are repressed (Smoak and Cidlowski, 2004, Kassel and 
Herrlich, 2007). A recent study proposed that tethering of the GR to C/EBPβ can either prevent 
DNA-binding to responsive elements and inhibit transcription of pro-inflammatory cytokines, for 
example IL-1β, or induce transcription of glucocorticoid-responsive genes lacking GREs, by 
binding to C/EBPβ binding sites (Roos and Nord, 2012). Further analysis by siRNA showed that 
C/EBPβ is needed for the progestogen-bound GR to mediate the upregulation of IL-12p40 gene 
expression (figure 3.6C). These results are consistent with a previous study showing that C/EBPβ 
plays a crucial role in the transcriptional activation of the mouse IL-12p40 gene (Plevy et al., 1997). 
Furthermore, using the co-immunoprecipitation (figure 3.7) and re-ChIP (figure 3.8) analyses this 
study also provides evidence that the endogenous GR and C/EBPβ occurs as a cellular complex in 
Ect1/E6E7 cell line. Moreover, the re-ChIP analysis revealed significant recruitment of the GR-
C/EBPβ complex to the endogenous IL-12p40 promoter, most likely via the C/EBPβ regulatory 
element, by Prog, MPA and NET-A. 
 
In summary, a model is proposed in figure 5.1 for the mechanism whereby IL-12p40 mRNA 
expression is upregulated by the progestogens in the human ectocervical epithelial cell line. It is 
proposed that the transcription factor C/EBPβ is recruited to the C/EBPβ regulatory element of the 
Il-12p40 promoter in response to TNF-α. However, the recruitment of C/EBPβ to the IL-12p40 
promoter will need to be confirmed by ChIP analysis. When Prog, MPA or NET-A binds to the 
endogenous GR, the liganded-GR then tethers to the DNA-bound C/EBPβ, thereby increasing the 





but may also be relevant to other pro-inflammatory cytokine or chemokine genes containing 
C/EBPβ cis-regulatory elements within their promoters, such as MIP-1α. Indeed, the upregulation 
of MIP-1α by Prog and MPA in human vaginal epithelial cells has previously been shown to be 
mediated by the GR (Noeth, 2012). 
 
The reason for the observed recruitment of the progestogen-bound GR to the NFκB-C/EBPβ 
regulatory element, rather than to AP-1 or Sp1 elements of the endogenous IL-12p40 promoter in 
the ectocervical cell line is not clear. Considering that gene regulation is dependent on the nature of 
the chromatin, in terms of whether it is open or closed, certain cis-regulatory elements may or may 
not be blocked by nucleosomes, thereby affecting the accessibility of these elements to transcription 
factors (Bell et al., 2011). Thus, it may be that the AP-1 or Sp1 binding sites of the IL-12p40 
promoter are blocked by nucleosomes in these cells, and are thus not accessible to the progestogen-
bound GR. It should be noted that role of the NFκB binding element was not investigated as the 
results showed complete abrogation of the progestogen-induced upregulation of IL-12p40 gene 
expression when C/EBPβ protein levels were reduced. Although unlikely, the possibility that the 
GR may be recruited to the NFκB binding element can thus not be definitively excluded. Future 










Figure 5.1. Schematic model for the progestogen-induced upregulation of IL-12p40 gene expression 
via the GR in the ectocervical epithelial cell line. Upon Prog, MPA or NET-A binding to the GR, the GR 
undergoes a conformational change and the progestogen-bound GR translocates to the nucleus, where it co-
localise to the IL-12p40 promoter with the transcription factor C/EBPβ via the C/EBPβ binding elements to 
upregulate transcription of the IL-12p40 gene. Abbreviations: AP-1: activator protein-1; C/EBPβ: CCAAT 
enhancer binding protein-β; GR: glucocorticoid receptor; Hsp90: heat shock protein-90; MPA: 
medroxyprogesterone acetate; NET-A: norethisterone acetate; NFκB: nuclear factor kappa-B; Prog: 
progesterone; Sp1: specific protein-1; TNF-α: tumor necrosis factor-α; TNFR: tumor necrosis factor 
receptor;  
 
ChIP, siRNA, co-immunoprecipitation and re-ChIP analyses were also used for an in-depth 
investigation into the GR-mediated downregulation of IL-10 gene expression by the progestins 
(figure 3.9 - figure 3.11). Figure 5.2 summarises the results of these experiments, and illustrates that 





factor STAT-3, on the endogenous IL-10 promoter, in the Ect1/E6E7 cell line, likely via a STAT-3 
regulatory element in the IL-10 promoter. It is proposed that the transcription factor STAT-3 is 
recruited to the STAT-3 regulatory element of the Il-10 promoter in response to TNF-α, as other 
studies have shown that TNF-α can activate STAT-3 (Miscia et al., 2002, Robinson et al., 2006). 
Using co-immunoprecipitation assays, previous studies identified the formation of a complex 
between the GR and STAT-3 in rat liver extracts, to upregulate the mRNA expression of the 
haemoglobin binding protein haptoglobin (Arambasic et al., 2010), and a rat hepatoma cell line, 
indicating a novel mechanism for the interaction between the glucocorticoid and IL-6 signaling 
pathways (Zhang et al., 1997). Interestingly, IL-10 gene expression was upregulated by Prog and 
MPA when STAT-3 was silenced. The latter may suggest that when the levels of STAT-3 are 
reduced, the GR recruits to other transcription factors at other cis-regulatory elements within the 
endogenous IL-10 promoter, for example a GRE. Future studies should investigate the role of other 
transcription factors and recruitment of the GR to the endogenous IL-10 promoter using ChIP 
assays after STAT-3 levels are reduced. As mentioned for IL-12p40, the mechanism proposed here 
may not be unique for IL-10, but may also be relevant to other anti-inflammatory cytokine genes 
containing STAT-3 cis-regulatory elements within their promoters.  
 
As discussed above the nature of the chromatin could affect the accessibility of the GRE or Sp1 
elements of endogenous IL-10 promoter, and therefore explain why the progestogen-bound GR 
recruits to STAT-3 regulatory elements, rather than to GRE or Sp1 elements. Thus, it may be that 
the GRE and Sp1 binding sites of the IL-10 promoter are blocked by nucleosomes in these cells, 
and are thus not accessible to the progestogen-bound GR. Considering that the role for the AP-1 
binding element was not investigated, the possibility that the GR may be recruited to the AP-1 
binding element cannot be definitively excluded. Future studies can address this by performing 






Figure 5.2. . Schematic model for the progestogen-induced downregulation of IL-10 gene expression 
via the GR in the ectocervical epithelial cell line. Upon Prog, MPA or NET-A binding to the GR, the GR 
undergoes a conformational change and the progestogen-bound GR translocates to the nucleus, where it co-
localise to the IL-10 promoter with the transcription factor STAT-3 via the STAT-3 binding elements to 
decrease transcription of the IL-10 gene. Abbreviations: AP-1: activator protein-1; GR: glucocorticoid 
receptor; GRE: glucocorticoid response element; Hsp90: heat shock protein-90; MPA: medroxyprogesterone 
acetate; NET-A: norethisterone acetate; Prog: progesterone; Sp1: specific protein-1; STAT-3:signal 
transducer and activator of transcription-3; TNF-α: tumor necrosis factor-α; TNFR: tumor necrosis factor 
receptor;  
 
5.2. Vpr modulates the effects of the progestogens on the expression of the 
endogenous cytokine genes  
Previous studies have described HIV-1 Vpr as a co-activator of the GR (Kino et al., 1999, Kino et 
al., 2002), that downregulates the expression of pro-inflammatory cytokine genes and upregulates 
the expression of anti-inflammatory cytokine genes (reviewed in Muthumani et al., 2004). The 





expression of IL-12 and IL-10, by decreasing the expression of the former and increasing the 
expression of the latter via the GR. Chapter 4 thus focussed on the influence of Vpr on cytokine 
gene expression, specifically on progestogen-induced regulation of IL-12p40, IL-10 and IL-12p35. 
The latter was included as it has previously been shown that Vpr suppresses the mRNA expression 
of IL-12p35, but not IL-12p40 and IL-10, in human peripheral monocytes (Mirani et al., 2002). 
Figure 5.3 summarises the results of this chapter in the form of a model showing the role of the GR 
in the modulation of progestogen-induced cytokine gene expression by Vpr.  
 
Results from this study show that Vpr, independent of ligand, significantly suppresses the TNF-α 
induced mRNA expression of both IL-12p40 and IL-12p35 (figure 4.7A and figure 4.7B), but not 
that of IL-10 (figure 4.7C). The Vpr results on IL-12p35 and IL-10, but not IL-12p40, are in 
agreement with the study in PBMCs (Mirani et al., 2002). These authors showed that Vpr had no 
effect on IL-12p40 gene expression. However, the results presented in this study, indicating a 
decrease in IL-12p40 gene expression in the presence of Vpr, correlate to the literature showing 
decreased or impaired IL-12 levels in PBMCs of HIV-infected individuals (Chehimi and Trinchieri, 
1994, Ma and Montaner, 2000, Byrnes et al., 2008). Vpr significantly modulated the effects of Prog, 
MPA and NET-A on the mRNA expression of IL-12p40 (figure 4.3A) and IL-10 (figure 4.3C), 
while only the effect of NET-A on IL-12p35 was modulated (figure 4.3B). As the effects of NET-A 
on IL-12p35 gene expression is only partly mediated by the GR, suggesting that other steroid 
receptors such as the PR, AR or ER may be involved, it may be that Vpr needs one of these steroid 
receptors rather than the GR.  
 
Reducing the GR protein levels suggested that Vpr requires the GR to alter the Prog, MPA and 
NET-A induced regulation of IL-12p40 (figure 4.5A or figure 4.6A) mRNA expression. 





4.5B or figure 4.6B), GR siRNA indicated that the GR is not needed for this response. This result 
supports the above suggestion that Vpr needs a receptor other than the GR, for its effects on NET-
A-induced upregulation of IL-12p35 gene expression (figure 4.3B). As Vpr have previously been 
shown to also interact with the PR and ER (Kino et al., 1999), one can postulate that in the presence 
of Vpr, NET-A or one of its metabolites, elicits its response by binding to either one of these 
receptors, but most likely the ER. A similar speculation could explain why the Prog- and MPA-
induced IL-10 gene expression in the presence of Vpr does not change when the GR protein levels 
are reduced (figure 4.5C or figure 4.6C). Surprisingly, Vpr requires the GR to modulate the NET-A, 
but not the MPA, effect on IL-10 mRNA expression. As it could be argued that the differences 
observed with Vpr and the progestogens could be due to Vpr altering the endogenous GR levels, 
Western blotting was performed. This study showed that Vpr did not significantly alter the 
progestogen-bound GR levels (figure 4.8C and 4.8D). Although Vpr has previously been shown to 
be a co-activator of the GR (Kino et al., 1999, Kino et al., 2002), the results in this chapter do not 
agree with this. Vpr did not enhance the GR-mediated activation of the IL-12 gene, or the GR-
mediated repression of the IL-10 gene by Prog, MPA and NET-A. Furthermore, the results in 
Chapter 4 showed that Vpr needs the unliganded GR to significantly suppress the TNF-α induced 
mRNA expression of both IL-12p40 and IL-12p35 (figure 4.7A and figure 4.7B). The results 
suggest that HIV-1 Vpr may reduce inflammation in the ectocervical environment by decreasing the 
expression of pro-inflammatory cytokines. Considering that pro-inflammatory 
cytokines/chemokines and mucosal inflammation in the genital tract are associated with lower 
systemic CD4+ cell counts during acute HIV-1 infection, reducing genital tract inflammation may 
slow disease progression (Bebell et al., 2008, Roberts et al., 2012b). On the other hand, reducing 
inflammation in the cervix in the presence of HIV may facilitate other opportunistic infections (Ma 




















Figure 5.3. Proposed schematic model summarising the possible role of the GR in the modulation of 
the progestogen-induced cytokine gene expression by Vpr in the ectocervical epithelial cell line. (A) IL-
12p40, (B) IL-12p35, (C) IL-10. The proposed model was constructed from the replotted data in figure 4.6 of 
Chapter 4. Abbreviations: AP-1: activator protein-1; C/EBPβ: CCAAT enhancer binding protein-β; ER: 
estrogen receptor; GR: glucocorticoid receptor; GRE: glucocorticoid response element; MPA: 
medroxyprogesterone acetate; NET-A: norethisterone acetate; NFκB: nuclear factor kappa-B; Prog: 
progesterone; PR: progesterone receptor; Sp1: specific protein-1; SR, STAT-3: signal transducer and 
activator of transcription-3; TF: transcription factor.  
 
Taken together, the results presented in Chapter 4 shows a shift from pro-inflammatory (IL-12) to 
anti-inflammatory (IL-10) immune responses in the presence of Vpr, which are consistent with the 
evidence in the literature suggesting a switch from the Th1 (e.g. IL-12, IFNγ and TNF-α) to Th2 
(e.g. IL-4 and IL-10) cytokine profiles in PBMCs (Clerici and Shearer, 1994, Hasko and Szabo, 
1999) during HIV-1 disease progression. As this study showed that Vpr altered the regulation of IL-






most part requiring the GR, this study supports the hypothesis that the GR is used by HIV-1 Vpr to 
ensure successful pathogenesis (reviewed in Hapgood and Tomasicchio, 2010). However, although 
in vitro cell culture models have shown that Vpr interacts with the GR (Kino et al., 1999, Sherman 
et al., 2000, Kino et al., 2002, Muthumani et al., 2006), evidence for a direct in vivo association 
between Vpr and the GR is lacking. To determine whether Vpr associates directly with the GR in 
vivo, a fluorescence resonance energy transfer (FRET) assay could be performed. This assay uses 
the principle of photo-excitation to excite an electron on a fluorophore tagged protein, which 
transfer its energy to a second fluorophore tagged protein when these proteins are in close 
association (Karpova and McNally, 2006). As an alternative, the putative association between Vpr 
and the GR could also be investigated by using a mammalian two-hybrid assay, a technique used to 
study protein-protein interactions (Luo et al., 1997).  
 
Considering the inhibition of IL-12p40 gene activation when Vpr is present (figure 4.3.A), Vpr may 
also be a co-repressor of the GR. It may be better to refer to Vpr as a co-regulator, as some proteins 
can have either a role of a co-activator or co-repressor depending on the cell context. For example, 
GRIP-1 has been shown to act as both a GR co-activor and a GR co-repressor in different cell types 
(Rogatsky et al., 2002, Avenant et al., 2010a, Verhoog et al., 2011). Furthermore, it would be 
interesting to investigate the localisation of the GR in the presence of Vpr on the IL-12p40 and IL-
10 promoters, using ChIP assays. In addition, Vpr appears to prevent Prog and MPA from binding 
to the GR and thereby induce IL-10 mRNA expression. It would be interesting to investigate 
whether Vpr can affect the dissociation constant (Kd) values of Prog and MPA for the GR, or even 
other steroid receptors present in the ectocervical epithelial cell line, by means of whole cell binding 
assays. Furthermore, Western blotting can also be performed to determine whether Vpr affects the 






Although not statistically significant, the results in Chapter 4 show a general trend for Vpr 
decreasing the GR protein levels, in the absence and presence of ligands, in the ectocervical 
epithelial cell line. However, a shortcoming of this study was that we were unable to verify the 
overexpression of Vpr in these experiments as Western blotting using the commercially available 
antibody for the detection of HA (HA tagged Vpr) was not reproducible. Thus, these experiments 
should be repeated by either optimising the conditions of the currently available antibody or by 
acquiring another HA-tagged antibody with more specificity. In fact, it would be ideal to use a Vpr 
specific antibody to exclude the possibility that Vpr is endogenously expressed in this cell line. 
Moreover, overexpressing the HIV-1 Vpr in the Ect1/E6E7 cell line may not be the best way to 
investigate the effects of Vpr on the regulation of IL-12 and IL-10 in these cells. It may be useful to 
investigate alternate methods for the delivery of Vpr into the ectocervical epithelial cell line, such as 
delivering Vpr with a virus and/or adding Vpr as a whole protein.  
 
Finally, the current study could be expanded by investigating concentration-dependent effects of 
MPA and NET-A, on a wide variety of immune mediators in cell lines and primary tissues of 
different anatomical sites of the female genital tract from healthy and HIV infected women using 
PCR arrays, multiplex protein arrays and ChIP-sequencing.  
 
5.3. Conclusion 
In summary, the results presented in this thesis provide evidence that Prog, MPA and NET-A may 
promote the pro-inflammatory milieu in the ectocervical environment. The expression of both the 
pro-inflammatory cytokine genes, IL-12p40 and IL-12p35, by Prog, MPA and NET-A, was 
upregulated, while the expression of the anti-inflammatory cytokine IL-10, was downregulated. 
These results imply that the use of MPA or NET in vivo may have adverse local 





which may increase the risk of susceptibility to infections such as HIV-1 (Bebell et al., 2008, 
Gumbi et al., 2008, Nkwanyana et al., 2009), reviewed in (Roberts et al., 2012a). The proposed 
mechanisms (figure 5.1. and 5.2.) may be particularly relevant to infections such as HIV-1 in the 
cervix, as both IL-12 and IL-10 have been shown to be key role players in HIV-1 pathogenesis. The 
results from the first part of the study showing increased inflammation (Chapter 3), may provide a 
potential mechanism whereby the injectable contraceptive Depo-Provera (Heffron et al., 2012), and 
possibly Nuristerate, increase the risk of women using these contraceptives of acquiring HIV-1.  
 
In the second part of the study (Chapter 4), we showed that the progestogen-induced cytokine 
milieu in the ectocervical environment changes from pro- to anti-inflammatory when HIV-1 Vpr is 
present. In the absence of the progestogens, Vpr also suppressed IL-12p40 and IL-12p35, but not 
IL-10 gene expression. These results for IL-12p40 and IL-12p35 in the ectocervical epithelial cells 
are in agreement with the evidence in the literature showing decreased or impaired IL-12 levels in 
PBMCs of HIV-infected individuals, but are inconsistent with the reports of increased IL-10 levels 
in PBMCs of HIV-infected individuals (Chehimi and Trinchieri, 1994, Trinchieri and Scott, 1995a, 
Ma and Montaner, 2000, Li and Lau, 2007, Byrnes et al., 2008). The results from this study may 
suggest that in the presence of Vpr (HIV-1 infection), inflammation in the ectocervical environment 
is reduced, and may render women more susceptibility to other opportunistic genital infections due 
to a weaker defense mechanism (Kelly et al., 1997, Stringer and Antonsen, 2008). Moreover, the 
result of this study is in agreement with others showing that the GR is needed for the effects elicited 
by Vpr. This implies that the GR could be a key protein exploited by HIV-1 to ensure successful 
pathogenesis. To conclude, the combined results from this thesis suggest that the contraceptive use 
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A.1: Mycoplasma-negative Ect1/E6E7 cells  
 
Figure A.1. Mycoplasma-negative Ect1/E6E7 cells. The human Ect1/E6E7 cell line was stained with the 
DNA Hoechst 33258 dye, and a photograph was taken using a fluorescence microscope. Only DNA-
containing nuclei are stained with the Hoechst dye and fluoresce brightly. As shown in this photograph only 













A.2: Time course to establish equilibrium time for binding of 10 nM [
3
H]-Dex 
to endogenously expressed GR in the human Ect1/E6E7 cell line 
 






































Figure A.2. The equilibrium time for 10 nM [
3
H]-Dex to bind to the endogenously expressed GR in the 
Ect1/E6E7 cell line is 6 hours. Human Ect1/E6E7 cells (1x105 cells per well in a 24-well plate) were 
incubated with 10 nM [3H]-Dex in the absence (total binding) and presence of 10 µM unlabelled (non-
specific binding) Dex for varying times. Specific binding (total binding minus non-specific binding) 





















































































































































































































































































































Figure A.3. Effect of Prog, MPA and NET-A on the TNF-α induced protein levels of IL-12p40 and IL-
10 in the human ectocervical cell line. The human Ect1/E6E7 cell line was incubated with 0.02 µg/ml 
TNF-α in the presence of 0.1% EtOH (control) or 1 µM Prog, MPA or NET-A for 24, 48 or 96 hours. The 
supernatants were collected and analysed by using (A and C) a Multiplex bead array to simultaneously 
quantify the protein levels of (A) IL-12p40 and (C) IL-10 in the cell culture supernatants according to the 
manufacturer’s instructions. All samples, as well as two quality controls included in the kit, were analysed in 
duplicate. The levels of all the analytes in the quality controls were within the expected ranges. A standard 
curve ranging from 3.2 pg/ml to 10 000 pg/ml was used for all the cytokines. Bio-Plex Manager Software, 
version 4.1.1., was used to analyse the data. (B and D) Commercial ELISA kits were used to measure the 
protein levels of (B) IL-12p40 and (D) IL-10. The standard curve ranged from 62.5 pg/ml to 4 000 pg/ml for 
IL-12p40 and from 2 pg/ml to 300 pg/ml for IL-10. The relative protein levels of the treated samples were 





Multiplex bead array 






A.4: The effect of the progestogens on the pro-inflammatory 
cytokines/chemokines IL-6, IL-8 and RANTES protein expression 
 




























































































































































































Figure A.4. Protein expression of the pro-inflammatory cytokine IL-6 and the chemokines, IL-8 and 
RANTES as determined by Multiplex bead array. The Human Ect1/E6E7 cell line was treated with 0.02 
µg/ml TNF-α and 0.1% EtOH (control) or 1 µM Prog, MPA, NET-A or cortisol for 24 hours. The human 8-
plex Luminex assay (cat# MPXHCYTO-60K, Millipore, USA) was used to simultaneously quantify the 
protein levels of (A) IL-6, (B) IL-8, and (C) RANTES in the cell culture supernatants according to the 
manufacturer’s instructions. All samples, as well as two quality controls included in the kit, were analysed in 
duplicate. The levels of all the analytes in the quality controls were within the expected ranges. A standard 
curve ranging from 3.2 pg/ml to 10 000 pg/ml was used for all the cytokines. Bio-Plex Manager Software, 
version 4.1.1., was used to analyse the data. One-way ANOVA and Bonferonni post-test were used for 
statistical analysis. Statistical significance of difference is indicated by *, **, ***, to indicate p<0.05, p<0.01 
























B1: Realtime quantitative polymerase chain reaction (qPCR) optimisation 
 
The relative mRNA gene expression levels of the human cytokines IL-12 and IL-10 were 
quantitatively measured using real-time qPCR. The first crucial step in the analysis of gene 
expression is the isolation of high quality, intact RNA, as poor quality RNA can compromise 
experimental results. The RNA quality was therefore assessed firstly by the optical density (OD) of 
the RNA and secondly by analysing the RNA on a 1% denaturing formaldehyde agarose gel. The 
OD was measured with a NanoDrop (ND-100 Spectrophotometer) at 260 nm (specific for nucleic 
acids) and 280 nm (specific for proteins) and the 260/280 ratio was determined. A ratio of greater 
than 1.9 is generally considered acceptable (Sambrook et al., 1989). The denaturing gel was used to 
determine the RNA integrity, as the 260 nm OD reading can be compromised by the presence of 
genomic DNA. On the gel intact total RNA from eukaryotic samples will show sharp, clear 28S and 
18S RNA bands. If the 28S RNA band is approximately twice as intense as the 18S RNA band (2:1 
ratio), it is a good indication that the RNA is completely intact. Figure B1.1 is an example of a 1% 
denaturing formaldehyde agarose gel showing intact RNA.  
 
Figure B1.1. A representative 1% denaturing formaldehyde agarose gel showing intact RNA. 
RNA was isolated from the human Ect1/E6E7 cell line using Tri-reagent (Sigma-Aldrich, South 
Africa) according to the manufacturer’s instructions, and 1 µg RNA was loaded onto an agarose gel.  
 
The intact total RNA was subsequently used to synthetise complementary DNA (cDNA) as 
described in Chapter 2. The next step in this technique involves the rapid amplification of the short 
DNA sequences in a realtime PCR thermal cycler (Roche LightCycler). Theoretically the amount of 
DNA in the reaction should double at each cycle, thus leading to the exponential amplification of 







linear ground phase, early exponential phase, log-linear phase and plateau phase (figure B1.2.) 
(Wong and Medrano, 2005, Fraga et al., 2008). The first phase, linear ground phase, refers to the 
initiation of the PCR reaction (first 10 – 15 cycles), where the emitted fluorescence is below 
background level. During the early exponential phase the amount of fluorescence reaches a 
threshold which is significantly higher than the background levels. The point at which the 
fluorescence exceeds the background fluorescence is called the crossing point (CP). The log-linear 
phase is defined as the phase where the amplicon increases exponentially until an optimal 
amplification period is reached, thus the PCR product doubles after every cycle due to ideal reaction 
conditions. After a while, the PCR reaction will reach a plateau as the PCR reaction components 
become depleted.  
 
Figure B1.2. A PCR amplification curve indicating the four major phases of real-time qPCR. An 
increase in the PCR product (amount of DNA) is indicated as an increase in the fluorescence. Figure taken 
from Wong and Medrano, 2005.  
 
B1.1. Determination of primer pair efficiency 
In order to validate the PCR results obtained, the amplification efficiency of each of the primers 






the primer efficiencies were determined. Standard curves were created by making serial dilutions of 
a single cDNA sample (EtOH+TNF-α) with each dilution analysed by qPCR in triplicate. A no 
template control was used to confirm that no contamination occurred. A standard curve is generated 
by plotting the CP for each dilution (Y-axis) against the log cDNA concentration (X-axis) as shown 
in figure B.1.3. The slope of the standard curve is used to calculate the exponential amplification 
value (PCR efficiency) (E) for each of the primers according to the following equation (1) (Pfaffl, 
2001):  
 
E = 10 [-1/slope]       (1) 
 
Table B1.1 summarises the average primer efficiencies for IL-12p40, IL-12p35, IL-10 and GAPDH 
determined by pooling the primer efficiencies from two independent experiments, and show 
efficiencies of >2 for IL-12p40, IL-12p35 and IL-10. It has been suggested that the primer 
efficiencies for IL-12p40 and IL-10 are acceptable, while the primer efficiency for IL-12p35 is 
considered high (Realtime qPCR guide, Eurogentec). Primer efficiencies exceeding a value of two 
have been suggested to be due to the formation of primer-dimers and non-specific amplicons 
(Realtime qPCR guide, Biorad). As the determination of primer efficiencies were from only two 
independent experiments, it would be ideal to repeat these experiments. Particular care should be 
given to accurate pipetting, removal of inhibitors of the qPCR reaction e.g. reverse transcriptase 
inhibitors (Suslov and Steindler, 2005), decreasing the primer concentrations as well as adjusting 










Figure B.1.3. Representative standard curves showing the cycle number versus the log concentration 
of the amplified cDNA. The standard curves shown in A, B, C and D were generated for the human IL-
12p40, IL-12p35, IL-10 and GAPDH primers, respectively.  
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B1.2. Determination of relative expression values 
Following the determination of the primer efficiency, the relative expression levels of the target 
gene could be calculated by normalising to the levels of a housekeeping gene (Giulietti et al., 2001) 
to correct for amplification efficiencies. Housekeeping genes, such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), are used for normalisation because they are constantly expressed in 
different tissues and are not affected by experimental treatment. Using the mathematical model of 
Pfaffl, the relative expression of a target gene was calculated as a relative expression ratio (R) of 
target gene to reference gene (Pfaffl, 2001): 
 
    (2) 
The expression ratio (R) of a target gene is calculated based on E (PCR efficiency as determined 
from equation 1) and a change in the crossing point (∆CP). The value for ∆CP is obtained by 
subtracting the CP value for the test compound treated sample from the CP value for the EtOH 
(solvent; control). A relative expression ratio (R) of =1 indicates that there is no difference between 
samples treated with test compounds and the solvent (EtOH). If R > 1 the mRNA expression of the 
target gene of interest is upregulated, whereas R < 1 indicates that the mRNA expression of the 
target gene is inhibited. 
 
B1.3. Melting point analysis 
It should be noted that prior to the calculation of the relative expression levels, the conditions for 
optimal mRNA expression of each target gene was optimised. Also, melting point analysis was 
performed for each qPCR reaction to confirm amplicon specificity, as the melting curve generated 
is used to distinguish between the target amplicons, primer-dimers and any non-specific products 





artefacts. In addition, the optimal time for the relative expression levels of IL-12p40, IL-12p35, IL-
10 and GAPDH had to be determined as different genes are expressed at different times. To 
determine the optimal time for expression of the target genes, as well as the MgCl2 concentration, a 
time-course and MgCl2 titration was performed. Optimal IL-12p40 gene expression in the presence 
of TNF-α was observed at 6 hours using a final MgCl2 concentration of 3 mM (figure B1.4). Similar 
optimisations were performed for IL-12p35 (figure B1.5) and IL-10 (figure B1.6). From these 
results, the mRNA expression of all target genes (IL-12p40, IL-12p35 and IL-10) was analysed at 6 
hours, due to time and financial constraints, using a final concentration of 3 mM MgCl2 for IL-




Figure B1.4. Melting curve analysis for human IL-12p40 at different times using varying MgCl2 
concentrations. Ect1/E6E7 cells were stimulated with TNF-α (0.02 µg/ml) and treated with 0.1% EtOH 
(vehicle control) for 2 hours, 6 hours and 24 hours. A MgCl2 titration was performed to obtain a final 
concentration of (A) 2 mM, (B) 3 mM, (C) 4 mM and (D) 5 mM. A no template was included for each 

















A 2 mM 3 mM 










Figure B1.5. Melting curves for human IL-12p35 at 6 hours using varying MgCl2 concentrations. 
Ect1/E6E7 cells were treated with 0.1% EtOH (solvent) and TNF-α (0.02 µg/ml) (denoted as a) for 6 hours. 
A MgCl2 titration was performed to obtain a final concentration of (A) 2 mM, (B) 2.5 mM, (C) 3 mM and 
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Figure B1.6. Melting curves for human IL-10 at 6 hours using varying MgCl2 concentrations. 
Ect1/E6E7 cells were induced with (a) 0.1% EtOH (vehicle control) and (b) stimulated with TNF-α (0.02 
µg/ml) for 6 hours. A MgCl2 titration was performed to obtain a final concentration of (A) 2 mM, (B) 3 mM, 
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B2: Chromatin immunoprecipitation (ChIP) assay optimisation 
The recruitment of proteins to specific DNA cis-elements within the promoter area of target genes, 
i.e. protein-DNA interactions, was investigated by means of ChIP assays. This entailed (i) cross-
linking the DNA-binding proteins to the chromatin, (ii) fragmenting the protein-DNA complex by 
sonication, (iii) immunoprecipitation with an antibody specific for the protein of interest, followed 
by the (iv) amplification and quantification of the specific DNA sequence associated with the 
protein of interest using qPCR. Optimal sonication of the chromatin is crucial as it aids in further 
lysing of the formaldehyde cross-linked cells, as well as allowing the determination of the average 
size of the DNA fragments. As very small fragments may be lost during the DNA purification step 
and large DNA fragments may cause inefficient immunoprecipitation, the optimal DNA fragment 
size should range between 300 and 800 bp (Ma et al., 2003). Thus, the sonification step needs to be 
optimised for different cell lines. For the Ect1/E6E7 epithelial cell line, we used varying cell 
numbers, power settings and times, and evaluated the size of the fragmented chromatin by agarose 
gel electrophoresis. As shown in figure B2.1 chromatin fragments with an average size of 300 bp 
were produced, when the human Ect1/E6E7 cells were sonicated using the Misonix sonicator on 
















Figure B2.1. An example of an agarose gel electrophoresis analysis of chromatin after sonication. The 
human Ect1/E6E7 cell line was treated with 0.1% EtOH (vehicle control) in the (A) absence and (B) 
presence of 0.02 µg/ml TNF-α for 2 hours. Thereafter, the cells were cross-linked, harvested and sonicated at 
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